<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230000974</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>29</s160></s100><s200><s210>1</s210><s211>469</s211><s212>PRT</s212><s213>Influenza A virus</s213></s200><s400> 1Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Thr Cys Met Thr1               5                   10                  15Ile Gly Met Ala Asn Leu Ile Leu Gln Ile Gly Asn Ile Ile Ser Ile            20                  25                  30Trp Val Ser His Ser Ile Gln Ile Gly Asn Gln Ser Gln Ile Glu Thr        35                  40                  45Cys Asn Gln Ser Val Ile Thr Tyr Glu Asn Asn Thr Trp Val Asn Gln    50                  55                  60Thr Tyr Val Asn Ile Ser Asn Thr Asn Phe Ala Ala Arg Gln Ser Val65                  70                  75                  80Ala Ser Val Lys Leu Ala Gly Asn Ser Ser Leu Cys Pro Val Ser Gly                85                  90                  95Trp Ala Ile Tyr Ser Lys Asp Asn Ser Val Arg Ile Gly Ser Lys Gly            100                 105                 110Asp Val Phe Val Ile Arg Glu Pro Phe Ile Ser Cys Ser Pro Leu Glu        115                 120                 125Cys Arg Thr Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp Lys His    130                 135                 140Ser Asn Gly Thr Ile Lys Asp Arg Ser Pro Tyr Arg Thr Leu Met Ser145                 150                 155                 160Cys Pro Ile Gly Glu Val Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser                165                 170                 175Val Ala Trp Ser Ala Ser Ala Cys His Asp Gly Thr Asn Trp Leu Thr            180                 185                 190Ile Gly Ile Ser Gly Pro Asp Ser Gly Ala Val Ala Val Leu Lys Tyr        195                 200                 205Asn Gly Ile Ile Thr Asp Thr Ile Lys Ser Trp Arg Asn Asn Ile Leu    210                 215                 220Arg Thr Gln Glu Ser Glu Cys Ala Cys Val Asn Gly Ser Cys Phe Thr225                 230                 235                 240Ile Met Thr Asp Gly Pro Ser Asp Gly Gln Ala Ser Tyr Lys Ile Phe                245                 250                 255Arg Ile Glu Lys Gly Lys Ile Ile Lys Ser Val Glu Met Lys Ala Pro            260                 265                 270Asn Tyr His Tyr Glu Glu Cys Ser Cys Tyr Pro Asp Ser Ser Glu Ile        275                 280                 285Thr Cys Val Cys Arg Asp Asn Trp His Gly Ser Asn Arg Pro Trp Val    290                 295                 300Ser Phe Asn Gln Asn Leu Glu Tyr Gln Met Gly Tyr Ile Cys Ser Gly305                 310                 315                 320Val Phe Gly Asp Asn Pro Arg Pro Asn Asp Lys Thr Gly Ser Cys Gly                325                 330                 335Pro Val Ser Ser Asn Gly Ala Asn Gly Val Lys Gly Phe Ser Phe Lys            340                 345                 350Tyr Gly Asn Gly Val Trp Ile Gly Arg Thr Lys Ser Ile Ser Ser Arg        355                 360                 365Lys Gly Phe Glu Met Ile Trp Asp Pro Asn Gly Trp Thr Gly Thr Asp    370                 375                 380Asn Lys Phe Ser Ile Lys Gln Asp Ile Val Gly Ile Asn Glu Trp Ser385                 390                 395                 400Gly Tyr Ser Gly Ser Phe Val Gln His Pro Glu Leu Thr Gly Leu Asp                405                 410                 415Cys Ile Arg Pro Cys Phe Trp Val Glu Leu Ile Arg Gly Arg Pro Glu            420                 425                 430Glu Asn Thr Ile Trp Thr Ser Gly Ser Ser Ile Ser Phe Cys Gly Val        435                 440                 445Asp Ser Asp Thr Val Gly Trp Ser Trp Pro Asp Gly Ala Glu Leu Pro    450                 455                 460Phe Thr Ile Asp Lys465</s400><s200><s210>2</s210><s211>469</s211><s212>PRT</s212><s213>Influenza A virus</s213></s200><s400> 2Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Val Ser Leu Thr1               5                   10                  15Ile Ser Thr Ile Cys Phe Phe Met Gln Ile Ala Ile Leu Ile Thr Thr            20                  25                  30Val Thr Leu His Phe Lys Gln Tyr Glu Phe Asn Ser Pro Pro Asn Asn        35                  40                  45Gln Val Met Leu Cys Glu Pro Thr Ile Ile Glu Arg Asn Ile Thr Glu    50                  55                  60Ile Val Tyr Leu Thr Asn Thr Thr Ile Glu Arg Glu Ile Cys Pro Lys65                  70                  75                  80Pro Ala Glu Tyr Arg Asn Trp Ser Lys Pro Gln Cys Gly Ile Thr Gly                85                  90                  95Phe Ala Pro Phe Ser Lys Asp Asn Ser Ile Arg Leu Ser Ala Gly Gly            100                 105                 110Asp Ile Trp Val Thr Arg Glu Pro Tyr Val Ser Cys Asp Pro Asp Lys        115                 120                 125Cys Tyr Gln Phe Ala Leu Gly Gln Gly Thr Thr Ile Asn Asn Val His    130                 135                 140Ser Asn Asn Thr Ala Arg Asp Arg Thr Pro His Arg Thr Leu Leu Met145                 150                 155                 160Asn Glu Leu Gly Val Pro Phe His Leu Gly Thr Lys Gln Val Cys Ile                165                 170                 175Ala Trp Ser Ser Ser Ser Cys His Asp Gly Lys Ala Trp Leu His Val            180                 185                 190Cys Ile Thr Gly Asp Asp Lys Asn Ala Thr Ala Ser Phe Ile Tyr Asn        195                 200                 205Gly Arg Leu Val Asp Ser Val Val Ser Trp Ser Lys Asp Ile Leu Arg    210                 215                 220Thr Gln Glu Ser Glu Cys Val Cys Ile Asn Gly Thr Cys Thr Val Val225                 230                 235                 240Met Thr Asp Gly Asn Ala Thr Gly Lys Ala Asp Thr Lys Ile Leu Phe                245                 250                 255Ile Glu Glu Gly Lys Ile Val His Thr Ser Lys Leu Ser Gly Ser Ala            260                 265                 270Gln His Val Glu Glu Cys Ser Cys Tyr Pro Arg Tyr Pro Gly Val Arg        275                 280                 285Cys Val Cys Arg Asp Asn Trp Lys Gly Ser Asn Arg Pro Ile Val Asp    290                 295                 300Ile Asn Ile Lys Asp His Ser Ile Val Ser Ser Tyr Val Cys Ser Gly305                 310                 315                 320Leu Val Gly Asp Thr Pro Arg Lys Thr Asp Ser Ser Ser Ser Ser His                325                 330                 335Cys Leu Asn Pro Asn Asn Glu Lys Gly Gly His Gly Val Lys Gly Trp            340                 345                 350Ala Phe Asp Asp Gly Asn Asp Val Trp Met Gly Arg Thr Ile Asn Glu        355                 360                 365Thr Ser Arg Leu Gly Tyr Glu Thr Phe Lys Val Val Glu Gly Trp Ser    370                 375                 380Asn Pro Lys Ser Lys Leu Gln Ile Asn Arg Gln Val Ile Val Asp Arg385                 390                 395                 400Gly Asp Arg Ser Gly Tyr Ser Gly Ile Phe Ser Val Glu Gly Lys Ser                405                 410                 415Cys Ile Asn Arg Cys Phe Tyr Val Glu Leu Ile Arg Gly Arg Lys Glu            420                 425                 430Glu Thr Glu Val Leu Trp Thr Ser Asn Ser Ile Val Val Phe Cys Gly        435                 440                 445Thr Ser Gly Thr Tyr Gly Thr Gly Ser Trp Pro Asp Gly Ala Asp Leu    450                 455                 460Asn Leu Met His Ile465</s400><s200><s210>3</s210><s211>466</s211><s212>PRT</s212><s213>Influenza B virus</s213></s200><s400> 3Met Leu Pro Ser Thr Ile Gln Thr Leu Thr Leu Phe Leu Thr Ser Gly1               5                   10                  15Gly Val Leu Leu Ser Leu Tyr Val Ser Ala Ser Leu Ser Tyr Leu Leu            20                  25                  30Tyr Ser Asp Ile Leu Leu Lys Phe Ser Pro Thr Glu Ile Thr Ala Pro        35                  40                  45Thr Met Pro Leu Asp Cys Ala Asn Ala Ser Asn Val Gln Ala Val Asn    50                  55                  60Arg Ser Ala Thr Lys Gly Val Thr Leu Leu Leu Pro Glu Pro Glu Trp65                  70                  75                  80Thr Tyr Pro Arg Leu Ser Cys Pro Gly Ser Thr Phe Gln Lys Ala Leu                85                  90                  95Leu Ile Ser Pro His Arg Phe Gly Glu Thr Lys Gly Asn Ser Ala Pro            100                 105                 110Leu Ile Ile Arg Glu Pro Phe Val Ala Cys Gly Pro Asn Glu Cys Lys        115                 120                 125His Phe Ala Leu Thr His Tyr Ala Ala Gln Pro Gly Gly Tyr Tyr Asn    130                 135                 140Gly Thr Arg Gly Asp Arg Asn Lys Leu Arg His Leu Ile Ser Val Lys145                 150                 155                 160Leu Gly Lys Ile Pro Thr Val Glu Asn Ser Ile Phe His Met Ala Ala                165                 170                 175Trp Ser Gly Ser Ala Cys His Asp Gly Lys Glu Trp Thr Tyr Ile Gly            180                 185                 190Val Asp Gly Pro Asp Asn Asn Ala Leu Leu Lys Val Lys Tyr Gly Glu        195                 200                 205Ala Tyr Thr Asp Thr Tyr His Ser Tyr Ala Asn Asn Ile Leu Arg Thr    210                 215                 220Gln Glu Ser Ala Cys Asn Cys Ile Gly Gly Asn Cys Tyr Leu Met Ile225                 230                 235                 240Thr Asp Gly Ser Ala Ser Gly Val Ser Glu Cys Arg Phe Leu Lys Ile                245                 250                 255Arg Glu Gly Arg Ile Ile Lys Glu Ile Phe Pro Thr Gly Arg Val Lys            260                 265                 270His Thr Glu Glu Cys Thr Cys Gly Phe Ala Ser Asn Lys Thr Ile Glu        275                 280                 285Cys Ala Cys Arg Asp Asn Arg Tyr Thr Ala Lys Arg Pro Phe Val Lys    290                 295                 300Leu Asn Val Glu Thr Asp Thr Ala Glu Ile Arg Leu Met Cys Thr Asp305                 310                 315                 320Thr Tyr Leu Asp Thr Pro Arg Pro Asn Asp Gly Ser Ile Thr Gly Pro                325                 330                 335Cys Glu Ser Asp Gly Asp Lys Gly Ser Gly Gly Ile Lys Gly Gly Phe            340                 345                 350Val His Gln Arg Met Lys Ser Lys Ile Gly Arg Trp Tyr Ser Arg Thr        355                 360                 365Met Ser Gln Thr Glu Arg Met Gly Met Gly Leu Tyr Val Lys Tyr Gly    370                 375                 380Gly Asp Pro Trp Ala Asp Ser Asp Ala Leu Ala Phe Ser Gly Val Met385                 390                 395                 400Val Ser Met Lys Glu Pro Gly Trp Tyr Ser Phe Gly Phe Glu Ile Lys                405                 410                 415Asp Lys Lys Cys Asp Val Pro Cys Ile Gly Ile Glu Met Val His Asp            420                 425                 430Gly Gly Lys Glu Thr Trp His Ser Ala Ala Thr Ala Ile Tyr Cys Leu        435                 440                 445Met Gly Ser Gly Gln Leu Leu Trp Asp Thr Val Thr Gly Val Asp Met    450                 455                 460Ala Leu465</s400><s200><s210>4</s210><s211>466</s211><s212>PRT</s212><s213>Influenza B virus</s213></s200><s400> 4Met Leu Pro Ser Thr Ile Gln Thr Leu Thr Leu Phe Leu Thr Ser Gly1               5                   10                  15Gly Val Leu Leu Ser Leu Tyr Val Ser Ala Ser Leu Ser Tyr Leu Leu            20                  25                  30Tyr Ser Asp Ile Leu Leu Lys Phe Ser Arg Thr Glu Val Thr Ala Pro        35                  40                  45Ile Met Pro Leu Asp Cys Ala Asn Ala Ser Asn Val Gln Ala Val Asn    50                  55                  60Arg Ser Ala Thr Lys Gly Val Thr Pro Leu Leu Pro Glu Pro Glu Trp65                  70                  75                  80Thr Tyr Pro Arg Leu Ser Cys Pro Gly Ser Thr Phe Gln Lys Ala Leu                85                  90                  95Leu Ile Ser Pro His Arg Phe Gly Glu Thr Lys Gly Asn Ser Ala Pro            100                 105                 110Leu Ile Ile Arg Glu Pro Phe Ile Ala Cys Gly Pro Lys Glu Cys Lys        115                 120                 125His Phe Ala Leu Thr His Tyr Ala Ala Gln Pro Gly Gly Tyr Tyr Asn    130                 135                 140Gly Thr Arg Glu Asp Arg Asn Lys Leu Arg His Leu Ile Ser Val Lys145                 150                 155                 160Leu Gly Lys Ile Pro Thr Val Glu Asn Ser Ile Phe His Met Ala Ala                165                 170                 175Trp Ser Gly Ser Ala Cys His Asp Gly Arg Glu Trp Thr Tyr Ile Gly            180                 185                 190Val Asp Gly Pro Asp Ser Asn Ala Leu Leu Lys Ile Lys Tyr Gly Glu        195                 200                 205Ala Tyr Thr Asp Thr Tyr His Ser Tyr Ala Lys Asn Ile Leu Arg Thr    210                 215                 220Gln Glu Ser Ala Cys Asn Cys Ile Gly Gly Asp Cys Tyr Leu Met Ile225                 230                 235                 240Thr Asp Gly Pro Ala Ser Gly Ile Ser Glu Cys Arg Phe Leu Lys Ile                245                 250                 255Arg Glu Gly Arg Ile Ile Lys Glu Ile Phe Pro Thr Gly Arg Val Lys            260                 265                 270His Thr Glu Glu Cys Thr Cys Gly Phe Ala Ser Asn Lys Thr Ile Glu        275                 280                 285Cys Ala Cys Arg Asp Asn Ser Tyr Thr Ala Lys Arg Pro Phe Val Lys    290                 295                 300Leu Asn Val Glu Thr Asp Thr Ala Glu Ile Arg Leu Met Cys Thr Lys305                 310                 315                 320Thr Tyr Leu Asp Thr Pro Arg Pro Asn Asp Gly Ser Ile Thr Gly Pro                325                 330                 335Cys Glu Ser Asp Gly Asp Glu Gly Ser Gly Gly Ile Lys Gly Gly Phe            340                 345                 350Val His Gln Arg Met Ala Ser Lys Ile Gly Arg Trp Tyr Ser Arg Thr        355                 360                 365Met Ser Lys Thr Lys Arg Met Gly Met Gly Leu Tyr Val Lys Tyr Asp    370                 375                 380Gly Asp Pro Trp Thr Asp Ser Glu Ala Leu Ala Leu Ser Gly Val Met385                 390                 395                 400Val Ser Met Glu Glu Pro Gly Trp Tyr Ser Phe Gly Phe Glu Ile Lys                405                 410                 415Asp Lys Lys Cys Asp Val Pro Cys Ile Gly Ile Glu Met Val His Asp            420                 425                 430Gly Gly Lys Thr Thr Trp His Ser Ala Ala Thr Ala Ile Tyr Cys Leu        435                 440                 445Met Gly Ser Gly Gln Leu Leu Trp Asp Thr Val Thr Gly Val Asn Met    450                 455                 460Thr Leu465</s400><s200><s210>5</s210><s211>566</s211><s212>PRT</s212><s213>Influenza A virus</s213></s200><s400> 5Met Lys Ala Ile Leu Val Val Leu Leu Tyr Thr Phe Thr Thr Ala Asn1               5                   10                  15Ala Asp Thr Leu Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr            20                  25                  30Val Asp Thr Val Leu Glu Lys Asn Val Thr Val Thr His Ser Val Asn        35                  40                  45Leu Leu Glu Asp Lys His Asn Gly Lys Leu Cys Lys Leu Gly Gly Val    50                  55                  60Ala Pro Leu His Leu Gly Lys Cys Asn Ile Ala Gly Trp Ile Leu Gly65                  70                  75                  80Asn Pro Glu Cys Glu Ser Leu Ser Thr Ala Arg Ser Trp Ser Tyr Ile                85                  90                  95Val Glu Thr Ser Asn Ser Asp Asn Gly Thr Cys Tyr Pro Gly Asp Phe            100                 105                 110Ile Asn Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser Phe        115                 120                 125Glu Arg Phe Glu Ile Phe Pro Lys Thr Ser Ser Trp Pro Asn His Asp    130                 135                 140Ser Asn Lys Gly Val Thr Ala Ala Cys Pro His Ala Gly Ala Lys Ser145                 150                 155                 160Phe Tyr Lys Asn Leu Ile Trp Leu Val Lys Lys Gly Asn Ser Tyr Pro                165                 170                 175Lys Leu Asn Gln Thr Tyr Ile Asn Asp Lys Gly Lys Glu Val Leu Val            180                 185                 190Leu Trp Gly Ile His His Pro Pro Thr Thr Ala Asp Gln Gln Ser Leu        195                 200                 205Tyr Gln Asn Ala Asp Ala Tyr Val Phe Val Gly Thr Ser Arg Tyr Ser    210                 215                 220Lys Lys Phe Lys Pro Glu Ile Ala Thr Arg Pro Lys Val Arg Asp Arg225                 230                 235                 240Glu Gly Arg Met Asn Tyr Tyr Trp Thr Leu Val Glu Pro Gly Asp Lys                245                 250                 255Ile Thr Phe Glu Ala Thr Gly Asn Leu Val Val Pro Arg Tyr Ala Phe            260                 265                 270Thr Met Glu Arg Asn Ala Gly Ser Gly Ile Ile Ile Ser Asp Thr Pro        275                 280                 285Val His Asp Cys Asn Thr Thr Cys Gln Thr Ala Glu Gly Ala Ile Asn    290                 295                 300Thr Ser Leu Pro Phe Gln Asn Val His Pro Val Thr Ile Gly Lys Cys305                 310                 315                 320Pro Lys Tyr Val Lys Ser Thr Lys Leu Arg Leu Ala Thr Gly Leu Arg                325                 330                 335Asn Val Pro Ser Ile Gln Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly            340                 345                 350Phe Ile Glu Gly Gly Trp Thr Gly Met Val Asp Gly Trp Tyr Gly Tyr        355                 360                 365His His Gln Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Leu Lys Ser    370                 375                 380Thr Gln Asn Ala Ile Asp Lys Ile Thr Asn Lys Val Asn Ser Val Ile385                 390                 395                 400Glu Lys Met Asn Thr Gln Phe Thr Ala Val Gly Lys Glu Phe Asn His                405                 410                 415Leu Glu Lys Arg Ile Glu Asn Leu Asn Lys Lys Val Asp Asp Gly Phe            420                 425                 430Leu Asp Ile Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Leu Glu Asn        435                 440                 445Glu Arg Thr Leu Asp Tyr His Asp Ser Asn Val Lys Asn Leu Tyr Glu    450                 455                 460Lys Val Arg Asn Gln Leu Lys Asn Asn Ala Lys Glu Ile Gly Asn Gly465                 470                 475                 480Cys Phe Glu Phe Tyr His Lys Cys Asp Asn Thr Cys Met Glu Ser Val                485                 490                 495Lys Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu Ala Lys Leu            500                 505                 510Asn Arg Glu Lys Ile Asp Gly Val Lys Leu Glu Ser Thr Arg Ile Tyr        515                 520                 525Gln Ile Leu Ala Ile Tyr Ser Thr Val Ala Ser Ser Leu Val Leu Val    530                 535                 540Val Ser Leu Gly Ala Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu545                 550                 555                 560Gln Cys Arg Ile Cys Ile                565</s400><s200><s210>6</s210><s211>566</s211><s212>PRT</s212><s213>Influenza A virus</s213></s200><s400> 6Met Lys Thr Ile Ile Ala Leu Ser Cys Ile Leu Cys Leu Val Phe Ala1               5                   10                  15Gln Lys Ile Pro Gly Asn Asp Asn Ser Thr Ala Thr Leu Cys Leu Gly            20                  25                  30His His Ala Val Pro Asn Gly Thr Ile Val Lys Thr Ile Thr Asn Asp        35                  40                  45Arg Ile Glu Val Thr Asn Ala Thr Glu Leu Val Gln Asn Ser Ser Ile    50                  55                  60Gly Glu Ile Cys Asp Ser Pro His Gln Ile Leu Asp Gly Glu Asn Cys65                  70                  75                  80Thr Leu Ile Asp Ala Leu Leu Gly Asp Pro Gln Cys Asp Gly Phe Gln                85                  90                  95Asn Lys Lys Trp Asp Leu Phe Val Glu Arg Asn Lys Ala Tyr Ser Asn            100                 105                 110Cys Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Leu Arg Ser Leu Val        115                 120                 125Ala Ser Ser Gly Thr Leu Glu Phe Asn Asn Glu Ser Phe Asn Trp Ala    130                 135                 140Gly Val Thr Gln Asn Gly Thr Ser Ser Ser Cys Ile Arg Gly Ser Lys145                 150                 155                 160Ser Ser Phe Phe Ser Arg Leu Asn Trp Leu Thr His Leu Asn Ser Lys                165                 170                 175Tyr Pro Ala Leu Asn Val Thr Met Pro Asn Asn Glu Gln Phe Asp Lys            180                 185                 190Leu Tyr Ile Trp Gly Val His His Pro Gly Thr Asp Lys Asp Gln Ile        195                 200                 205Ser Leu Tyr Ala Gln Ser Ser Gly Arg Ile Thr Val Ser Thr Lys Arg    210                 215                 220Ser Gln Gln Ala Val Ile Pro Asn Ile Gly Ser Arg Pro Arg Ile Arg225                 230                 235                 240Asp Ile Pro Ser Arg Ile Ser Ile Tyr Trp Thr Ile Val Lys Pro Gly                245                 250                 255Asp Ile Leu Leu Ile Asn Ser Thr Gly Asn Leu Ile Ala Pro Arg Gly            260                 265                 270Tyr Phe Lys Ile Arg Ser Gly Lys Ser Ser Ile Met Arg Ser Asp Ala        275                 280                 285Pro Ile Gly Lys Cys Lys Ser Glu Cys Ile Thr Pro Asn Gly Ser Ile    290                 295                 300Pro Asn Asp Lys Pro Phe Gln Asn Val Asn Arg Ile Thr Tyr Gly Ala305                 310                 315                 320Cys Pro Arg Tyr Val Lys Gln Ser Thr Leu Lys Leu Ala Thr Gly Met                325                 330                 335Arg Asn Val Pro Glu Arg Gln Thr Arg Gly Ile Phe Gly Ala Ile Ala            340                 345                 350Gly Phe Ile Glu Asn Gly Trp Glu Gly Met Val Asp Gly Trp Tyr Gly        355                 360                 365Phe Arg His Gln Asn Ser Glu Gly Arg Gly Gln Ala Ala Asp Leu Lys    370                 375                 380Ser Thr Gln Ala Ala Ile Asp Gln Ile Asn Gly Lys Leu Asn Arg Leu385                 390                 395                 400Ile Gly Lys Thr Asn Glu Lys Phe His Gln Ile Glu Lys Glu Phe Ser                405                 410                 415Glu Val Glu Gly Arg Ile Gln Asp Leu Glu Lys Tyr Val Glu Asp Thr            420                 425                 430Lys Ile Asp Leu Trp Ser Tyr Asn Ala Glu Leu Leu Val Ala Leu Glu        435                 440                 445Asn Gln His Thr Ile Asp Leu Thr Asp Ser Glu Met Asn Lys Leu Phe    450                 455                 460Glu Lys Thr Lys Lys Gln Leu Arg Glu Asn Ala Glu Asp Met Gly Asn465                 470                 475                 480Gly Cys Phe Lys Ile Tyr His Lys Cys Asp Asn Ala Cys Met Gly Ser                485                 490                 495Ile Arg Asn Gly Thr Tyr Asp His Asn Val Tyr Arg Asp Glu Ala Leu            500                 505                 510Asn Asn Arg Phe Gln Ile Lys Gly Val Glu Leu Lys Ser Gly Tyr Lys        515                 520                 525Asp Trp Ile Leu Trp Ile Ser Phe Ala Ile Ser Cys Phe Leu Leu Cys    530                 535                 540Val Ala Leu Leu Gly Phe Ile Met Trp Ala Cys Gln Lys Gly Asn Ile545                 550                 555                 560Arg Cys Asn Ile Cys Ile                565</s400><s200><s210>7</s210><s211>566</s211><s212>PRT</s212><s213>Influenza B virus</s213></s200><s400> 7Met Lys Thr Ile Ile Ala Leu Ser Tyr Ile Leu Cys Leu Val Phe Ala1               5                   10                  15Gln Lys Ile Pro Gly Asn Asp Asn Ser Thr Ala Thr Leu Cys Leu Gly            20                  25                  30His His Ala Val Pro Asn Gly Thr Ile Val Lys Thr Ile Thr Asn Asp        35                  40                  45Arg Ile Glu Val Thr Asn Ala Thr Glu Leu Val Gln Asn Ser Ser Ile    50                  55                  60Gly Glu Ile Cys Asp Ser Pro His Gln Ile Leu Asp Gly Glu Asn Cys65                  70                  75                  80Thr Leu Ile Asp Ala Leu Leu Gly Asp Pro Gln Cys Asp Gly Phe Gln                85                  90                  95Asn Lys Lys Trp Asp Leu Phe Val Glu Arg Ser Lys Ala Tyr Ser Asn            100                 105                 110Cys Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Leu Arg Ser Leu Val        115                 120                 125Ala Ser Ser Gly Thr Leu Glu Phe Lys Asn Glu Ser Phe Asn Trp Thr    130                 135                 140Gly Val Thr Gln Asn Gly Lys Ser Ser Ala Cys Ile Arg Gly Ser Ser145                 150                 155                 160Ser Ser Phe Phe Ser Arg Leu Asn Trp Leu Thr His Leu Asn Tyr Thr                165                 170                 175Tyr Pro Ala Leu Asn Val Thr Met Pro Asn Lys Glu Gln Phe Asp Lys            180                 185                 190Leu Tyr Ile Trp Gly Val His His Pro Gly Thr Asp Lys Asp Gln Ile        195                 200                 205Phe Leu Tyr Ala Gln Ser Ser Gly Arg Ile Thr Val Ser Thr Lys Arg    210                 215                 220Ser Gln Gln Ala Val Ile Pro Asn Ile Gly Ser Arg Pro Arg Ile Arg225                 230                 235                 240Asp Ile Pro Ser Arg Ile Ser Ile Tyr Trp Thr Ile Val Lys Pro Gly                245                 250                 255Asp Ile Leu Leu Ile Asn Ser Thr Gly Asn Leu Ile Ala Pro Arg Gly            260                 265                 270Tyr Phe Lys Ile Arg Ser Gly Lys Ser Ser Ile Met Arg Ser Asp Ala        275                 280                 285Pro Ile Gly Lys Cys Lys Ser Glu Cys Ile Thr Pro Asn Gly Ser Ile    290                 295                 300Pro Asn Asp Lys Pro Phe Gln Asn Val Asn Arg Ile Thr Tyr Gly Ala305                 310                 315                 320Cys Pro Arg Tyr Val Lys His Ser Thr Leu Lys Leu Ala Thr Gly Met                325                 330                 335Arg Asn Val Pro Glu Lys Gln Thr Arg Gly Ile Phe Gly Ala Ile Ala            340                 345                 350Gly Phe Ile Glu Asn Gly Trp Glu Gly Met Val Asp Gly Trp Tyr Gly        355                 360                 365Phe Arg His Gln Asn Ser Glu Gly Arg Gly Gln Ala Ala Asp Leu Lys    370                 375                 380Ser Thr Gln Ala Ala Ile Asp Gln Ile Asn Gly Lys Leu Asn Arg Leu385                 390                 395                 400Ile Gly Lys Thr Asn Glu Lys Phe His Gln Ile Glu Lys Glu Phe Ser                405                 410                 415Glu Val Glu Gly Arg Val Gln Asp Leu Glu Lys Tyr Val Glu Asp Thr            420                 425                 430Lys Ile Asp Leu Trp Ser Tyr Asn Ala Glu Leu Leu Val Ala Leu Glu        435                 440                 445Asn Gln His Thr Ile Asp Leu Thr Asp Ser Glu Met Asn Lys Leu Phe    450                 455                 460Glu Lys Thr Lys Lys Gln Leu Arg Glu Asn Ala Glu Asp Met Gly Asn465                 470                 475                 480Gly Cys Phe Lys Ile Tyr His Lys Cys Asp Asn Ala Cys Ile Gly Ser                485                 490                 495Ile Arg Asn Glu Thr Tyr Asp His Asn Val Tyr Arg Asp Glu Ala Leu            500                 505                 510Asn Asn Arg Phe Gln Ile Lys Gly Val Glu Leu Lys Ser Gly Tyr Lys        515                 520                 525Asp Trp Ile Leu Trp Ile Ser Phe Ala Ile Ser Cys Phe Leu Leu Cys    530                 535                 540Val Ala Leu Leu Gly Phe Ile Met Trp Ala Cys Gln Lys Gly Asn Ile545                 550                 555                 560Arg Cys Asn Ile Cys Ile                565</s400><s200><s210>8</s210><s211>584</s211><s212>PRT</s212><s213>Influenza B virus</s213></s200><s400> 8Met Lys Ala Ile Ile Val Leu Leu Met Val Val Thr Ser Asn Ala Asp1               5                   10                  15Arg Ile Cys Thr Gly Ile Thr Ser Ser Asn Ser Pro His Val Val Lys            20                  25                  30Thr Ala Thr Gln Gly Glu Val Asn Val Thr Gly Val Ile Pro Leu Thr        35                  40                  45Thr Thr Pro Thr Lys Ser Tyr Phe Ala Asn Leu Lys Gly Thr Arg Thr    50                  55                  60Arg Gly Lys Leu Cys Pro Asp Cys Leu Asn Cys Thr Asp Leu Asp Val65                  70                  75                  80Ala Leu Gly Arg Pro Met Cys Val Gly Thr Thr Pro Ser Ala Lys Ala                85                  90                  95Ser Ile Leu His Glu Val Arg Pro Val Thr Ser Gly Cys Phe Pro Ile            100                 105                 110Met His Asp Arg Thr Lys Ile Arg Gln Leu Pro Asn Leu Leu Arg Gly        115                 120                 125Tyr Glu Lys Ile Arg Leu Ser Thr Gln Asn Val Ile Asp Ala Glu Lys    130                 135                 140Ala Pro Gly Gly Pro Tyr Arg Leu Gly Thr Ser Gly Ser Cys Pro Asn145                 150                 155                 160Ala Thr Ser Lys Ile Gly Phe Phe Ala Thr Met Ala Trp Ala Val Pro                165                 170                 175Lys Asp Asn Tyr Lys Asn Ala Thr Asn Pro Leu Thr Val Glu Val Pro            180                 185                 190Tyr Ile Cys Thr Glu Gly Glu Asp Gln Ile Thr Val Trp Gly Phe His        195                 200                 205Ser Asp Asn Lys Thr Gln Met Lys Ser Leu Tyr Gly Asp Ser Asn Pro    210                 215                 220Gln Lys Phe Thr Ser Ser Ala Asn Gly Val Thr Thr His Tyr Val Ser225                 230                 235                 240Gln Ile Gly Asp Phe Pro Asp Gln Thr Glu Asp Gly Gly Leu Pro Gln                245                 250                 255Ser Gly Arg Ile Val Val Asp Tyr Met Met Gln Lys Pro Gly Lys Thr            260                 265                 270Gly Thr Ile Val Tyr Gln Arg Gly Val Leu Leu Pro Gln Lys Val Trp        275                 280                 285Cys Ala Ser Gly Arg Ser Lys Val Ile Lys Gly Ser Leu Pro Leu Ile    290                 295                 300Gly Glu Ala Asp Cys Leu His Glu Glu Tyr Gly Gly Leu Asn Lys Ser305                 310                 315                 320Lys Pro Tyr Tyr Thr Gly Lys His Ala Lys Ala Ile Gly Asn Cys Pro                325                 330                 335Ile Trp Val Lys Thr Pro Leu Lys Leu Ala Asn Gly Thr Lys Tyr Arg            340                 345                 350Pro Pro Ala Lys Leu Leu Lys Glu Arg Gly Phe Phe Gly Ala Ile Ala        355                 360                 365Gly Phe Leu Glu Gly Gly Trp Glu Gly Met Ile Ala Gly Trp His Gly    370                 375                 380Tyr Thr Ser His Gly Ala His Gly Val Ala Val Ala Ala Asp Leu Lys385                 390                 395                 400Ser Thr Gln Glu Ala Ile Asn Lys Ile Thr Lys Asn Leu Asn Ser Leu                405                 410                 415Ser Glu Leu Glu Val Lys Asn Leu Gln Arg Leu Ser Gly Ala Met Asp            420                 425                 430Glu Leu His Asn Glu Ile Leu Glu Leu Asp Glu Lys Val Asp Asp Leu        435                 440                 445Arg Ala Asp Thr Ile Ser Ser Gln Ile Glu Leu Ala Val Leu Leu Ser    450                 455                 460Asn Glu Gly Ile Ile Asn Ser Glu Asp Glu His Leu Leu Ala Leu Glu465                 470                 475                 480Arg Lys Leu Lys Lys Met Leu Gly Pro Ser Ala Val Asp Ile Gly Asn                485                 490                 495Gly Cys Phe Glu Thr Lys His Lys Cys Asn Gln Thr Cys Leu Asp Arg            500                 505                 510Ile Ala Ala Gly Thr Phe Asn Ala Gly Glu Phe Ser Leu Pro Thr Phe        515                 520                 525Asp Ser Leu Asn Ile Thr Ala Ala Ser Leu Asn Asp Asp Gly Leu Asp    530                 535                 540Asn His Thr Ile Leu Leu Tyr Tyr Ser Thr Ala Ala Ser Ser Leu Ala545                 550                 555                 560Val Thr Leu Met Leu Ala Ile Phe Ile Val Tyr Met Val Ser Arg Asp                565                 570                 575Asn Val Ser Cys Ser Ile Cys Leu            580</s400><s200><s210>9</s210><s211>97</s211><s212>PRT</s212><s213>Influenza A virus</s213></s200><s400> 9Met Ser Leu Leu Thr Glu Val Glu Thr His Thr Arg Ser Glu Trp Glu1               5                   10                  15Cys Arg Cys Ser Gly Ser Ser Asp Pro Leu Val Ile Ala Ala Asn Ile            20                  25                  30Ile Gly Ile Leu His Leu Ile Leu Trp Ile Thr Asp Arg Leu Phe Phe        35                  40                  45Lys Cys Ile Tyr Arg Arg Phe Lys Tyr Gly Leu Lys Arg Gly Pro Ser    50                  55                  60Thr Glu Gly Val Pro Glu Ser Met Arg Glu Glu Tyr Gln Gln Glu Gln65                  70                  75                  80Gln Ser Ala Val Asp Val Asp Asp Gly His Phe Val Asn Ile Glu Leu                85                  90                  95Glu</s400><s200><s210>10</s210><s211>97</s211><s212>PRT</s212><s213>Influenza A virus</s213></s200><s400> 10Met Ser Leu Leu Thr Glu Val Glu Thr Pro Ile Arg Asn Glu Trp Gly1               5                   10                  15Cys Arg Cys Asn Asp Ser Ser Asp Pro Leu Ile Val Ala Ala Asn Ile            20                  25                  30Ile Gly Ile Leu His Leu Ile Leu Trp Ile Leu Asp Arg Leu Phe Phe        35                  40                  45Lys Cys Val Cys Arg Leu Phe Lys His Gly Leu Lys Arg Gly Pro Ser    50                  55                  60Thr Glu Gly Val Pro Glu Ser Met Arg Glu Glu Tyr Arg Lys Glu Gln65                  70                  75                  80Gln Asn Ala Val Asp Ala Asp Asp Ser His Phe Val Ser Ile Glu Leu                85                  90                  95Glu</s400><s200><s210>11</s210><s211>109</s211><s212>PRT</s212><s213>Influenza B virus</s213></s200><s400> 11Met Leu Glu Pro Phe Gln Ile Leu Thr Ile Cys Ser Phe Ile Leu Ser1               5                   10                  15Ala Leu His Phe Met Ala Trp Thr Ile Gly His Leu Asn Gln Ile Lys            20                  25                  30Arg Gly Ile Asn Met Lys Ile Arg Ile Lys Gly Pro Asn Lys Glu Thr        35                  40                  45Ile Thr Arg Glu Val Ser Ile Leu Arg His Ser Tyr Gln Lys Glu Ile    50                  55                  60Gln Ala Lys Glu Thr Met Lys Glu Val Leu Ser Asp Asn Met Glu Val65                  70                  75                  80Leu Asn Asp His Ile Ile Ile Glu Gly Leu Ser Ala Glu Glu Ile Ile                85                  90                  95Lys Met Gly Glu Thr Val Leu Glu Ile Glu Glu Leu His            100                 105</s400><s200><s210>12</s210><s211>109</s211><s212>PRT</s212><s213>Influenza B virus</s213></s200><s400> 12Met Phe Glu Pro Phe Gln Ile Leu Ser Ile Cys Ser Phe Ile Leu Ser1               5                   10                  15Ala Leu His Phe Met Ala Trp Thr Ile Gly His Leu Asn Gln Ile Lys            20                  25                  30Arg Gly Val Asn Met Lys Ile Arg Ile Lys Gly Pro Asn Lys Glu Thr        35                  40                  45Ile Asn Arg Glu Val Ser Ile Leu Arg His Ser Tyr Gln Lys Glu Ile    50                  55                  60Gln Ala Lys Glu Ala Met Lys Glu Val Leu Ser Asp Asn Met Glu Val65                  70                  75                  80Leu Ser Asp His Ile Val Ile Glu Gly Leu Ser Ala Glu Glu Ile Ile                85                  90                  95Lys Met Gly Glu Thr Val Leu Glu Val Glu Glu Ser His            100                 105</s400><s200><s210>13</s210><s211>100</s211><s212>PRT</s212><s213>Influenza B virus</s213></s200><s400> 13Met Asn Asn Ala Thr Phe Asn Tyr Thr Asn Val Asn Pro Ile Ser His1               5                   10                  15Ile Arg Gly Ser Ile Ile Ile Thr Ile Cys Val Ser Phe Ile Ile Ile            20                  25                  30Leu Thr Ile Leu Gly Tyr Ile Ala Lys Ile Leu Thr Asn Arg Asn Asn        35                  40                  45Cys Thr Asn Asn Ala Ile Gly Leu Cys Lys Arg Ile Lys Cys Ser Gly    50                  55                  60Cys Glu Pro Phe Cys Asn Lys Arg Gly Asp Thr Ser Ser Pro Arg Thr65                  70                  75                  80Gly Val Asp Ile Pro Ala Phe Ile Leu Pro Gly Leu Asn Leu Ser Glu                85                  90                  95Ser Thr Pro Asn            100</s400><s200><s210>14</s210><s211>100</s211><s212>PRT</s212><s213>Influenza B virus</s213></s200><s400> 14Met Asn Asn Ala Thr Phe Asn Tyr Thr Asn Val Asn Leu Ile Ser His1               5                   10                  15Ile Arg Gly Ser Val Ile Ile Thr Ile Cys Val Ser Phe Ile Val Ile            20                  25                  30Leu Thr Ile Phe Gly Tyr Ile Ala Lys Ile Phe Thr Asn Arg Ser Asn        35                  40                  45Cys Thr Asn Asn Ala Ile Gly Leu Cys Lys Arg Ile Lys Cys Ser Gly    50                  55                  60Cys Glu Pro Phe Cys Asn Lys Arg Gly Asp Thr Ser Ser Pro Arg Thr65                  70                  75                  80Gly Val Asp Val Pro Ser Phe Ile Leu Pro Gly Leu Asn Leu Ser Glu                85                  90                  95Ser Thr Pro Asn            100</s400><s200><s210>15</s210><s211>594</s211><s212>PRT</s212><s213>Influenza B virus</s213></s200><s400> 15Met Lys Ala Ile Ile Val Leu Leu Met Val Val Thr Ser Ser Ala Asp1               5                   10                  15Arg Ile Cys Thr Gly Ile Thr Ser Ser Asn Ser Pro His Val Val Lys            20                  25                  30Thr Ala Thr Gln Gly Glu Val Asn Val Thr Gly Val Ile Pro Leu Thr        35                  40                  45Thr Thr Pro Thr Lys Ser His Phe Ala Asn Leu Lys Gly Thr Glu Thr    50                  55                  60Arg Gly Lys Leu Cys Pro Lys Cys Leu Asn Cys Thr Asp Leu Asp Val65                  70                  75                  80Ala Leu Gly Arg Pro Lys Cys Thr Gly Lys Ile Pro Ser Ala Arg Val                85                  90                  95Ser Ile Leu His Glu Val Arg Pro Val Thr Ser Gly Cys Phe Pro Ile            100                 105                 110Met His Asp Arg Thr Lys Ile Arg Gln Leu Pro Asn Leu Leu Arg Gly        115                 120                 125Tyr Glu His Val Arg Leu Ser Thr His Asn Val Ile Asn Ala Glu Gly    130                 135                 140Ala Pro Gly Gly Pro Tyr Lys Ile Gly Thr Ser Gly Ser Cys Pro Asn145                 150                 155                 160Ile Thr Asn Gly Asn Gly Phe Phe Ala Thr Met Ala Trp Ala Val Pro                165                 170                 175Asp Lys Asn Lys Thr Ala Thr Asn Pro Leu Thr Ile Glu Val Pro Tyr            180                 185                 190Val Cys Thr Glu Gly Glu Asp Gln Ile Thr Val Trp Gly Phe His Ser        195                 200                 205Asp Asn Glu Thr Gln Met Ala Lys Leu Tyr Gly Asp Ser Lys Pro Gln    210                 215                 220Lys Phe Thr Ser Ser Ala Asn Gly Val Thr Thr His Tyr Val Ser Gln225                 230                 235                 240Ile Gly Gly Phe Pro Asn Gln Thr Glu Asp Gly Gly Leu Pro Gln Ser                245                 250                 255Gly Arg Ile Val Val Asp Tyr Met Val Gln Lys Ser Gly Lys Thr Gly            260                 265                 270Thr Ile Thr Tyr Gln Arg Gly Ile Leu Leu Pro Gln Lys Val Trp Cys        275                 280                 285Ala Ser Gly Arg Ser Lys Val Ile Lys Gly Ser Leu Pro Leu Ile Gly    290                 295                 300Glu Ala Asp Cys Leu His Glu Lys Tyr Gly Gly Leu Asn Lys Ser Lys305                 310                 315                 320Pro Tyr Tyr Thr Gly Glu His Ala Lys Ala Ile Gly Asn Cys Pro Ile                325                 330                 335Trp Val Lys Thr Pro Leu Lys Leu Ala Asn Gly Thr Lys Tyr Arg Pro            340                 345                 350Pro Ala Lys Leu Leu Lys Glu Arg Gly Phe Phe Gly Ala Ile Ala Gly        355                 360                 365Phe Leu Glu Gly Gly Trp Glu Gly Met Ile Ala Gly Trp His Gly Tyr    370                 375                 380Thr Ser His Gly Ala His Gly Val Ala Val Ala Ala Asp Leu Lys Ser385                 390                 395                 400Thr Gln Glu Ala Ile Asn Lys Ile Thr Lys Asn Leu Asn Ser Leu Ser                405                 410                 415Glu Leu Glu Val Lys Asn Leu Gln Arg Leu Ser Gly Ala Met Asp Glu            420                 425                 430Leu His Asn Glu Ile Leu Glu Leu Asp Glu Lys Val Asp Asp Leu Arg        435                 440                 445Ala Asp Thr Ile Ser Ser Gln Ile Glu Leu Ala Val Leu Leu Ser Asn    450                 455                 460Glu Gly Ile Ile Asn Ser Glu Asp Glu His Leu Leu Ala Leu Glu Arg465                 470                 475                 480Lys Leu Lys Lys Met Leu Gly Pro Ser Ala Val Glu Ile Gly Asn Gly                485                 490                 495Cys Phe Glu Thr Lys His Lys Cys Asn Gln Thr Cys Leu Asp Lys Ile            500                 505                 510Ala Ala Gly Thr Phe Asp Ala Gly Glu Phe Ser Leu Pro Thr Phe Asp        515                 520                 525Ser Leu Asn Ile Thr Ala Ala Ser Leu Asn Asp Asp Gly Leu Asp Asn    530                 535                 540His Thr Ile Leu Leu Tyr Tyr Ser Thr Ala Ala Ser Ser Leu Ala Val545                 550                 555                 560Thr Leu Met Ile Ala Ile Phe Val Val Tyr Met Val Ser Arg Asp Asn                565                 570                 575Val Ser Cys Ser Ile Cys Leu Val Pro Arg Gly Ser His His His His            580                 585                 590His His</s400><s200><s210>16</s210><s211>1788</s211><s212>DNA</s212><s213>Influenza B virus</s213></s200><s400> 16atgaaggcca tcatcgtgct tctcatggtg gtgaccagct cagcggaccg gatctgcacc     60ggcattacca gctccaactc cccccacgtc gtgaaaactg cgacccaggg agaagtgaac    120gtcactggcg tgattccgct gaccaccacc cccaccaagt cccatttcgc caacctgaag    180gggaccgaaa cacggggcaa actctgcccg aagtgcctga actgtaccga tctggacgtg    240gcactgggaa ggccaaagtg caccgggaag attccgagcg ccagagtgtc gatcttgcac    300gaagtcagac ctgtgacctc gggatgtttc cccattatgc acgaccggac aaagatccgc    360cagctcccta atctgttgcg gggatatgag cacgtccgcc tttcgactca caacgtgatc    420aacgccgaag gcgcacctgg tggtccttac aagatcggga cttcgggttc ctgcccgaac    480atcaccaacg gaaacggctt tttcgccacc atggcctggg ctgtgccaga caagaacaag    540actgccacca atcccctgac catcgaagtg ccgtacgtgt gcacggaggg ggaagatcag    600attactgtgt gggggttcca cagcgataac gaaacccaga tggccaagct gtacggagat    660tcaaagcccc agaaattcac ttcgagcgct aacggtgtca ccactcacta cgtgtcccaa    720atcggagggt tcccgaatca aaccgaggac gggggattgc cgcaatccgg tcgcatcgtg    780gtcgactata tggtgcagaa gtcgggcaaa actggcacta tcacgtacca gaggggaatc    840ctgctgcctc aaaaagtgtg gtgtgcgtca ggccggtcta aggtcatcaa gggttccctg    900cccctcatcg gagaggccga ctgcctccac gaaaaatacg gaggcctcaa caagtccaag    960ccctactaca ccggggaaca tgccaaggcc atcgggaact gccccatttg ggttaagacc   1020ccactgaagc tcgccaacgg cactaagtac agacctccgg ccaagttgct gaaggaacgg   1080ggatttttcg gagccattgc gggattcctg gaaggaggct gggagggaat gattgcgggg   1140tggcacggat acactagcca tggcgctcac ggagtggcag tggcggcaga cctgaagtcc   1200actcaggagg ccatcaacaa gattaccaag aacctgaaca gcctgtccga gctggaagtc   1260aagaatctcc agaggctcag cggcgctatg gacgagcttc ataatgagat cctggagctg   1320gatgagaagg tcgacgatct ccgcgcggac accataagct cgcagatcga gctggccgtg   1380cttctgtcga acgagggcat catcaactcc gaggacgagc acctcctggc acttgaacgg   1440aagctcaaga aaatgctggg accttccgct gtggaaattg gcaacggctg cttcgagact   1500aagcacaagt gcaaccagac gtgcctggat aagattgccg ccggaacctt cgacgccgga   1560gagtttagcc tgcccacctt cgactccctg aacatcaccg cggcctcact gaatgatgac   1620ggccttgata accacaccat cctcctgtac tactccaccg ccgcatcctc actcgccgtg   1680actctgatga tcgccatctt cgtggtgtac atggtcagcc gcgacaacgt gtcctgttcc   1740atttgcctgg tgccgagagg ttcccaccat catcaccatc actaatga                1788</s400><s200><s210>17</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 17Tyr Val Ala Asp Ala Pro Lys1               5</s400><s200><s210>18</s210><s211>80</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 18Met Ser Ser Ser Ser Trp Leu Leu Leu Ser Leu Val Ala Val Thr Ala1               5                   10                  15Ala Gln Ser Thr Ile Glu Glu Gln Ala Lys Thr Phe Leu Asp Lys Phe            20                  25                  30Asn His Glu Ala Glu Asp Leu Phe Tyr Gln Ser Ser Leu Ala Ser Trp        35                  40                  45Asn Tyr Asn Thr Asn Ile Thr Glu Glu Asn Val Gln Asn Met Asn Asn    50                  55                  60Ala Gly Asp Lys Trp Ser Ala Phe Leu Lys Glu Gln Ser Thr Leu Ala65                  70                  75                  80</s400><s200><s210>19</s210><s211>805</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 19Met Ser Ser Ser Ser Trp Leu Leu Leu Ser Leu Val Ala Val Thr Ala1               5                   10                  15Ala Gln Ser Thr Ile Glu Glu Gln Ala Lys Thr Phe Leu Asp Lys Phe            20                  25                  30Asn His Glu Ala Glu Asp Leu Phe Tyr Gln Ser Ser Leu Ala Ser Trp        35                  40                  45Asn Tyr Asn Thr Asn Ile Thr Glu Glu Asn Val Gln Asn Met Asn Asn    50                  55                  60Ala Gly Asp Lys Trp Ser Ala Phe Leu Lys Glu Gln Ser Thr Leu Ala65                  70                  75                  80Gln Met Tyr Pro Leu Gln Glu Ile Gln Asn Leu Thr Val Lys Leu Gln                85                  90                  95Leu Gln Ala Leu Gln Gln Asn Gly Ser Ser Val Leu Ser Glu Asp Lys            100                 105                 110Ser Lys Arg Leu Asn Thr Ile Leu Asn Thr Met Ser Thr Ile Tyr Ser        115                 120                 125Thr Gly Lys Val Cys Asn Pro Asp Asn Pro Gln Glu Cys Leu Leu Leu    130                 135                 140Glu Pro Gly Leu Asn Glu Ile Met Ala Asn Ser Leu Asp Tyr Asn Glu145                 150                 155                 160Arg Leu Trp Ala Trp Glu Ser Trp Arg Ser Glu Val Gly Lys Gln Leu                165                 170                 175Arg Pro Leu Tyr Glu Glu Tyr Val Val Leu Lys Asn Glu Met Ala Arg            180                 185                 190Ala Asn His Tyr Glu Asp Tyr Gly Asp Tyr Trp Arg Gly Asp Tyr Glu        195                 200                 205Val Asn Gly Val Asp Gly Tyr Asp Tyr Ser Arg Gly Gln Leu Ile Glu    210                 215                 220Asp Val Glu His Thr Phe Glu Glu Ile Lys Pro Leu Tyr Glu His Leu225                 230                 235                 240His Ala Tyr Val Arg Ala Lys Leu Met Asn Ala Tyr Pro Ser Tyr Ile                245                 250                 255Ser Pro Ile Gly Cys Leu Pro Ala His Leu Leu Gly Asp Met Trp Gly            260                 265                 270Arg Phe Trp Thr Asn Leu Tyr Ser Leu Thr Val Pro Phe Gly Gln Lys        275                 280                 285Pro Asn Ile Asp Val Thr Asp Ala Met Val Asp Gln Ala Trp Asp Ala    290                 295                 300Gln Arg Ile Phe Lys Glu Ala Glu Lys Phe Phe Val Ser Val Gly Leu305                 310                 315                 320Pro Asn Met Thr Gln Gly Phe Trp Glu Asn Ser Met Leu Thr Asp Pro                325                 330                 335Gly Asn Val Gln Lys Ala Val Cys His Pro Thr Ala Trp Asp Leu Gly            340                 345                 350Lys Gly Asp Phe Arg Ile Leu Met Cys Thr Lys Val Thr Met Asp Asp        355                 360                 365Phe Leu Thr Ala His His Glu Met Gly His Ile Gln Tyr Asp Met Ala    370                 375                 380Tyr Ala Ala Gln Pro Phe Leu Leu Arg Asn Gly Ala Asn Glu Gly Phe385                 390                 395                 400His Glu Ala Val Gly Glu Ile Met Ser Leu Ser Ala Ala Thr Pro Lys                405                 410                 415His Leu Lys Ser Ile Gly Leu Leu Ser Pro Asp Phe Gln Glu Asp Asn            420                 425                 430Glu Thr Glu Ile Asn Phe Leu Leu Lys Gln Ala Leu Thr Ile Val Gly        435                 440                 445Thr Leu Pro Phe Thr Tyr Met Leu Glu Lys Trp Arg Trp Met Val Phe    450                 455                 460Lys Gly Glu Ile Pro Lys Asp Gln Trp Met Lys Lys Trp Trp Glu Met465                 470                 475                 480Lys Arg Glu Ile Val Gly Val Val Glu Pro Val Pro His Asp Glu Thr                485                 490                 495Tyr Cys Asp Pro Ala Ser Leu Phe His Val Ser Asn Asp Tyr Ser Phe            500                 505                 510Ile Arg Tyr Tyr Thr Arg Thr Leu Tyr Gln Phe Gln Phe Gln Glu Ala        515                 520                 525Leu Cys Gln Ala Ala Lys His Glu Gly Pro Leu His Lys Cys Asp Ile    530                 535                 540Ser Asn Ser Thr Glu Ala Gly Gln Lys Leu Phe Asn Met Leu Arg Leu545                 550                 555                 560Gly Lys Ser Glu Pro Trp Thr Leu Ala Leu Glu Asn Val Val Gly Ala                565                 570                 575Lys Asn Met Asn Val Arg Pro Leu Leu Asn Tyr Phe Glu Pro Leu Phe            580                 585                 590Thr Trp Leu Lys Asp Gln Asn Lys Asn Ser Phe Val Gly Trp Ser Thr        595                 600                 605Asp Trp Ser Pro Tyr Ala Asp Gln Ser Ile Lys Val Arg Ile Ser Leu    610                 615                 620Lys Ser Ala Leu Gly Asp Lys Ala Tyr Glu Trp Asn Asp Asn Glu Met625                 630                 635                 640Tyr Leu Phe Arg Ser Ser Val Ala Tyr Ala Met Arg Gln Tyr Phe Leu                645                 650                 655Lys Val Lys Asn Gln Met Ile Leu Phe Gly Glu Glu Asp Val Arg Val            660                 665                 670Ala Asn Leu Lys Pro Arg Ile Ser Phe Asn Phe Phe Val Thr Ala Pro        675                 680                 685Lys Asn Val Ser Asp Ile Ile Pro Arg Thr Glu Val Glu Lys Ala Ile    690                 695                 700Arg Met Ser Arg Ser Arg Ile Asn Asp Ala Phe Arg Leu Asn Asp Asn705                 710                 715                 720Ser Leu Glu Phe Leu Gly Ile Gln Pro Thr Leu Gly Pro Pro Asn Gln                725                 730                 735Pro Pro Val Ser Ile Trp Leu Ile Val Phe Gly Val Val Met Gly Val            740                 745                 750Ile Val Val Gly Ile Val Ile Leu Ile Phe Thr Gly Ile Arg Asp Arg        755                 760                 765Lys Lys Lys Asn Lys Ala Arg Ser Gly Glu Asn Pro Tyr Ala Ser Ile    770                 775                 780Asp Ile Ser Lys Gly Glu Asn Asn Pro Gly Phe Gln Asn Thr Asp Asp785                 790                 795                 800Val Gln Thr Ser Phe                805</s400><s200><s210>20</s210><s211>38</s211><s212>PRT</s212><s213>Severe acute respiratory syndrome coronavirus 2</s213></s200><s400> 20Met Gly Tyr Ile Asn Val Phe Ala Phe Pro Phe Thr Ile Tyr Ser Leu1               5                   10                  15Leu Leu Cys Arg Met Asn Ser Arg Asn Tyr Ile Ala Gln Val Asp Val            20                  25                  30Val Asn Phe Asn Leu Thr        35</s400><s200><s210>21</s210><s211>419</s211><s212>PRT</s212><s213>Severe acute respiratory syndrome coronavirus 2</s213></s200><s400> 21Met Ser Asp Asn Gly Pro Gln Asn Gln Arg Asn Ala Pro Arg Ile Thr1               5                   10                  15Phe Gly Gly Pro Ser Asp Ser Thr Gly Ser Asn Gln Asn Gly Glu Arg            20                  25                  30Ser Gly Ala Arg Ser Lys Gln Arg Arg Pro Gln Gly Leu Pro Asn Asn        35                  40                  45Thr Ala Ser Trp Phe Thr Ala Leu Thr Gln His Gly Lys Glu Asp Leu    50                  55                  60Lys Phe Pro Arg Gly Gln Gly Val Pro Ile Asn Thr Asn Ser Ser Pro65                  70                  75                  80Asp Asp Gln Ile Gly Tyr Tyr Arg Arg Ala Thr Arg Arg Ile Arg Gly                85                  90                  95Gly Asp Gly Lys Met Lys Asp Leu Ser Pro Arg Trp Tyr Phe Tyr Tyr            100                 105                 110Leu Gly Thr Gly Pro Glu Ala Gly Leu Pro Tyr Gly Ala Asn Lys Asp        115                 120                 125Gly Ile Ile Trp Val Ala Thr Glu Gly Ala Leu Asn Thr Pro Lys Asp    130                 135                 140His Ile Gly Thr Arg Asn Pro Ala Asn Asn Ala Ala Ile Val Leu Gln145                 150                 155                 160Leu Pro Gln Gly Thr Thr Leu Pro Lys Gly Phe Tyr Ala Glu Gly Ser                165                 170                 175Arg Gly Gly Ser Gln Ala Ser Ser Arg Ser Ser Ser Arg Ser Arg Asn            180                 185                 190Ser Ser Arg Asn Ser Thr Pro Gly Ser Ser Arg Gly Thr Ser Pro Ala        195                 200                 205Arg Met Ala Gly Asn Gly Gly Asp Ala Ala Leu Ala Leu Leu Leu Leu    210                 215                 220Asp Arg Leu Asn Gln Leu Glu Ser Lys Met Ser Gly Lys Gly Gln Gln225                 230                 235                 240Gln Gln Gly Gln Thr Val Thr Lys Lys Ser Ala Ala Glu Ala Ser Lys                245                 250                 255Lys Pro Arg Gln Lys Arg Thr Ala Thr Lys Ala Tyr Asn Val Thr Gln            260                 265                 270Ala Phe Gly Arg Arg Gly Pro Glu Gln Thr Gln Gly Asn Phe Gly Asp        275                 280                 285Gln Glu Leu Ile Arg Gln Gly Thr Asp Tyr Lys His Trp Pro Gln Ile    290                 295                 300Ala Gln Phe Ala Pro Ser Ala Ser Ala Phe Phe Gly Met Ser Arg Ile305                 310                 315                 320Gly Met Glu Val Thr Pro Ser Gly Thr Trp Leu Thr Tyr Thr Gly Ala                325                 330                 335Ile Lys Leu Asp Asp Lys Asp Pro Asn Phe Lys Asp Gln Val Ile Leu            340                 345                 350Leu Asn Lys His Ile Asp Ala Tyr Lys Thr Phe Pro Pro Thr Glu Pro        355                 360                 365Lys Lys Asp Lys Lys Lys Lys Ala Asp Glu Thr Gln Ala Leu Pro Gln    370                 375                 380Arg Gln Lys Lys Gln Gln Thr Val Thr Leu Leu Pro Ala Ala Asp Leu385                 390                 395                 400Asp Asp Phe Ser Lys Gln Leu Gln Gln Ser Met Ser Ser Ala Asp Ser                405                 410                 415Thr Gln Ala</s400><s200><s210>22</s210><s211>61</s211><s212>PRT</s212><s213>Severe acute respiratory syndrome coronavirus 2</s213></s200><s400> 22Met Phe His Leu Val Asp Phe Gln Val Thr Ile Ala Glu Ile Leu Leu1               5                   10                  15Ile Ile Met Arg Thr Phe Lys Val Ser Ile Trp Asn Leu Asp Tyr Ile            20                  25                  30Ile Asn Leu Ile Ile Lys Asn Leu Ser Lys Ser Leu Thr Glu Asn Lys        35                  40                  45Tyr Ser Gln Leu Asp Glu Glu Gln Pro Met Glu Ile Asp    50                  55                  60</s400><s200><s210>23</s210><s211>7096</s211><s212>PRT</s212><s213>Severe acute respiratory syndrome coronavirus 2</s213></s200><s400> 23Met Glu Ser Leu Val Pro Gly Phe Asn Glu Lys Thr His Val Gln Leu1               5                   10                  15Ser Leu Pro Val Leu Gln Val Arg Asp Val Leu Val Arg Gly Phe Gly            20                  25                  30Asp Ser Val Glu Glu Val Leu Ser Glu Ala Arg Gln His Leu Lys Asp        35                  40                  45Gly Thr Cys Gly Leu Val Glu Val Glu Lys Gly Val Leu Pro Gln Leu    50                  55                  60Glu Gln Pro Tyr Val Phe Ile Lys Arg Ser Asp Ala Arg Thr Ala Pro65                  70                  75                  80His Gly His Val Met Val Glu Leu Val Ala Glu Leu Glu Gly Ile Gln                85                  90                  95Tyr Gly Arg Ser Gly Glu Thr Leu Gly Val Leu Val Pro His Val Gly            100                 105                 110Glu Ile Pro Val Ala Tyr Arg Lys Val Leu Leu Arg Lys Asn Gly Asn        115                 120                 125Lys Gly Ala Gly Gly His Ser Tyr Gly Ala Asp Leu Lys Ser Phe Asp    130                 135                 140Leu Gly Asp Glu Leu Gly Thr Asp Pro Tyr Glu Asp Phe Gln Glu Asn145                 150                 155                 160Trp Asn Thr Lys His Ser Ser Gly Val Thr Arg Glu Leu Met Arg Glu                165                 170                 175Leu Asn Gly Gly Ala Tyr Thr Arg Tyr Val Asp Asn Asn Phe Cys Gly            180                 185                 190Pro Asp Gly Tyr Pro Leu Glu Cys Ile Lys Asp Leu Leu Ala Arg Ala        195                 200                 205Gly Lys Ala Ser Cys Thr Leu Ser Glu Gln Leu Asp Phe Ile Asp Thr    210                 215                 220Lys Arg Gly Val Tyr Cys Cys Arg Glu His Glu His Glu Ile Ala Trp225                 230                 235                 240Tyr Thr Glu Arg Ser Glu Lys Ser Tyr Glu Leu Gln Thr Pro Phe Glu                245                 250                 255Ile Lys Leu Ala Lys Lys Phe Asp Thr Phe Asn Gly Glu Cys Pro Asn            260                 265                 270Phe Val Phe Pro Leu Asn Ser Ile Ile Lys Thr Ile Gln Pro Arg Val        275                 280                 285Glu Lys Lys Lys Leu Asp Gly Phe Met Gly Arg Ile Arg Ser Val Tyr    290                 295                 300Pro Val Ala Ser Pro Asn Glu Cys Asn Gln Met Cys Leu Ser Thr Leu305                 310                 315                 320Met Lys Cys Asp His Cys Gly Glu Thr Ser Trp Gln Thr Gly Asp Phe                325                 330                 335Val Lys Ala Thr Cys Glu Phe Cys Gly Thr Glu Asn Leu Thr Lys Glu            340                 345                 350Gly Ala Thr Thr Cys Gly Tyr Leu Pro Gln Asn Ala Val Val Lys Ile        355                 360                 365Tyr Cys Pro Ala Cys His Asn Ser Glu Val Gly Pro Glu His Ser Leu    370                 375                 380Ala Glu Tyr His Asn Glu Ser Gly Leu Lys Thr Ile Leu Arg Lys Gly385                 390                 395                 400Gly Arg Thr Ile Ala Phe Gly Gly Cys Val Phe Ser Tyr Val Gly Cys                405                 410                 415His Asn Lys Cys Ala Tyr Trp Val Pro Arg Ala Ser Ala Asn Ile Gly            420                 425                 430Cys Asn His Thr Gly Val Val Gly Glu Gly Ser Glu Gly Leu Asn Asp        435                 440                 445Asn Leu Leu Glu Ile Leu Gln Lys Glu Lys Val Asn Ile Asn Ile Val    450                 455                 460Gly Asp Phe Lys Leu Asn Glu Glu Ile Ala Ile Ile Leu Ala Ser Phe465                 470                 475                 480Ser Ala Ser Thr Ser Ala Phe Val Glu Thr Val Lys Gly Leu Asp Tyr                485                 490                 495Lys Ala Phe Lys Gln Ile Val Glu Ser Cys Gly Asn Phe Lys Val Thr            500                 505                 510Lys Gly Lys Ala Lys Lys Gly Ala Trp Asn Ile Gly Glu Gln Lys Ser        515                 520                 525Ile Leu Ser Pro Leu Tyr Ala Phe Ala Ser Glu Ala Ala Arg Val Val    530                 535                 540Arg Ser Ile Phe Ser Arg Thr Leu Glu Thr Ala Gln Asn Ser Val Arg545                 550                 555                 560Val Leu Gln Lys Ala Ala Ile Thr Ile Leu Asp Gly Ile Ser Gln Tyr                565                 570                 575Ser Leu Arg Leu Ile Asp Ala Met Met Phe Thr Ser Asp Leu Ala Thr            580                 585                 590Asn Asn Leu Val Val Met Ala Tyr Ile Thr Gly Gly Val Val Gln Leu        595                 600                 605Thr Ser Gln Trp Leu Thr Asn Ile Phe Gly Thr Val Tyr Glu Lys Leu    610                 615                 620Lys Pro Val Leu Asp Trp Leu Glu Glu Lys Phe Lys Glu Gly Val Glu625                 630                 635                 640Phe Leu Arg Asp Gly Trp Glu Ile Val Lys Phe Ile Ser Thr Cys Ala                645                 650                 655Cys Glu Ile Val Gly Gly Gln Ile Val Thr Cys Ala Lys Glu Ile Lys            660                 665                 670Glu Ser Val Gln Thr Phe Phe Lys Leu Val Asn Lys Phe Leu Ala Leu        675                 680                 685Cys Ala Asp Ser Ile Ile Ile Gly Gly Ala Lys Leu Lys Ala Leu Asn    690                 695                 700Leu Gly Glu Thr Phe Val Thr His Ser Lys Gly Leu Tyr Arg Lys Cys705                 710                 715                 720Val Lys Ser Arg Glu Glu Thr Gly Leu Leu Met Pro Leu Lys Ala Pro                725                 730                 735Lys Glu Ile Ile Phe Leu Glu Gly Glu Thr Leu Pro Thr Glu Val Leu            740                 745                 750Thr Glu Glu Val Val Leu Lys Thr Gly Asp Leu Gln Pro Leu Glu Gln        755                 760                 765Pro Thr Ser Glu Ala Val Glu Ala Pro Leu Val Gly Thr Pro Val Cys    770                 775                 780Ile Asn Gly Leu Met Leu Leu Glu Ile Lys Asp Thr Glu Lys Tyr Cys785                 790                 795                 800Ala Leu Ala Pro Asn Met Met Val Thr Asn Asn Thr Phe Thr Leu Lys                805                 810                 815Gly Gly Ala Pro Thr Lys Val Thr Phe Gly Asp Asp Thr Val Ile Glu            820                 825                 830Val Gln Gly Tyr Lys Ser Val Asn Ile Thr Phe Glu Leu Asp Glu Arg        835                 840                 845Ile Asp Lys Val Leu Asn Glu Lys Cys Ser Ala Tyr Thr Val Glu Leu    850                 855                 860Gly Thr Glu Val Asn Glu Phe Ala Cys Val Val Ala Asp Ala Val Ile865                 870                 875                 880Lys Thr Leu Gln Pro Val Ser Glu Leu Leu Thr Pro Leu Gly Ile Asp                885                 890                 895Leu Asp Glu Trp Ser Met Ala Thr Tyr Tyr Leu Phe Asp Glu Ser Gly            900                 905                 910Glu Phe Lys Leu Ala Ser His Met Tyr Cys Ser Phe Tyr Pro Pro Asp        915                 920                 925Glu Asp Glu Glu Glu Gly Asp Cys Glu Glu Glu Glu Phe Glu Pro Ser    930                 935                 940Thr Gln Tyr Glu Tyr Gly Thr Glu Asp Asp Tyr Gln Gly Lys Pro Leu945                 950                 955                 960Glu Phe Gly Ala Thr Ser Ala Ala Leu Gln Pro Glu Glu Glu Gln Glu                965                 970                 975Glu Asp Trp Leu Asp Asp Asp Ser Gln Gln Thr Val Gly Gln Gln Asp            980                 985                 990Gly Ser Glu Asp Asn Gln Thr Thr  Thr Ile Gln Thr Ile  Val Glu Val        995                 1000                 1005Gln Pro  Gln Leu Glu Met Glu  Leu Thr Pro Val Val  Gln Thr Ile    1010                 1015                 1020Glu Val  Asn Ser Phe Ser Gly  Tyr Leu Lys Leu Thr  Asp Asn Val    1025                 1030                 1035Tyr Ile  Lys Asn Ala Asp Ile  Val Glu Glu Ala Lys  Lys Val Lys    1040                 1045                 1050Pro Thr  Val Val Val Asn Ala  Ala Asn Val Tyr Leu  Lys His Gly    1055                 1060                 1065Gly Gly  Val Ala Gly Ala Leu  Asn Lys Ala Thr Asn  Asn Ala Met    1070                 1075                 1080Gln Val  Glu Ser Asp Asp Tyr  Ile Ala Thr Asn Gly  Pro Leu Lys    1085                 1090                 1095Val Gly  Gly Ser Cys Val Leu  Ser Gly His Asn Leu  Ala Lys His    1100                 1105                 1110Cys Leu  His Val Val Gly Pro  Asn Val Asn Lys Gly  Glu Asp Ile    1115                 1120                 1125Gln Leu  Leu Lys Ser Ala Tyr  Glu Asn Phe Asn Gln  His Glu Val    1130                 1135                 1140Leu Leu  Ala Pro Leu Leu Ser  Ala Gly Ile Phe Gly  Ala Asp Pro    1145                 1150                 1155Ile His  Ser Leu Arg Val Cys  Val Asp Thr Val Arg  Thr Asn Val    1160                 1165                 1170Tyr Leu  Ala Val Phe Asp Lys  Asn Leu Tyr Asp Lys  Leu Val Ser    1175                 1180                 1185Ser Phe  Leu Glu Met Lys Ser  Glu Lys Gln Val Glu  Gln Lys Ile    1190                 1195                 1200Ala Glu  Ile Pro Lys Glu Glu  Val Lys Pro Phe Ile  Thr Glu Ser    1205                 1210                 1215Lys Pro  Ser Val Glu Gln Arg  Lys Gln Asp Asp Lys  Lys Ile Lys    1220                 1225                 1230Ala Cys  Val Glu Glu Val Thr  Thr Thr Leu Glu Glu  Thr Lys Phe    1235                 1240                 1245Leu Thr  Glu Asn Leu Leu Leu  Tyr Ile Asp Ile Asn  Gly Asn Leu    1250                 1255                 1260His Pro  Asp Ser Ala Thr Leu  Val Ser Asp Ile Asp  Ile Thr Phe    1265                 1270                 1275Leu Lys  Lys Asp Ala Pro Tyr  Ile Val Gly Asp Val  Val Gln Glu    1280                 1285                 1290Gly Val  Leu Thr Ala Val Val  Ile Pro Thr Lys Lys  Ala Gly Gly    1295                 1300                 1305Thr Thr  Glu Met Leu Ala Lys  Ala Leu Arg Lys Val  Pro Thr Asp    1310                 1315                 1320Asn Tyr  Ile Thr Thr Tyr Pro  Gly Gln Gly Leu Asn  Gly Tyr Thr    1325                 1330                 1335Val Glu  Glu Ala Lys Thr Val  Leu Lys Lys Cys Lys  Ser Ala Phe    1340                 1345                 1350Tyr Ile  Leu Pro Ser Ile Ile  Ser Asn Glu Lys Gln  Glu Ile Leu    1355                 1360                 1365Gly Thr  Val Ser Trp Asn Leu  Arg Glu Met Leu Ala  His Ala Glu    1370                 1375                 1380Glu Thr  Arg Lys Leu Met Pro  Val Cys Val Glu Thr  Lys Ala Ile    1385                 1390                 1395Val Ser  Thr Ile Gln Arg Lys  Tyr Lys Gly Ile Lys  Ile Gln Glu    1400                 1405                 1410Gly Val  Val Asp Tyr Gly Ala  Arg Phe Tyr Phe Tyr  Thr Ser Lys    1415                 1420                 1425Thr Thr  Val Ala Ser Leu Ile  Asn Thr Leu Asn Asp  Leu Asn Glu    1430                 1435                 1440Thr Leu  Val Thr Met Pro Leu  Gly Tyr Val Thr His  Gly Leu Asn    1445                 1450                 1455Leu Glu  Glu Ala Ala Arg Tyr  Met Arg Ser Leu Lys  Val Pro Ala    1460                 1465                 1470Thr Val  Ser Val Ser Ser Pro  Asp Ala Val Thr Ala  Tyr Asn Gly    1475                 1480                 1485Tyr Leu  Thr Ser Ser Ser Lys  Thr Pro Glu Glu His  Phe Ile Glu    1490                 1495                 1500Thr Ile  Ser Leu Ala Gly Ser  Tyr Lys Asp Trp Ser  Tyr Ser Gly    1505                 1510                 1515Gln Ser  Thr Gln Leu Gly Ile  Glu Phe Leu Lys Arg  Gly Asp Lys    1520                 1525                 1530Ser Val  Tyr Tyr Thr Ser Asn  Pro Thr Thr Phe His  Leu Asp Gly    1535                 1540                 1545Glu Val  Ile Thr Phe Asp Asn  Leu Lys Thr Leu Leu  Ser Leu Arg    1550                 1555                 1560Glu Val  Arg Thr Ile Lys Val  Phe Thr Thr Val Asp  Asn Ile Asn    1565                 1570                 1575Leu His  Thr Gln Val Val Asp  Met Ser Met Thr Tyr  Gly Gln Gln    1580                 1585                 1590Phe Gly  Pro Thr Tyr Leu Asp  Gly Ala Asp Val Thr  Lys Ile Lys    1595                 1600                 1605Pro His  Asn Ser His Glu Gly  Lys Thr Phe Tyr Val  Leu Pro Asn    1610                 1615                 1620Asp Asp  Thr Leu Arg Val Glu  Ala Phe Glu Tyr Tyr  His Thr Thr    1625                 1630                 1635Asp Pro  Ser Phe Leu Gly Arg  Tyr Met Ser Ala Leu  Asn His Thr    1640                 1645                 1650Lys Lys  Trp Lys Tyr Pro Gln  Val Asn Gly Leu Thr  Ser Ile Lys    1655                 1660                 1665Trp Ala  Asp Asn Asn Cys Tyr  Leu Ala Thr Ala Leu  Leu Thr Leu    1670                 1675                 1680Gln Gln  Ile Glu Leu Lys Phe  Asn Pro Pro Ala Leu  Gln Asp Ala    1685                 1690                 1695Tyr Tyr  Arg Ala Arg Ala Gly  Glu Ala Ala Asn Phe  Cys Ala Leu    1700                 1705                 1710Ile Leu  Ala Tyr Cys Asn Lys  Thr Val Gly Glu Leu  Gly Asp Val    1715                 1720                 1725Arg Glu  Thr Met Ser Tyr Leu  Phe Gln His Ala Asn  Leu Asp Ser    1730                 1735                 1740Cys Lys  Arg Val Leu Asn Val  Val Cys Lys Thr Cys  Gly Gln Gln    1745                 1750                 1755Gln Thr  Thr Leu Lys Gly Val  Glu Ala Val Met Tyr  Met Gly Thr    1760                 1765                 1770Leu Ser  Tyr Glu Gln Phe Lys  Lys Gly Val Gln Ile  Pro Cys Thr    1775                 1780                 1785Cys Gly  Lys Gln Ala Thr Lys  Tyr Leu Val Gln Gln  Glu Ser Pro    1790                 1795                 1800Phe Val  Met Met Ser Ala Pro  Pro Ala Gln Tyr Glu  Leu Lys His    1805                 1810                 1815Gly Thr  Phe Thr Cys Ala Ser  Glu Tyr Thr Gly Asn  Tyr Gln Cys    1820                 1825                 1830Gly His  Tyr Lys His Ile Thr  Ser Lys Glu Thr Leu  Tyr Cys Ile    1835                 1840                 1845Asp Gly  Ala Leu Leu Thr Lys  Ser Ser Glu Tyr Lys  Gly Pro Ile    1850                 1855                 1860Thr Asp  Val Phe Tyr Lys Glu  Asn Ser Tyr Thr Thr  Thr Ile Lys    1865                 1870                 1875Pro Val  Thr Tyr Lys Leu Asp  Gly Val Val Cys Thr  Glu Ile Asp    1880                 1885                 1890Pro Lys  Leu Asp Asn Tyr Tyr  Lys Lys Asp Asn Ser  Tyr Phe Thr    1895                 1900                 1905Glu Gln  Pro Ile Asp Leu Val  Pro Asn Gln Pro Tyr  Pro Asn Ala    1910                 1915                 1920Ser Phe  Asp Asn Phe Lys Phe  Val Cys Asp Asn Ile  Lys Phe Ala    1925                 1930                 1935Asp Asp  Leu Asn Gln Leu Thr  Gly Tyr Lys Lys Pro  Ala Ser Arg    1940                 1945                 1950Glu Leu  Lys Val Thr Phe Phe  Pro Asp Leu Asn Gly  Asp Val Val    1955                 1960                 1965Ala Ile  Asp Tyr Lys His Tyr  Thr Pro Ser Phe Lys  Lys Gly Ala    1970                 1975                 1980Lys Leu  Leu His Lys Pro Ile  Val Trp His Val Asn  Asn Ala Thr    1985                 1990                 1995Asn Lys  Ala Thr Tyr Lys Pro  Asn Thr Trp Cys Ile  Arg Cys Leu    2000                 2005                 2010Trp Ser  Thr Lys Pro Val Glu  Thr Ser Asn Ser Phe  Asp Val Leu    2015                 2020                 2025Lys Ser  Glu Asp Ala Gln Gly  Met Asp Asn Leu Ala  Cys Glu Asp    2030                 2035                 2040Leu Lys  Pro Val Ser Glu Glu  Val Val Glu Asn Pro  Thr Ile Gln    2045                 2050                 2055Lys Asp  Val Leu Glu Cys Asn  Val Lys Thr Thr Glu  Val Val Gly    2060                 2065                 2070Asp Ile  Ile Leu Lys Pro Ala  Asn Asn Ser Leu Lys  Ile Thr Glu    2075                 2080                 2085Glu Val  Gly His Thr Asp Leu  Met Ala Ala Tyr Val  Asp Asn Ser    2090                 2095                 2100Ser Leu  Thr Ile Lys Lys Pro  Asn Glu Leu Ser Arg  Val Leu Gly    2105                 2110                 2115Leu Lys  Thr Leu Ala Thr His  Gly Leu Ala Ala Val  Asn Ser Val    2120                 2125                 2130Pro Trp  Asp Thr Ile Ala Asn  Tyr Ala Lys Pro Phe  Leu Asn Lys    2135                 2140                 2145Val Val  Ser Thr Thr Thr Asn  Ile Val Thr Arg Cys  Leu Asn Arg    2150                 2155                 2160Val Cys  Thr Asn Tyr Met Pro  Tyr Phe Phe Thr Leu  Leu Leu Gln    2165                 2170                 2175Leu Cys  Thr Phe Thr Arg Ser  Thr Asn Ser Arg Ile  Lys Ala Ser    2180                 2185                 2190Met Pro  Thr Thr Ile Ala Lys  Asn Thr Val Lys Ser  Val Gly Lys    2195                 2200                 2205Phe Cys  Leu Glu Ala Ser Phe  Asn Tyr Leu Lys Ser  Pro Asn Phe    2210                 2215                 2220Ser Lys  Leu Ile Asn Ile Ile  Ile Trp Phe Leu Leu  Leu Ser Val    2225                 2230                 2235Cys Leu  Gly Ser Leu Ile Tyr  Ser Thr Ala Ala Leu  Gly Val Leu    2240                 2245                 2250Met Ser  Asn Leu Gly Met Pro  Ser Tyr Cys Thr Gly  Tyr Arg Glu    2255                 2260                 2265Gly Tyr  Leu Asn Ser Thr Asn  Val Thr Ile Ala Thr  Tyr Cys Thr    2270                 2275                 2280Gly Ser  Ile Pro Cys Ser Val  Cys Leu Ser Gly Leu  Asp Ser Leu    2285                 2290                 2295Asp Thr  Tyr Pro Ser Leu Glu  Thr Ile Gln Ile Thr  Ile Ser Ser    2300                 2305                 2310Phe Lys  Trp Asp Leu Thr Ala  Phe Gly Leu Val Ala  Glu Trp Phe    2315                 2320                 2325Leu Ala  Tyr Ile Leu Phe Thr  Arg Phe Phe Tyr Val  Leu Gly Leu    2330                 2335                 2340Ala Ala  Ile Met Gln Leu Phe  Phe Ser Tyr Phe Ala  Val His Phe    2345                 2350                 2355Ile Ser  Asn Ser Trp Leu Met  Trp Leu Ile Ile Asn  Leu Val Gln    2360                 2365                 2370Met Ala  Pro Ile Ser Ala Met  Val Arg Met Tyr Ile  Phe Phe Ala    2375                 2380                 2385Ser Phe  Tyr Tyr Val Trp Lys  Ser Tyr Val His Val  Val Asp Gly    2390                 2395                 2400Cys Asn  Ser Ser Thr Cys Met  Met Cys Tyr Lys Arg  Asn Arg Ala    2405                 2410                 2415Thr Arg  Val Glu Cys Thr Thr  Ile Val Asn Gly Val  Arg Arg Ser    2420                 2425                 2430Phe Tyr  Val Tyr Ala Asn Gly  Gly Lys Gly Phe Cys  Lys Leu His    2435                 2440                 2445Asn Trp  Asn Cys Val Asn Cys  Asp Thr Phe Cys Ala  Gly Ser Thr    2450                 2455                 2460Phe Ile  Ser Asp Glu Val Ala  Arg Asp Leu Ser Leu  Gln Phe Lys    2465                 2470                 2475Arg Pro  Ile Asn Pro Thr Asp  Gln Ser Ser Tyr Ile  Val Asp Ser    2480                 2485                 2490Val Thr  Val Lys Asn Gly Ser  Ile His Leu Tyr Phe  Asp Lys Ala    2495                 2500                 2505Gly Gln  Lys Thr Tyr Glu Arg  His Ser Leu Ser His  Phe Val Asn    2510                 2515                 2520Leu Asp  Asn Leu Arg Ala Asn  Asn Thr Lys Gly Ser  Leu Pro Ile    2525                 2530                 2535Asn Val  Ile Val Phe Asp Gly  Lys Ser Lys Cys Glu  Glu Ser Ser    2540                 2545                 2550Ala Lys  Ser Ala Ser Val Tyr  Tyr Ser Gln Leu Met  Cys Gln Pro    2555                 2560                 2565Ile Leu  Leu Leu Asp Gln Ala  Leu Val Ser Asp Val  Gly Asp Ser    2570                 2575                 2580Ala Glu  Val Ala Val Lys Met  Phe Asp Ala Tyr Val  Asn Thr Phe    2585                 2590                 2595Ser Ser  Thr Phe Asn Val Pro  Met Glu Lys Leu Lys  Thr Leu Val    2600                 2605                 2610Ala Thr  Ala Glu Ala Glu Leu  Ala Lys Asn Val Ser  Leu Asp Asn    2615                 2620                 2625Val Leu  Ser Thr Phe Ile Ser  Ala Ala Arg Gln Gly  Phe Val Asp    2630                 2635                 2640Ser Asp  Val Glu Thr Lys Asp  Val Val Glu Cys Leu  Lys Leu Ser    2645                 2650                 2655His Gln  Ser Asp Ile Glu Val  Thr Gly Asp Ser Cys  Asn Asn Tyr    2660                 2665                 2670Met Leu  Thr Tyr Asn Lys Val  Glu Asn Met Thr Pro  Arg Asp Leu    2675                 2680                 2685Gly Ala  Cys Ile Asp Cys Ser  Ala Arg His Ile Asn  Ala Gln Val    2690                 2695                 2700Ala Lys  Ser His Asn Ile Ala  Leu Ile Trp Asn Val  Lys Asp Phe    2705                 2710                 2715Met Ser  Leu Ser Glu Gln Leu  Arg Lys Gln Ile Arg  Ser Ala Ala    2720                 2725                 2730Lys Lys  Asn Asn Leu Pro Phe  Lys Leu Thr Cys Ala  Thr Thr Arg    2735                 2740                 2745Gln Val  Val Asn Val Val Thr  Thr Lys Ile Ala Leu  Lys Gly Gly    2750                 2755                 2760Lys Ile  Val Asn Asn Trp Leu  Lys Gln Leu Ile Lys  Val Thr Leu    2765                 2770                 2775Val Phe  Leu Phe Val Ala Ala  Ile Phe Tyr Leu Ile  Thr Pro Val    2780                 2785                 2790His Val  Met Ser Lys His Thr  Asp Phe Ser Ser Glu  Ile Ile Gly    2795                 2800                 2805Tyr Lys  Ala Ile Asp Gly Gly  Val Thr Arg Asp Ile  Ala Ser Thr    2810                 2815                 2820Asp Thr  Cys Phe Ala Asn Lys  His Ala Asp Phe Asp  Thr Trp Phe    2825                 2830                 2835Ser Gln  Arg Gly Gly Ser Tyr  Thr Asn Asp Lys Ala  Cys Pro Leu    2840                 2845                 2850Ile Ala  Ala Val Ile Thr Arg  Glu Val Gly Phe Val  Val Pro Gly    2855                 2860                 2865Leu Pro  Gly Thr Ile Leu Arg  Thr Thr Asn Gly Asp  Phe Leu His    2870                 2875                 2880Phe Leu  Pro Arg Val Phe Ser  Ala Val Gly Asn Ile  Cys Tyr Thr    2885                 2890                 2895Pro Ser  Lys Leu Ile Glu Tyr  Thr Asp Phe Ala Thr  Ser Ala Cys    2900                 2905                 2910Val Leu  Ala Ala Glu Cys Thr  Ile Phe Lys Asp Ala  Ser Gly Lys    2915                 2920                 2925Pro Val  Pro Tyr Cys Tyr Asp  Thr Asn Val Leu Glu  Gly Ser Val    2930                 2935                 2940Ala Tyr  Glu Ser Leu Arg Pro  Asp Thr Arg Tyr Val  Leu Met Asp    2945                 2950                 2955Gly Ser  Ile Ile Gln Phe Pro  Asn Thr Tyr Leu Glu  Gly Ser Val    2960                 2965                 2970Arg Val  Val Thr Thr Phe Asp  Ser Glu Tyr Cys Arg  His Gly Thr    2975                 2980                 2985Cys Glu  Arg Ser Glu Ala Gly  Val Cys Val Ser Thr  Ser Gly Arg    2990                 2995                 3000Trp Val  Leu Asn Asn Asp Tyr  Tyr Arg Ser Leu Pro  Gly Val Phe    3005                 3010                 3015Cys Gly  Val Asp Ala Val Asn  Leu Leu Thr Asn Met  Phe Thr Pro    3020                 3025                 3030Leu Ile  Gln Pro Ile Gly Ala  Leu Asp Ile Ser Ala  Ser Ile Val    3035                 3040                 3045Ala Gly  Gly Ile Val Ala Ile  Val Val Thr Cys Leu  Ala Tyr Tyr    3050                 3055                 3060Phe Met  Arg Phe Arg Arg Ala  Phe Gly Glu Tyr Ser  His Val Val    3065                 3070                 3075Ala Phe  Asn Thr Leu Leu Phe  Leu Met Ser Phe Thr  Val Leu Cys    3080                 3085                 3090Leu Thr  Pro Val Tyr Ser Phe  Leu Pro Gly Val Tyr  Ser Val Ile    3095                 3100                 3105Tyr Leu  Tyr Leu Thr Phe Tyr  Leu Thr Asn Asp Val  Ser Phe Leu    3110                 3115                 3120Ala His  Ile Gln Trp Met Val  Met Phe Thr Pro Leu  Val Pro Phe    3125                 3130                 3135Trp Ile  Thr Ile Ala Tyr Ile  Ile Cys Ile Ser Thr  Lys His Phe    3140                 3145                 3150Tyr Trp  Phe Phe Ser Asn Tyr  Leu Lys Arg Arg Val  Val Phe Asn    3155                 3160                 3165Gly Val  Ser Phe Ser Thr Phe  Glu Glu Ala Ala Leu  Cys Thr Phe    3170                 3175                 3180Leu Leu  Asn Lys Glu Met Tyr  Leu Lys Leu Arg Ser  Asp Val Leu    3185                 3190                 3195Leu Pro  Leu Thr Gln Tyr Asn  Arg Tyr Leu Ala Leu  Tyr Asn Lys    3200                 3205                 3210Tyr Lys  Tyr Phe Ser Gly Ala  Met Asp Thr Thr Ser  Tyr Arg Glu    3215                 3220                 3225Ala Ala  Cys Cys His Leu Ala  Lys Ala Leu Asn Asp  Phe Ser Asn    3230                 3235                 3240Ser Gly  Ser Asp Val Leu Tyr  Gln Pro Pro Gln Thr  Ser Ile Thr    3245                 3250                 3255Ser Ala  Val Leu Gln Ser Gly  Phe Arg Lys Met Ala  Phe Pro Ser    3260                 3265                 3270Gly Lys  Val Glu Gly Cys Met  Val Gln Val Thr Cys  Gly Thr Thr    3275                 3280                 3285Thr Leu  Asn Gly Leu Trp Leu  Asp Asp Val Val Tyr  Cys Pro Arg    3290                 3295                 3300His Val  Ile Cys Thr Ser Glu  Asp Met Leu Asn Pro  Asn Tyr Glu    3305                 3310                 3315Asp Leu  Leu Ile Arg Lys Ser  Asn His Asn Phe Leu  Val Gln Ala    3320                 3325                 3330Gly Asn  Val Gln Leu Arg Val  Ile Gly His Ser Met  Gln Asn Cys    3335                 3340                 3345Val Leu  Lys Leu Lys Val Asp  Thr Ala Asn Pro Lys  Thr Pro Lys    3350                 3355                 3360Tyr Lys  Phe Val Arg Ile Gln  Pro Gly Gln Thr Phe  Ser Val Leu    3365                 3370                 3375Ala Cys  Tyr Asn Gly Ser Pro  Ser Gly Val Tyr Gln  Cys Ala Met    3380                 3385                 3390Arg Pro  Asn Phe Thr Ile Lys  Gly Ser Phe Leu Asn  Gly Ser Cys    3395                 3400                 3405Gly Ser  Val Gly Phe Asn Ile  Asp Tyr Asp Cys Val  Ser Phe Cys    3410                 3415                 3420Tyr Met  His His Met Glu Leu  Pro Thr Gly Val His  Ala Gly Thr    3425                 3430                 3435Asp Leu  Glu Gly Asn Phe Tyr  Gly Pro Phe Val Asp  Arg Gln Thr    3440                 3445                 3450Ala Gln  Ala Ala Gly Thr Asp  Thr Thr Ile Thr Val  Asn Val Leu    3455                 3460                 3465Ala Trp  Leu Tyr Ala Ala Val  Ile Asn Gly Asp Arg  Trp Phe Leu    3470                 3475                 3480Asn Arg  Phe Thr Thr Thr Leu  Asn Asp Phe Asn Leu  Val Ala Met    3485                 3490                 3495Lys Tyr  Asn Tyr Glu Pro Leu  Thr Gln Asp His Val  Asp Ile Leu    3500                 3505                 3510Gly Pro  Leu Ser Ala Gln Thr  Gly Ile Ala Val Leu  Asp Met Cys    3515                 3520                 3525Ala Ser  Leu Lys Glu Leu Leu  Gln Asn Gly Met Asn  Gly Arg Thr    3530                 3535                 3540Ile Leu  Gly Ser Ala Leu Leu  Glu Asp Glu Phe Thr  Pro Phe Asp    3545                 3550                 3555Val Val  Arg Gln Cys Ser Gly  Val Thr Phe Gln Ser  Ala Val Lys    3560                 3565                 3570Arg Thr  Ile Lys Gly Thr His  His Trp Leu Leu Leu  Thr Ile Leu    3575                 3580                 3585Thr Ser  Leu Leu Val Leu Val  Gln Ser Thr Gln Trp  Ser Leu Phe    3590                 3595                 3600Phe Phe  Leu Tyr Glu Asn Ala  Phe Leu Pro Phe Ala  Met Gly Ile    3605                 3610                 3615Ile Ala  Met Ser Ala Phe Ala  Met Met Phe Val Lys  His Lys His    3620                 3625                 3630Ala Phe  Leu Cys Leu Phe Leu  Leu Pro Ser Leu Ala  Thr Val Ala    3635                 3640                 3645Tyr Phe  Asn Met Val Tyr Met  Pro Ala Ser Trp Val  Met Arg Ile    3650                 3655                 3660Met Thr  Trp Leu Asp Met Val  Asp Thr Ser Leu Ser  Gly Phe Lys    3665                 3670                 3675Leu Lys  Asp Cys Val Met Tyr  Ala Ser Ala Val Val  Leu Leu Ile    3680                 3685                 3690Leu Met  Thr Ala Arg Thr Val  Tyr Asp Asp Gly Ala  Arg Arg Val    3695                 3700                 3705Trp Thr  Leu Met Asn Val Leu  Thr Leu Val Tyr Lys  Val Tyr Tyr    3710                 3715                 3720Gly Asn  Ala Leu Asp Gln Ala  Ile Ser Met Trp Ala  Leu Ile Ile    3725                 3730                 3735Ser Val  Thr Ser Asn Tyr Ser  Gly Val Val Thr Thr  Val Met Phe    3740                 3745                 3750Leu Ala  Arg Gly Ile Val Phe  Met Cys Val Glu Tyr  Cys Pro Ile    3755                 3760                 3765Phe Phe  Ile Thr Gly Asn Thr  Leu Gln Cys Ile Met  Leu Val Tyr    3770                 3775                 3780Cys Phe  Leu Gly Tyr Phe Cys  Thr Cys Tyr Phe Gly  Leu Phe Cys    3785                 3790                 3795Leu Leu  Asn Arg Tyr Phe Arg  Leu Thr Leu Gly Val  Tyr Asp Tyr    3800                 3805                 3810Leu Val  Ser Thr Gln Glu Phe  Arg Tyr Met Asn Ser  Gln Gly Leu    3815                 3820                 3825Leu Pro  Pro Lys Asn Ser Ile  Asp Ala Phe Lys Leu  Asn Ile Lys    3830                 3835                 3840Leu Leu  Gly Val Gly Gly Lys  Pro Cys Ile Lys Val  Ala Thr Val    3845                 3850                 3855Gln Ser  Lys Met Ser Asp Val  Lys Cys Thr Ser Val  Val Leu Leu    3860                 3865                 3870Ser Val  Leu Gln Gln Leu Arg  Val Glu Ser Ser Ser  Lys Leu Trp    3875                 3880                 3885Ala Gln  Cys Val Gln Leu His  Asn Asp Ile Leu Leu  Ala Lys Asp    3890                 3895                 3900Thr Thr  Glu Ala Phe Glu Lys  Met Val Ser Leu Leu  Ser Val Leu    3905                 3910                 3915Leu Ser  Met Gln Gly Ala Val  Asp Ile Asn Lys Leu  Cys Glu Glu    3920                 3925                 3930Met Leu  Asp Asn Arg Ala Thr  Leu Gln Ala Ile Ala  Ser Glu Phe    3935                 3940                 3945Ser Ser  Leu Pro Ser Tyr Ala  Ala Phe Ala Thr Ala  Gln Glu Ala    3950                 3955                 3960Tyr Glu  Gln Ala Val Ala Asn  Gly Asp Ser Glu Val  Val Leu Lys    3965                 3970                 3975Lys Leu  Lys Lys Ser Leu Asn  Val Ala Lys Ser Glu  Phe Asp Arg    3980                 3985                 3990Asp Ala  Ala Met Gln Arg Lys  Leu Glu Lys Met Ala  Asp Gln Ala    3995                 4000                 4005Met Thr  Gln Met Tyr Lys Gln  Ala Arg Ser Glu Asp  Lys Arg Ala    4010                 4015                 4020Lys Val  Thr Ser Ala Met Gln  Thr Met Leu Phe Thr  Met Leu Arg    4025                 4030                 4035Lys Leu  Asp Asn Asp Ala Leu  Asn Asn Ile Ile Asn  Asn Ala Arg    4040                 4045                 4050Asp Gly  Cys Val Pro Leu Asn  Ile Ile Pro Leu Thr  Thr Ala Ala    4055                 4060                 4065Lys Leu  Met Val Val Ile Pro  Asp Tyr Asn Thr Tyr  Lys Asn Thr    4070                 4075                 4080Cys Asp  Gly Thr Thr Phe Thr  Tyr Ala Ser Ala Leu  Trp Glu Ile    4085                 4090                 4095Gln Gln  Val Val Asp Ala Asp  Ser Lys Ile Val Gln  Leu Ser Glu    4100                 4105                 4110Ile Ser  Met Asp Asn Ser Pro  Asn Leu Ala Trp Pro  Leu Ile Val    4115                 4120                 4125Thr Ala  Leu Arg Ala Asn Ser  Ala Val Lys Leu Gln  Asn Asn Glu    4130                 4135                 4140Leu Ser  Pro Val Ala Leu Arg  Gln Met Ser Cys Ala  Ala Gly Thr    4145                 4150                 4155Thr Gln  Thr Ala Cys Thr Asp  Asp Asn Ala Leu Ala  Tyr Tyr Asn    4160                 4165                 4170Thr Thr  Lys Gly Gly Arg Phe  Val Leu Ala Leu Leu  Ser Asp Leu    4175                 4180                 4185Gln Asp  Leu Lys Trp Ala Arg  Phe Pro Lys Ser Asp  Gly Thr Gly    4190                 4195                 4200Thr Ile  Tyr Thr Glu Leu Glu  Pro Pro Cys Arg Phe  Val Thr Asp    4205                 4210                 4215Thr Pro  Lys Gly Pro Lys Val  Lys Tyr Leu Tyr Phe  Ile Lys Gly    4220                 4225                 4230Leu Asn  Asn Leu Asn Arg Gly  Met Val Leu Gly Ser  Leu Ala Ala    4235                 4240                 4245Thr Val  Arg Leu Gln Ala Gly  Asn Ala Thr Glu Val  Pro Ala Asn    4250                 4255                 4260Ser Thr  Val Leu Ser Phe Cys  Ala Phe Ala Val Asp  Ala Ala Lys    4265                 4270                 4275Ala Tyr  Lys Asp Tyr Leu Ala  Ser Gly Gly Gln Pro  Ile Thr Asn    4280                 4285                 4290Cys Val  Lys Met Leu Cys Thr  His Thr Gly Thr Gly  Gln Ala Ile    4295                 4300                 4305Thr Val  Thr Pro Glu Ala Asn  Met Asp Gln Glu Ser  Phe Gly Gly    4310                 4315                 4320Ala Ser  Cys Cys Leu Tyr Cys  Arg Cys His Ile Asp  His Pro Asn    4325                 4330                 4335Pro Lys  Gly Phe Cys Asp Leu  Lys Gly Lys Tyr Val  Gln Ile Pro    4340                 4345                 4350Thr Thr  Cys Ala Asn Asp Pro  Val Gly Phe Thr Leu  Lys Asn Thr    4355                 4360                 4365Val Cys  Thr Val Cys Gly Met  Trp Lys Gly Tyr Gly  Cys Ser Cys    4370                 4375                 4380Asp Gln  Leu Arg Glu Pro Met  Leu Gln Ser Ala Asp  Ala Gln Ser    4385                 4390                 4395Phe Leu  Asn Arg Val Cys Gly  Val Ser Ala Ala Arg  Leu Thr Pro    4400                 4405                 4410Cys Gly  Thr Gly Thr Ser Thr  Asp Val Val Tyr Arg  Ala Phe Asp    4415                 4420                 4425Ile Tyr  Asn Asp Lys Val Ala  Gly Phe Ala Lys Phe  Leu Lys Thr    4430                 4435                 4440Asn Cys  Cys Arg Phe Gln Glu  Lys Asp Glu Asp Asp  Asn Leu Ile    4445                 4450                 4455Asp Ser  Tyr Phe Val Val Lys  Arg His Thr Phe Ser  Asn Tyr Gln    4460                 4465                 4470His Glu  Glu Thr Ile Tyr Asn  Leu Leu Lys Asp Cys  Pro Ala Val    4475                 4480                 4485Ala Lys  His Asp Phe Phe Lys  Phe Arg Ile Asp Gly  Asp Met Val    4490                 4495                 4500Pro His  Ile Ser Arg Gln Arg  Leu Thr Lys Tyr Thr  Met Ala Asp    4505                 4510                 4515Leu Val  Tyr Ala Leu Arg His  Phe Asp Glu Gly Asn  Cys Asp Thr    4520                 4525                 4530Leu Lys  Glu Ile Leu Val Thr  Tyr Asn Cys Cys Asp  Asp Asp Tyr    4535                 4540                 4545Phe Asn  Lys Lys Asp Trp Tyr  Asp Phe Val Glu Asn  Pro Asp Ile    4550                 4555                 4560Leu Arg  Val Tyr Ala Asn Leu  Gly Glu Arg Val Arg  Gln Ala Leu    4565                 4570                 4575Leu Lys  Thr Val Gln Phe Cys  Asp Ala Met Arg Asn  Ala Gly Ile    4580                 4585                 4590Val Gly  Val Leu Thr Leu Asp  Asn Gln Asp Leu Asn  Gly Asn Trp    4595                 4600                 4605Tyr Asp  Phe Gly Asp Phe Ile  Gln Thr Thr Pro Gly  Ser Gly Val    4610                 4615                 4620Pro Val  Val Asp Ser Tyr Tyr  Ser Leu Leu Met Pro  Ile Leu Thr    4625                 4630                 4635Leu Thr  Arg Ala Leu Thr Ala  Glu Ser His Val Asp  Thr Asp Leu    4640                 4645                 4650Thr Lys  Pro Tyr Ile Lys Trp  Asp Leu Leu Lys Tyr  Asp Phe Thr    4655                 4660                 4665Glu Glu  Arg Leu Lys Leu Phe  Asp Arg Tyr Phe Lys  Tyr Trp Asp    4670                 4675                 4680Gln Thr  Tyr His Pro Asn Cys  Val Asn Cys Leu Asp  Asp Arg Cys    4685                 4690                 4695Ile Leu  His Cys Ala Asn Phe  Asn Val Leu Phe Ser  Thr Val Phe    4700                 4705                 4710Pro Pro  Thr Ser Phe Gly Pro  Leu Val Arg Lys Ile  Phe Val Asp    4715                 4720                 4725Gly Val  Pro Phe Val Val Ser  Thr Gly Tyr His Phe  Arg Glu Leu    4730                 4735                 4740Gly Val  Val His Asn Gln Asp  Val Asn Leu His Ser  Ser Arg Leu    4745                 4750                 4755Ser Phe  Lys Glu Leu Leu Val  Tyr Ala Ala Asp Pro  Ala Met His    4760                 4765                 4770Ala Ala  Ser Gly Asn Leu Leu  Leu Asp Lys Arg Thr  Thr Cys Phe    4775                 4780                 4785Ser Val  Ala Ala Leu Thr Asn  Asn Val Ala Phe Gln  Thr Val Lys    4790                 4795                 4800Pro Gly  Asn Phe Asn Lys Asp  Phe Tyr Asp Phe Ala  Val Ser Lys    4805                 4810                 4815Gly Phe  Phe Lys Glu Gly Ser  Ser Val Glu Leu Lys  His Phe Phe    4820                 4825                 4830Phe Ala  Gln Asp Gly Asn Ala  Ala Ile Ser Asp Tyr  Asp Tyr Tyr    4835                 4840                 4845Arg Tyr  Asn Leu Pro Thr Met  Cys Asp Ile Arg Gln  Leu Leu Phe    4850                 4855                 4860Val Val  Glu Val Val Asp Lys  Tyr Phe Asp Cys Tyr  Asp Gly Gly    4865                 4870                 4875Cys Ile  Asn Ala Asn Gln Val  Ile Val Asn Asn Leu  Asp Lys Ser    4880                 4885                 4890Ala Gly  Phe Pro Phe Asn Lys  Trp Gly Lys Ala Arg  Leu Tyr Tyr    4895                 4900                 4905Asp Ser  Met Ser Tyr Glu Asp  Gln Asp Ala Leu Phe  Ala Tyr Thr    4910                 4915                 4920Lys Arg  Asn Val Ile Pro Thr  Ile Thr Gln Met Asn  Leu Lys Tyr    4925                 4930                 4935Ala Ile  Ser Ala Lys Asn Arg  Ala Arg Thr Val Ala  Gly Val Ser    4940                 4945                 4950Ile Cys  Ser Thr Met Thr Asn  Arg Gln Phe His Gln  Lys Leu Leu    4955                 4960                 4965Lys Ser  Ile Ala Ala Thr Arg  Gly Ala Thr Val Val  Ile Gly Thr    4970                 4975                 4980Ser Lys  Phe Tyr Gly Gly Trp  His Asn Met Leu Lys  Thr Val Tyr    4985                 4990                 4995Ser Asp  Val Glu Asn Pro His  Leu Met Gly Trp Asp  Tyr Pro Lys    5000                 5005                 5010Cys Asp  Arg Ala Met Pro Asn  Met Leu Arg Ile Met  Ala Ser Leu    5015                 5020                 5025Val Leu  Ala Arg Lys His Thr  Thr Cys Cys Ser Leu  Ser His Arg    5030                 5035                 5040Phe Tyr  Arg Leu Ala Asn Glu  Cys Ala Gln Val Leu  Ser Glu Met    5045                 5050                 5055Val Met  Cys Gly Gly Ser Leu  Tyr Val Lys Pro Gly  Gly Thr Ser    5060                 5065                 5070Ser Gly  Asp Ala Thr Thr Ala  Tyr Ala Asn Ser Val  Phe Asn Ile    5075                 5080                 5085Cys Gln  Ala Val Thr Ala Asn  Val Asn Ala Leu Leu  Ser Thr Asp    5090                 5095                 5100Gly Asn  Lys Ile Ala Asp Lys  Tyr Val Arg Asn Leu  Gln His Arg    5105                 5110                 5115Leu Tyr  Glu Cys Leu Tyr Arg  Asn Arg Asp Val Asp  Thr Asp Phe    5120                 5125                 5130Val Asn  Glu Phe Tyr Ala Tyr  Leu Arg Lys His Phe  Ser Met Met    5135                 5140                 5145Ile Leu  Ser Asp Asp Ala Val  Val Cys Phe Asn Ser  Thr Tyr Ala    5150                 5155                 5160Ser Gln  Gly Leu Val Ala Ser  Ile Lys Asn Phe Lys  Ser Val Leu    5165                 5170                 5175Tyr Tyr  Gln Asn Asn Val Phe  Met Ser Glu Ala Lys  Cys Trp Thr    5180                 5185                 5190Glu Thr  Asp Leu Thr Lys Gly  Pro His Glu Phe Cys  Ser Gln His    5195                 5200                 5205Thr Met  Leu Val Lys Gln Gly  Asp Asp Tyr Val Tyr  Leu Pro Tyr    5210                 5215                 5220Pro Asp  Pro Ser Arg Ile Leu  Gly Ala Gly Cys Phe  Val Asp Asp    5225                 5230                 5235Ile Val  Lys Thr Asp Gly Thr  Leu Met Ile Glu Arg  Phe Val Ser    5240                 5245                 5250Leu Ala  Ile Asp Ala Tyr Pro  Leu Thr Lys His Pro  Asn Gln Glu    5255                 5260                 5265Tyr Ala  Asp Val Phe His Leu  Tyr Leu Gln Tyr Ile  Arg Lys Leu    5270                 5275                 5280His Asp  Glu Leu Thr Gly His  Met Leu Asp Met Tyr  Ser Val Met    5285                 5290                 5295Leu Thr  Asn Asp Asn Thr Ser  Arg Tyr Trp Glu Pro  Glu Phe Tyr    5300                 5305                 5310Glu Ala  Met Tyr Thr Pro His  Thr Val Leu Gln Ala  Val Gly Ala    5315                 5320                 5325Cys Val  Leu Cys Asn Ser Gln  Thr Ser Leu Arg Cys  Gly Ala Cys    5330                 5335                 5340Ile Arg  Arg Pro Phe Leu Cys  Cys Lys Cys Cys Tyr  Asp His Val    5345                 5350                 5355Ile Ser  Thr Ser His Lys Leu  Val Leu Ser Val Asn  Pro Tyr Val    5360                 5365                 5370Cys Asn  Ala Pro Gly Cys Asp  Val Thr Asp Val Thr  Gln Leu Tyr    5375                 5380                 5385Leu Gly  Gly Met Ser Tyr Tyr  Cys Lys Ser His Lys  Pro Pro Ile    5390                 5395                 5400Ser Phe  Pro Leu Cys Ala Asn  Gly Gln Val Phe Gly  Leu Tyr Lys    5405                 5410                 5415Asn Thr  Cys Val Gly Ser Asp  Asn Val Thr Asp Phe  Asn Ala Ile    5420                 5425                 5430Ala Thr  Cys Asp Trp Thr Asn  Ala Gly Asp Tyr Ile  Leu Ala Asn    5435                 5440                 5445Thr Cys  Thr Glu Arg Leu Lys  Leu Phe Ala Ala Glu  Thr Leu Lys    5450                 5455                 5460Ala Thr  Glu Glu Thr Phe Lys  Leu Ser Tyr Gly Ile  Ala Thr Val    5465                 5470                 5475Arg Glu  Val Leu Ser Asp Arg  Glu Leu His Leu Ser  Trp Glu Val    5480                 5485                 5490Gly Lys  Pro Arg Pro Pro Leu  Asn Arg Asn Tyr Val  Phe Thr Gly    5495                 5500                 5505Tyr Arg  Val Thr Lys Asn Ser  Lys Val Gln Ile Gly  Glu Tyr Thr    5510                 5515                 5520Phe Glu  Lys Gly Asp Tyr Gly  Asp Ala Val Val Tyr  Arg Gly Thr    5525                 5530                 5535Thr Thr  Tyr Lys Leu Asn Val  Gly Asp Tyr Phe Val  Leu Thr Ser    5540                 5545                 5550His Thr  Val Met Pro Leu Ser  Ala Pro Thr Leu Val  Pro Gln Glu    5555                 5560                 5565His Tyr  Val Arg Ile Thr Gly  Leu Tyr Pro Thr Leu  Asn Ile Ser    5570                 5575                 5580Asp Glu  Phe Ser Ser Asn Val  Ala Asn Tyr Gln Lys  Val Gly Met    5585                 5590                 5595Gln Lys  Tyr Ser Thr Leu Gln  Gly Pro Pro Gly Thr  Gly Lys Ser    5600                 5605                 5610His Phe  Ala Ile Gly Leu Ala  Leu Tyr Tyr Pro Ser  Ala Arg Ile    5615                 5620                 5625Val Tyr  Thr Ala Cys Ser His  Ala Ala Val Asp Ala  Leu Cys Glu    5630                 5635                 5640Lys Ala  Leu Lys Tyr Leu Pro  Ile Asp Lys Cys Ser  Arg Ile Ile    5645                 5650                 5655Pro Ala  Arg Ala Arg Val Glu  Cys Phe Asp Lys Phe  Lys Val Asn    5660                 5665                 5670Ser Thr  Leu Glu Gln Tyr Val  Phe Cys Thr Val Asn  Ala Leu Pro    5675                 5680                 5685Glu Thr  Thr Ala Asp Ile Val  Val Phe Asp Glu Ile  Ser Met Ala    5690                 5695                 5700Thr Asn  Tyr Asp Leu Ser Val  Val Asn Ala Arg Leu  Arg Ala Lys    5705                 5710                 5715His Tyr  Val Tyr Ile Gly Asp  Pro Ala Gln Leu Pro  Ala Pro Arg    5720                 5725                 5730Thr Leu  Leu Thr Lys Gly Thr  Leu Glu Pro Glu Tyr  Phe Asn Ser    5735                 5740                 5745Val Cys  Arg Leu Met Lys Thr  Ile Gly Pro Asp Met  Phe Leu Gly    5750                 5755                 5760Thr Cys  Arg Arg Cys Pro Ala  Glu Ile Val Asp Thr  Val Ser Ala    5765                 5770                 5775Leu Val  Tyr Asp Asn Lys Leu  Lys Ala His Lys Asp  Lys Ser Ala    5780                 5785                 5790Gln Cys  Phe Lys Met Phe Tyr  Lys Gly Val Ile Thr  His Asp Val    5795                 5800                 5805Ser Ser  Ala Ile Asn Arg Pro  Gln Ile Gly Val Val  Arg Glu Phe    5810                 5815                 5820Leu Thr  Arg Asn Pro Ala Trp  Arg Lys Ala Val Phe  Ile Ser Pro    5825                 5830                 5835Tyr Asn  Ser Gln Asn Ala Val  Ala Ser Lys Ile Leu  Gly Leu Pro    5840                 5845                 5850Thr Gln  Thr Val Asp Ser Ser  Gln Gly Ser Glu Tyr  Asp Tyr Val    5855                 5860                 5865Ile Phe  Thr Gln Thr Thr Glu  Thr Ala His Ser Cys  Asn Val Asn    5870                 5875                 5880Arg Phe  Asn Val Ala Ile Thr  Arg Ala Lys Val Gly  Ile Leu Cys    5885                 5890                 5895Ile Met  Ser Asp Arg Asp Leu  Tyr Asp Lys Leu Gln  Phe Thr Ser    5900                 5905                 5910Leu Glu  Ile Pro Arg Arg Asn  Val Ala Thr Leu Gln  Ala Glu Asn    5915                 5920                 5925Val Thr  Gly Leu Phe Lys Asp  Cys Ser Lys Val Ile  Thr Gly Leu    5930                 5935                 5940His Pro  Thr Gln Ala Pro Thr  His Leu Ser Val Asp  Thr Lys Phe    5945                 5950                 5955Lys Thr  Glu Gly Leu Cys Val  Asp Ile Pro Gly Ile  Pro Lys Asp    5960                 5965                 5970Met Thr  Tyr Arg Arg Leu Ile  Ser Met Met Gly Phe  Lys Met Asn    5975                 5980                 5985Tyr Gln  Val Asn Gly Tyr Pro  Asn Met Phe Ile Thr  Arg Glu Glu    5990                 5995                 6000Ala Ile  Arg His Val Arg Ala  Trp Ile Gly Phe Asp  Val Glu Gly    6005                 6010                 6015Cys His  Ala Thr Arg Glu Ala  Val Gly Thr Asn Leu  Pro Leu Gln    6020                 6025                 6030Leu Gly  Phe Ser Thr Gly Val  Asn Leu Val Ala Val  Pro Thr Gly    6035                 6040                 6045Tyr Val  Asp Thr Pro Asn Asn  Thr Asp Phe Ser Arg  Val Ser Ala    6050                 6055                 6060Lys Pro  Pro Pro Gly Asp Gln  Phe Lys His Leu Ile  Pro Leu Met    6065                 6070                 6075Tyr Lys  Gly Leu Pro Trp Asn  Val Val Arg Ile Lys  Ile Val Gln    6080                 6085                 6090Met Leu  Ser Asp Thr Leu Lys  Asn Leu Ser Asp Arg  Val Val Phe    6095                 6100                 6105Val Leu  Trp Ala His Gly Phe  Glu Leu Thr Ser Met  Lys Tyr Phe    6110                 6115                 6120Val Lys  Ile Gly Pro Glu Arg  Thr Cys Cys Leu Cys  Asp Arg Arg    6125                 6130                 6135Ala Thr  Cys Phe Ser Thr Ala  Ser Asp Thr Tyr Ala  Cys Trp His    6140                 6145                 6150His Ser  Ile Gly Phe Asp Tyr  Val Tyr Asn Pro Phe  Met Ile Asp    6155                 6160                 6165Val Gln  Gln Trp Gly Phe Thr  Gly Asn Leu Gln Ser  Asn His Asp    6170                 6175                 6180Leu Tyr  Cys Gln Val His Gly  Asn Ala His Val Ala  Ser Cys Asp    6185                 6190                 6195Ala Ile  Met Thr Arg Cys Leu  Ala Val His Glu Cys  Phe Val Lys    6200                 6205                 6210Arg Val  Asp Trp Thr Ile Glu  Tyr Pro Ile Ile Gly  Asp Glu Leu    6215                 6220                 6225Lys Ile  Asn Ala Ala Cys Arg  Lys Val Gln His Met  Val Val Lys    6230                 6235                 6240Ala Ala  Leu Leu Ala Asp Lys  Phe Pro Val Leu His  Asp Ile Gly    6245                 6250                 6255Asn Pro  Lys Ala Ile Lys Cys  Val Pro Gln Ala Asp  Val Glu Trp    6260                 6265                 6270Lys Phe  Tyr Asp Ala Gln Pro  Cys Ser Asp Lys Ala  Tyr Lys Ile    6275                 6280                 6285Glu Glu  Leu Phe Tyr Ser Tyr  Ala Thr His Ser Asp  Lys Phe Thr    6290                 6295                 6300Asp Gly  Val Cys Leu Phe Trp  Asn Cys Asn Val Asp  Arg Tyr Pro    6305                 6310                 6315Ala Asn  Ser Ile Val Cys Arg  Phe Asp Thr Arg Val  Leu Ser Asn    6320                 6325                 6330Leu Asn  Leu Pro Gly Cys Asp  Gly Gly Ser Leu Tyr  Val Asn Lys    6335                 6340                 6345His Ala  Phe His Thr Pro Ala  Phe Asp Lys Ser Ala  Phe Val Asn    6350                 6355                 6360Leu Lys  Gln Leu Pro Phe Phe  Tyr Tyr Ser Asp Ser  Pro Cys Glu    6365                 6370                 6375Ser His  Gly Lys Gln Val Val  Ser Asp Ile Asp Tyr  Val Pro Leu    6380                 6385                 6390Lys Ser  Ala Thr Cys Ile Thr  Arg Cys Asn Leu Gly  Gly Ala Val    6395                 6400                 6405Cys Arg  His His Ala Asn Glu  Tyr Arg Leu Tyr Leu  Asp Ala Tyr    6410                 6415                 6420Asn Met  Met Ile Ser Ala Gly  Phe Ser Leu Trp Val  Tyr Lys Gln    6425                 6430                 6435Phe Asp  Thr Tyr Asn Leu Trp  Asn Thr Phe Thr Arg  Leu Gln Ser    6440                 6445                 6450Leu Glu  Asn Val Ala Phe Asn  Val Val Asn Lys Gly  His Phe Asp    6455                 6460                 6465Gly Gln  Gln Gly Glu Val Pro  Val Ser Ile Ile Asn  Asn Thr Val    6470                 6475                 6480Tyr Thr  Lys Val Asp Gly Val  Asp Val Glu Leu Phe  Glu Asn Lys    6485                 6490                 6495Thr Thr  Leu Pro Val Asn Val  Ala Phe Glu Leu Trp  Ala Lys Arg    6500                 6505                 6510Asn Ile  Lys Pro Val Pro Glu  Val Lys Ile Leu Asn  Asn Leu Gly    6515                 6520                 6525Val Asp  Ile Ala Ala Asn Thr  Val Ile Trp Asp Tyr  Lys Arg Asp    6530                 6535                 6540Ala Pro  Ala His Ile Ser Thr  Ile Gly Val Cys Ser  Met Thr Asp    6545                 6550                 6555Ile Ala  Lys Lys Pro Thr Glu  Thr Ile Cys Ala Pro  Leu Thr Val    6560                 6565                 6570Phe Phe  Asp Gly Arg Val Asp  Gly Gln Val Asp Leu  Phe Arg Asn    6575                 6580                 6585Ala Arg  Asn Gly Val Leu Ile  Thr Glu Gly Ser Val  Lys Gly Leu    6590                 6595                 6600Gln Pro  Ser Val Gly Pro Lys  Gln Ala Ser Leu Asn  Gly Val Thr    6605                 6610                 6615Leu Ile  Gly Glu Ala Val Lys  Thr Gln Phe Asn Tyr  Tyr Lys Lys    6620                 6625                 6630Val Asp  Gly Val Val Gln Gln  Leu Pro Glu Thr Tyr  Phe Thr Gln    6635                 6640                 6645Ser Arg  Asn Leu Gln Glu Phe  Lys Pro Arg Ser Gln  Met Glu Ile    6650                 6655                 6660Asp Phe  Leu Glu Leu Ala Met  Asp Glu Phe Ile Glu  Arg Tyr Lys    6665                 6670                 6675Leu Glu  Gly Tyr Ala Phe Glu  His Ile Val Tyr Gly  Asp Phe Ser    6680                 6685                 6690His Ser  Gln Leu Gly Gly Leu  His Leu Leu Ile Gly  Leu Ala Lys    6695                 6700                 6705Arg Phe  Lys Glu Ser Pro Phe  Glu Leu Glu Asp Phe  Ile Pro Met    6710                 6715                 6720Asp Ser  Thr Val Lys Asn Tyr  Phe Ile Thr Asp Ala  Gln Thr Gly    6725                 6730                 6735Ser Ser  Lys Cys Val Cys Ser  Val Ile Asp Leu Leu  Leu Asp Asp    6740                 6745                 6750Phe Val  Glu Ile Ile Lys Ser  Gln Asp Leu Ser Val  Val Ser Lys    6755                 6760                 6765Val Val  Lys Val Thr Ile Asp  Tyr Thr Glu Ile Ser  Phe Met Leu    6770                 6775                 6780Trp Cys  Lys Asp Gly His Val  Glu Thr Phe Tyr Pro  Lys Leu Gln    6785                 6790                 6795Ser Ser  Gln Ala Trp Gln Pro  Gly Val Ala Met Pro  Asn Leu Tyr    6800                 6805                 6810Lys Met  Gln Arg Met Leu Leu  Glu Lys Cys Asp Leu  Gln Asn Tyr    6815                 6820                 6825Gly Asp  Ser Ala Thr Leu Pro  Lys Gly Ile Met Met  Asn Val Ala    6830                 6835                 6840Lys Tyr  Thr Gln Leu Cys Gln  Tyr Leu Asn Thr Leu  Thr Leu Ala    6845                 6850                 6855Val Pro  Tyr Asn Met Arg Val  Ile His Phe Gly Ala  Gly Ser Asp    6860                 6865                 6870Lys Gly  Val Ala Pro Gly Thr  Ala Val Leu Arg Gln  Trp Leu Pro    6875                 6880                 6885Thr Gly  Thr Leu Leu Val Asp  Ser Asp Leu Asn Asp  Phe Val Ser    6890                 6895                 6900Asp Ala  Asp Ser Thr Leu Ile  Gly Asp Cys Ala Thr  Val His Thr    6905                 6910                 6915Ala Asn  Lys Trp Asp Leu Ile  Ile Ser Asp Met Tyr  Asp Pro Lys    6920                 6925                 6930Thr Lys  Asn Val Thr Lys Glu  Asn Asp Ser Lys Glu  Gly Phe Phe    6935                 6940                 6945Thr Tyr  Ile Cys Gly Phe Ile  Gln Gln Lys Leu Ala  Leu Gly Gly    6950                 6955                 6960Ser Val  Ala Ile Lys Ile Thr  Glu His Ser Trp Asn  Ala Asp Leu    6965                 6970                 6975Tyr Lys  Leu Met Gly His Phe  Ala Trp Trp Thr Ala  Phe Val Thr    6980                 6985                 6990Asn Val  Asn Ala Ser Ser Ser  Glu Ala Phe Leu Ile  Gly Cys Asn    6995                 7000                 7005Tyr Leu  Gly Lys Pro Arg Glu  Gln Ile Asp Gly Tyr  Val Met His    7010                 7015                 7020Ala Asn  Tyr Ile Phe Trp Arg  Asn Thr Asn Pro Ile  Gln Leu Ser    7025                 7030                 7035Ser Tyr  Ser Leu Phe Asp Met  Ser Lys Phe Pro Leu  Lys Leu Arg    7040                 7045                 7050Gly Thr  Ala Val Met Ser Leu  Lys Glu Gly Gln Ile  Asn Asp Met    7055                 7060                 7065Ile Leu  Ser Leu Leu Ser Lys  Gly Arg Leu Ile Ile  Arg Glu Asn    7070                 7075                 7080Asn Arg  Val Val Ile Ser Ser  Asp Val Leu Val Asn  Asn    7085                 7090                 7095</s400><s200><s210>24</s210><s211>222</s211><s212>PRT</s212><s213>Severe acute respiratory syndrome coronavirus 2</s213></s200><s400> 24Met Ala Asp Ser Asn Gly Thr Ile Thr Val Glu Glu Leu Lys Lys Leu1               5                   10                  15Leu Glu Gln Trp Asn Leu Val Ile Gly Phe Leu Phe Leu Thr Trp Ile            20                  25                  30Cys Leu Leu Gln Phe Ala Tyr Ala Asn Arg Asn Arg Phe Leu Tyr Ile        35                  40                  45Ile Lys Leu Ile Phe Leu Trp Leu Leu Trp Pro Val Thr Leu Ala Cys    50                  55                  60Phe Val Leu Ala Ala Val Tyr Arg Ile Asn Trp Ile Thr Gly Gly Ile65                  70                  75                  80Ala Ile Ala Met Ala Cys Leu Val Gly Leu Met Trp Leu Ser Tyr Phe                85                  90                  95Ile Ala Ser Phe Arg Leu Phe Ala Arg Thr Arg Ser Met Trp Ser Phe            100                 105                 110Asn Pro Glu Thr Asn Ile Leu Leu Asn Val Pro Leu His Gly Thr Ile        115                 120                 125Leu Thr Arg Pro Leu Leu Glu Ser Glu Leu Val Ile Gly Ala Val Ile    130                 135                 140Leu Arg Gly His Leu Arg Ile Ala Gly His His Leu Gly Arg Cys Asp145                 150                 155                 160Ile Lys Asp Leu Pro Lys Glu Ile Thr Val Ala Thr Ser Arg Thr Leu                165                 170                 175Ser Tyr Tyr Lys Leu Gly Ala Ser Gln Arg Val Ala Gly Asp Ser Gly            180                 185                 190Phe Ala Ala Tyr Ser Arg Tyr Arg Ile Gly Asn Tyr Lys Leu Asn Thr        195                 200                 205Asp His Ser Ser Ser Ser Asp Asn Ile Ala Leu Leu Val Gln    210                 215                 220</s400><s200><s210>25</s210><s211>1273</s211><s212>PRT</s212><s213>Severe acute respiratory syndrome coronavirus 2</s213></s200><s400> 25Met Phe Val Phe Leu Val Leu Leu Pro Leu Val Ser Ser Gln Cys Val1               5                   10                  15Asn Leu Thr Thr Arg Thr Gln Leu Pro Pro Ala Tyr Thr Asn Ser Phe            20                  25                  30Thr Arg Gly Val Tyr Tyr Pro Asp Lys Val Phe Arg Ser Ser Val Leu        35                  40                  45His Ser Thr Gln Asp Leu Phe Leu Pro Phe Phe Ser Asn Val Thr Trp    50                  55                  60Phe His Ala Ile His Val Ser Gly Thr Asn Gly Thr Lys Arg Phe Asp65                  70                  75                  80Asn Pro Val Leu Pro Phe Asn Asp Gly Val Tyr Phe Ala Ser Thr Glu                85                  90                  95Lys Ser Asn Ile Ile Arg Gly Trp Ile Phe Gly Thr Thr Leu Asp Ser            100                 105                 110Lys Thr Gln Ser Leu Leu Ile Val Asn Asn Ala Thr Asn Val Val Ile        115                 120                 125Lys Val Cys Glu Phe Gln Phe Cys Asn Asp Pro Phe Leu Gly Val Tyr    130                 135                 140Tyr His Lys Asn Asn Lys Ser Trp Met Glu Ser Glu Phe Arg Val Tyr145                 150                 155                 160Ser Ser Ala Asn Asn Cys Thr Phe Glu Tyr Val Ser Gln Pro Phe Leu                165                 170                 175Met Asp Leu Glu Gly Lys Gln Gly Asn Phe Lys Asn Leu Arg Glu Phe            180                 185                 190Val Phe Lys Asn Ile Asp Gly Tyr Phe Lys Ile Tyr Ser Lys His Thr        195                 200                 205Pro Ile Asn Leu Val Arg Asp Leu Pro Gln Gly Phe Ser Ala Leu Glu    210                 215                 220Pro Leu Val Asp Leu Pro Ile Gly Ile Asn Ile Thr Arg Phe Gln Thr225                 230                 235                 240Leu Leu Ala Leu His Arg Ser Tyr Leu Thr Pro Gly Asp Ser Ser Ser                245                 250                 255Gly Trp Thr Ala Gly Ala Ala Ala Tyr Tyr Val Gly Tyr Leu Gln Pro            260                 265                 270Arg Thr Phe Leu Leu Lys Tyr Asn Glu Asn Gly Thr Ile Thr Asp Ala        275                 280                 285Val Asp Cys Ala Leu Asp Pro Leu Ser Glu Thr Lys Cys Thr Leu Lys    290                 295                 300Ser Phe Thr Val Glu Lys Gly Ile Tyr Gln Thr Ser Asn Phe Arg Val305                 310                 315                 320Gln Pro Thr Glu Ser Ile Val Arg Phe Pro Asn Ile Thr Asn Leu Cys                325                 330                 335Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val Tyr Ala            340                 345                 350Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser Val Leu        355                 360                 365Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val Ser Pro    370                 375                 380Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp Ser Phe385                 390                 395                 400Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln Thr Gly                405                 410                 415Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr Gly Cys            420                 425                 430Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly Gly Asn        435                 440                 445Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys Pro Phe    450                 455                 460Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr Pro Cys465                 470                 475                 480Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser Tyr Gly                485                 490                 495Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg Val Val Val            500                 505                 510Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly Pro Lys        515                 520                 525Lys Ser Thr Asn Leu Val Lys Asn Lys Cys Val Asn Phe Asn Phe Asn    530                 535                 540Gly Leu Thr Gly Thr Gly Val Leu Thr Glu Ser Asn Lys Lys Phe Leu545                 550                 555                 560Pro Phe Gln Gln Phe Gly Arg Asp Ile Ala Asp Thr Thr Asp Ala Val                565                 570                 575Arg Asp Pro Gln Thr Leu Glu Ile Leu Asp Ile Thr Pro Cys Ser Phe            580                 585                 590Gly Gly Val Ser Val Ile Thr Pro Gly Thr Asn Thr Ser Asn Gln Val        595                 600                 605Ala Val Leu Tyr Gln Asp Val Asn Cys Thr Glu Val Pro Val Ala Ile    610                 615                 620His Ala Asp Gln Leu Thr Pro Thr Trp Arg Val Tyr Ser Thr Gly Ser625                 630                 635                 640Asn Val Phe Gln Thr Arg Ala Gly Cys Leu Ile Gly Ala Glu His Val                645                 650                 655Asn Asn Ser Tyr Glu Cys Asp Ile Pro Ile Gly Ala Gly Ile Cys Ala            660                 665                 670Ser Tyr Gln Thr Gln Thr Asn Ser Pro Arg Arg Ala Arg Ser Val Ala        675                 680                 685Ser Gln Ser Ile Ile Ala Tyr Thr Met Ser Leu Gly Ala Glu Asn Ser    690                 695                 700Val Ala Tyr Ser Asn Asn Ser Ile Ala Ile Pro Thr Asn Phe Thr Ile705                 710                 715                 720Ser Val Thr Thr Glu Ile Leu Pro Val Ser Met Thr Lys Thr Ser Val                725                 730                 735Asp Cys Thr Met Tyr Ile Cys Gly Asp Ser Thr Glu Cys Ser Asn Leu            740                 745                 750Leu Leu Gln Tyr Gly Ser Phe Cys Thr Gln Leu Asn Arg Ala Leu Thr        755                 760                 765Gly Ile Ala Val Glu Gln Asp Lys Asn Thr Gln Glu Val Phe Ala Gln    770                 775                 780Val Lys Gln Ile Tyr Lys Thr Pro Pro Ile Lys Asp Phe Gly Gly Phe785                 790                 795                 800Asn Phe Ser Gln Ile Leu Pro Asp Pro Ser Lys Pro Ser Lys Arg Ser                805                 810                 815Phe Ile Glu Asp Leu Leu Phe Asn Lys Val Thr Leu Ala Asp Ala Gly            820                 825                 830Phe Ile Lys Gln Tyr Gly Asp Cys Leu Gly Asp Ile Ala Ala Arg Asp        835                 840                 845Leu Ile Cys Ala Gln Lys Phe Asn Gly Leu Thr Val Leu Pro Pro Leu    850                 855                 860Leu Thr Asp Glu Met Ile Ala Gln Tyr Thr Ser Ala Leu Leu Ala Gly865                 870                 875                 880Thr Ile Thr Ser Gly Trp Thr Phe Gly Ala Gly Ala Ala Leu Gln Ile                885                 890                 895Pro Phe Ala Met Gln Met Ala Tyr Arg Phe Asn Gly Ile Gly Val Thr            900                 905                 910Gln Asn Val Leu Tyr Glu Asn Gln Lys Leu Ile Ala Asn Gln Phe Asn        915                 920                 925Ser Ala Ile Gly Lys Ile Gln Asp Ser Leu Ser Ser Thr Ala Ser Ala    930                 935                 940Leu Gly Lys Leu Gln Asp Val Val Asn Gln Asn Ala Gln Ala Leu Asn945                 950                 955                 960Thr Leu Val Lys Gln Leu Ser Ser Asn Phe Gly Ala Ile Ser Ser Val                965                 970                 975Leu Asn Asp Ile Leu Ser Arg Leu Asp Lys Val Glu Ala Glu Val Gln            980                 985                 990Ile Asp Arg Leu Ile Thr Gly Arg  Leu Gln Ser Leu Gln  Thr Tyr Val        995                 1000                 1005Thr Gln  Gln Leu Ile Arg Ala  Ala Glu Ile Arg Ala  Ser Ala Asn    1010                 1015                 1020Leu Ala  Ala Thr Lys Met Ser  Glu Cys Val Leu Gly  Gln Ser Lys    1025                 1030                 1035Arg Val  Asp Phe Cys Gly Lys  Gly Tyr His Leu Met  Ser Phe Pro    1040                 1045                 1050Gln Ser  Ala Pro His Gly Val  Val Phe Leu His Val  Thr Tyr Val    1055                 1060                 1065Pro Ala  Gln Glu Lys Asn Phe  Thr Thr Ala Pro Ala  Ile Cys His    1070                 1075                 1080Asp Gly  Lys Ala His Phe Pro  Arg Glu Gly Val Phe  Val Ser Asn    1085                 1090                 1095Gly Thr  His Trp Phe Val Thr  Gln Arg Asn Phe Tyr  Glu Pro Gln    1100                 1105                 1110Ile Ile  Thr Thr Asp Asn Thr  Phe Val Ser Gly Asn  Cys Asp Val    1115                 1120                 1125Val Ile  Gly Ile Val Asn Asn  Thr Val Tyr Asp Pro  Leu Gln Pro    1130                 1135                 1140Glu Leu  Asp Ser Phe Lys Glu  Glu Leu Asp Lys Tyr  Phe Lys Asn    1145                 1150                 1155His Thr  Ser Pro Asp Val Asp  Leu Gly Asp Ile Ser  Gly Ile Asn    1160                 1165                 1170Ala Ser  Val Val Asn Ile Gln  Lys Glu Ile Asp Arg  Leu Asn Glu    1175                 1180                 1185Val Ala  Lys Asn Leu Asn Glu  Ser Leu Ile Asp Leu  Gln Glu Leu    1190                 1195                 1200Gly Lys  Tyr Glu Gln Tyr Ile  Lys Trp Pro Trp Tyr  Ile Trp Leu    1205                 1210                 1215Gly Phe  Ile Ala Gly Leu Ile  Ala Ile Val Met Val  Thr Ile Met    1220                 1225                 1230Leu Cys  Cys Met Thr Ser Cys  Cys Ser Cys Leu Lys  Gly Cys Cys    1235                 1240                 1245Ser Cys  Gly Ser Cys Cys Lys  Phe Asp Glu Asp Asp  Ser Glu Pro    1250                 1255                 1260Val Leu  Lys Gly Val Lys Leu  His Tyr Thr    1265                 1270</s400><s200><s210>26</s210><s211>275</s211><s212>PRT</s212><s213>Severe acute respiratory syndrome coronavirus 2</s213></s200><s400> 26Met Asp Leu Phe Met Arg Ile Phe Thr Ile Gly Thr Val Thr Leu Lys1               5                   10                  15Gln Gly Glu Ile Lys Asp Ala Thr Pro Ser Asp Phe Val Arg Ala Thr            20                  25                  30Ala Thr Ile Pro Ile Gln Ala Ser Leu Pro Phe Gly Trp Leu Ile Val        35                  40                  45Gly Val Ala Leu Leu Ala Val Phe Gln Ser Ala Ser Lys Ile Ile Thr    50                  55                  60Leu Lys Lys Arg Trp Gln Leu Ala Leu Ser Lys Gly Val His Phe Val65                  70                  75                  80Cys Asn Leu Leu Leu Leu Phe Val Thr Val Tyr Ser His Leu Leu Leu                85                  90                  95Val Ala Ala Gly Leu Glu Ala Pro Phe Leu Tyr Leu Tyr Ala Leu Val            100                 105                 110Tyr Phe Leu Gln Ser Ile Asn Phe Val Arg Ile Ile Met Arg Leu Trp        115                 120                 125Leu Cys Trp Lys Cys Arg Ser Lys Asn Pro Leu Leu Tyr Asp Ala Asn    130                 135                 140Tyr Phe Leu Cys Trp His Thr Asn Cys Tyr Asp Tyr Cys Ile Pro Tyr145                 150                 155                 160Asn Ser Val Thr Ser Ser Ile Val Ile Thr Ser Gly Asp Gly Thr Thr                165                 170                 175Ser Pro Ile Ser Glu His Asp Tyr Gln Ile Gly Gly Tyr Thr Glu Lys            180                 185                 190Trp Glu Ser Gly Val Lys Asp Cys Val Val Leu His Ser Tyr Phe Thr        195                 200                 205Ser Asp Tyr Tyr Gln Leu Tyr Ser Thr Gln Leu Ser Thr Asp Thr Gly    210                 215                 220Val Glu His Val Thr Phe Phe Ile Tyr Asn Lys Ile Val Asp Glu Pro225                 230                 235                 240Glu Glu His Val Gln Ile His Thr Ile Asp Gly Ser Ser Gly Val Val                245                 250                 255Asn Pro Val Met Glu Pro Ile Tyr Asp Glu Pro Thr Thr Thr Thr Ser            260                 265                 270Val Pro Leu        275</s400><s200><s210>27</s210><s211>121</s211><s212>PRT</s212><s213>Severe acute respiratory syndrome coronavirus 2</s213></s200><s400> 27Met Lys Ile Ile Leu Phe Leu Ala Leu Ile Thr Leu Ala Thr Cys Glu1               5                   10                  15Leu Tyr His Tyr Gln Glu Cys Val Arg Gly Thr Thr Val Leu Leu Lys            20                  25                  30Glu Pro Cys Ser Ser Gly Thr Tyr Glu Gly Asn Ser Pro Phe His Pro        35                  40                  45Leu Ala Asp Asn Lys Phe Ala Leu Thr Cys Phe Ser Thr Gln Phe Ala    50                  55                  60Phe Ala Cys Pro Asp Gly Val Lys His Val Tyr Gln Leu Arg Ala Arg65                  70                  75                  80Ser Val Ser Pro Lys Leu Phe Ile Arg Gln Glu Glu Val Gln Glu Leu                85                  90                  95Tyr Ser Pro Ile Phe Leu Ile Val Ala Ala Ile Val Phe Ile Thr Leu            100                 105                 110Cys Phe Thr Leu Lys Arg Lys Thr Glu        115                 120</s400><s200><s210>28</s210><s211>121</s211><s212>PRT</s212><s213>Severe acute respiratory syndrome coronavirus 2</s213></s200><s400> 28Met Lys Phe Leu Val Phe Leu Gly Ile Ile Thr Thr Val Ala Ala Phe1               5                   10                  15His Gln Glu Cys Ser Leu Gln Ser Cys Thr Gln His Gln Pro Tyr Val            20                  25                  30Val Asp Asp Pro Cys Pro Ile His Phe Tyr Ser Lys Trp Tyr Ile Arg        35                  40                  45Val Gly Ala Arg Lys Ser Ala Pro Leu Ile Glu Leu Cys Val Asp Glu    50                  55                  60Ala Gly Ser Lys Ser Pro Ile Gln Tyr Ile Asp Ile Gly Asn Tyr Thr65                  70                  75                  80Val Ser Cys Leu Pro Phe Thr Ile Asn Cys Gln Glu Pro Lys Leu Gly                85                  90                  95Ser Leu Val Val Arg Cys Ser Phe Tyr Glu Asp Phe Leu Glu Tyr His            100                 105                 110Asp Val Arg Val Val Leu Asp Phe Ile        115                 120</s400><s200><s210>29</s210><s211>75</s211><s212>PRT</s212><s213>Severe acute respiratory syndrome coronavirus 2</s213></s200><s400> 29Met Tyr Ser Phe Val Ser Glu Glu Thr Gly Thr Leu Ile Val Asn Ser1               5                   10                  15Val Leu Leu Phe Leu Ala Phe Val Val Phe Leu Leu Val Thr Leu Ala            20                  25                  30Ile Leu Thr Ala Leu Arg Leu Cys Ala Tyr Cys Cys Asn Ile Val Asn        35                  40                  45Val Ser Leu Val Lys Pro Ser Phe Tyr Val Tyr Ser Arg Val Lys Asn    50                  55                  60Leu Asn Ser Ser Arg Val Pro Asp Leu Leu Val65                  70                  75</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230000975A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230000975</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17778008</doc-number><date>20201211</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><priority-claims><priority-claim sequence="01" kind="regional"><country>EP</country><doc-number>19215272.6</doc-number><date>20191211</date></priority-claim></priority-claims><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>35</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>40</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>P</subclass><main-group>37</main-group><subgroup>08</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>35</main-group><subgroup>20</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>35</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>40</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>P</subclass><main-group>37</main-group><subgroup>08</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>0095</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>35</main-group><subgroup>20</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e61">NUTRITIONAL COMPOSITION FOR IMPROVING IMMUNE FITNESS</invention-title><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>N.V. Nutricia</orgname><address><city>Zoetermeer</city><country>NL</country></address></addressbook><residence><country>NL</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Potappel - van 't Land</last-name><first-name>Belinda</first-name><address><city>Utrecht</city><country>NL</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Lobato-Van Esch</last-name><first-name>Betty</first-name><address><city>Utrecht</city><country>NL</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Abbring</last-name><first-name>Suzanne</first-name><address><city>Utrecht</city><country>NL</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>Garssen</last-name><first-name>Johan</first-name><address><city>Utrecht</city><country>NL</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>N.V. Nutricia</orgname><role>03</role><address><city>Zoetermeer</city><country>NL</country></address></addressbook></assignee></assignees><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/EP2020/085752</doc-number><date>20201211</date></document-id><us-371c12-date><date>20220519</date></us-371c12-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The present invention relates to a nutritional composition comprising non-denatured lactoferrin for use in preventing or treating allergy, allergic rhinitis, asthma, urticaria, atopic eczema, allergic conjunctivitis, atopic dermatitis or atopic diseases in an infant or a toddler.</p></abstract><description id="description"><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0001" level="1">TECHNICAL FIELD OF THE INVENTION</heading><p id="p-0002" num="0001">The present invention is in the field of infant nutrition and relates to a nutritional composition for improving immune fitness, said nutritional composition containing non-denatured lactoferrin.</p><heading id="h-0002" level="1">TECHNICAL BACKGROUND OF THE INVENTION</heading><p id="p-0003" num="0002">Human milk is the uncontested gold standard concerning infant nutrition. However, in some cases breastfeeding is inadequate or unsuccessful. Also, mothers sometimes are unable to provide breastfeeding. For such situations infant or follow-on formulas have been developed. Commercial infant formulas are commonly used today to provide supplemental or sole source of nutrition early in life. These formulas comprise a range of nutrients to meet the nutritional needs of the growing infant, and typically include fat, carbohydrate, protein, vitamins, minerals, and other nutrients helpful for optimal infant growth and development. Commercial infant formulas are designed to mimic, as closely as possible, the composition and function of human milk.</p><p id="p-0004" num="0003">Immune fitness is a state where an individual's immune system is resilient, having an inbuilt capacity to adapt to challenges by establishing, maintaining and regulating an appropriate immune response. Resilience is the capacity of the immune system to return to homeostasis&#x2014;a healthy state of wellbeing&#x2014;after an external challenge. An appropriate response of the immune system is to eliminate a harmful agent, such as bacteria and viruses, but tolerate harmless ones, like food. This immune response should be of an optimal strength: not too weak, which will increase the risk of infections, or too strong, potentially resulting in allergy, chronic inflammation, or autoimmune disorders.</p><p id="p-0005" num="0004">Infants have limited exposure to antigens in utero to induce adaptive immunity. Therefore, in the early phase of life they are thought to be heavily dependent on their innate immune system for protection against infections. Babies who are breastfed have the additional protection of a complex mixture of immune-protective components present in the human milk and colostrum.</p><p id="p-0006" num="0005">The adaptive immune system consists of cell-mediated and antibody-mediated responses. The development of adaptive immune cells in early life is an understudied area of research. Low number of memory effector B cells and effector memory T cells are detected during early infancy. It has been shown that T cells recently produced by the thymus are present in large proportions in the periphery of human infants and these cells are impaired in their acquisition of Th1 function nor have been trained due to relatively limited exposure to foreign structures in the early phase of development. This characteristic contributes to an infant's vulnerability to infections and intracellular pathogens. Studies on cell mediated responses suggest that infants are able to mount T cell responses in most circumstances. However, the magnitude and quality of the response is inferior to those observed in adults. In addition, responses to some vaccines are diminished in Th1 activity and biased towards Th2 function.</p><p id="p-0007" num="0006">The ultimate aim of vaccination is to activate the adaptive immune system inducing highly specific responses against a specific pathogenic agent and generating potent and persistent protective responses. In general terms, antigens (or vaccines) are engulfed by antigen-presenting cells (APCs), and displayed on major histocompatibility complex (MHC) class II and I. The activated APCs alter their surface molecules and begin to release pro-inflammatory signals (cytokines and chemokines), which ideally activate naive T cells that will mature in effector T cells, including Th1 and Th2. Typically, the response to a vaccine/antigen is biased and results in a profile marked by more cellular elements or more humoral elements. It is a misconception that the central aim of vaccination is limited to the expression of antibodies. An effective long-lasting immunization is supported by the cellular response, which plays a central role in the induction of high-affinity antibodies and the immune memory.</p><p id="p-0008" num="0007">Allergy is an abnormal hypersensitivity to a substance which is normally tolerated and generally considered harmless. The first time an allergen meets the immune system, no allergic reaction occurs. Instead, the immune system prepares itself for future encounters with the allergen. The key players in the IgE-mediated allergic cascade are Th2 cells. Th2 cells secrete several cytokines that will activate B lymphocytes to produce antibodies of the subclass E (IgE). IgE antibodies are specific to that particular allergen. The interaction between an allergen and specific IgE antibodies on the surface of effector cells (mast cells and basophils) triggers hypersensitivity responses. This mast cell activation usually occurs within minutes after the second exposure to an allergen. IgE antibodies on mast cells, constructed during the sensitization phase, recognize the allergen and bind to the invader. Once the allergen is bound to the IgE antibody, granules in the mast cells release their contents. These contents, or mediators, are pro-inflammatory substances such as histamine, platelet-activating factor, prostaglandins, cytokines and leukotrienes. These mediators trigger the allergy attack. Histamine stimulates mucus production and causes redness, swelling, and inflammation. Prostaglandins constrict airways and enlarge blood vessels.</p><p id="p-0009" num="0008">The action of environmental factors on an immature, not yet balanced cellular immune system makes young infants especially prone to the development of allergies. Atopic individuals have a tendency to produce more IgE when exposed to certain antigens. Th1 cells and the cytokines released by them are necessary to mount an effective immune response against infection. Th2 cells play a dominant role in IgE production. Both types of T helper cells are reactive to allergens, but at the clonal level, the atopic response is predominantly Th2 as opposed to Th1 cells in non-allergic individuals. During early life, immature mucosal defences permit absorption of allergens, which then act on an immature immune system. In infants, the main exposure is to food allergens, whereas in older children, it is to inhalant allergens. As a consequence, allergy prone children may first suffer IgE-mediated food allergies and eczema. These manifestations may either improve or persist. In older children, asthma and allergic rhinitis provoked by inhalant allergens become predominant.</p><p id="p-0010" num="0009">Strategies to assist specific cellular immune responses at this developmental stage are needed to improve the health of this vulnerable population.</p><p id="p-0011" num="0010">WO 2012/091921 describes the use of nutritional compositions including lactoferrin produced by a non-human source in stimulating innate immune cells, such as macrophages, neutrophils, and dendritic cells.</p><p id="p-0012" num="0011">WO2014/055748 describes a method of increasing immune cell function in a new bom that has not consumed any colostrum or breast milk comprising administering an infant formula comprising 1.0 to about 10 g/L of bovine lactoferrin to the new bom mammal. This invention is directed to the innate capacity of the immune response.</p><p id="p-0013" num="0012">WO2012/077076 describes a method of decreasing a subject's risk of developing sensitivity to one or more bovine milk allergens, the method comprising orally administering to the subject one or more bovine milk allergens, wherein the one or more bovine milk allergens is present at a concentration at least 50% greater than the concentration(s) of the milk allergen(s) in whole bovine milk.</p><p id="p-0014" num="0013">Kruzel M L et al. (Lactoferrin decreases pollen antigen-induced allergic airway inflammation in a muine model of asthma, Immunology. 2006) describes that when pollen extract (RWE)-sensitized mice were challenged (intranasally) with RWE robust airway inflammation was observed. When RWE was administered together with LF there was a moderate accumulation of inflammatory cells in the BAL compartment and in the subepithelium.</p><p id="p-0015" num="0014">Sherman M P et al. (Lactoferrin acts as an adjuvant during influenza vaccination of neonatal mice, Biochem Biophys Res Commun. 2015) report a study in which three-day-old mice received subcutaneously 30 micrograms of H1N1 hemagglutinin+200 &#x3bc;g of bovine lactoferrin. The findings suggest that LF enhanced the response to H1N1 hemagglutinin.</p><heading id="h-0003" level="1">SUMMARY OF THE INVENTION</heading><p id="p-0016" num="0015">The inventors have found that the administration of a nutritional composition containing non-denatured lactoferrin has an unexpected effect on pediatric subjects in improving specific cellular immune responses, shifting the Th1/Th2 responses towards a Th1-biased response, which culminates in enhanced vaccine specific immune responses and reduced activation of the IgE pathway which is responsible for the clinical signs and symptoms of IgE-mediated allergy and atopic diseases.</p><p id="p-0017" num="0016">Consequently, the administration of a nutritional composition containing non-denatured lactoferrin has a beneficial effect on pediatric subjects in that it enhances (vaccine) specific immune response and further in that it can prevent or reduce the adverse effects of allergy, allergic rhinitis, asthma, urticaria, atopic eczema, allergic conjunctivitis, atopic dermatitis or atopic diseases.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0004" level="1">DETAILED DESCRIPTION OF THE INVENTION</heading><p id="p-0018" num="0017">Thus, one aspect of the present invention concerns a nutritional composition containing non-denatured lactoferrin for use in the prevention or treatment of allergy, allergic rhinitis, asthma, urticaria, atopic eczema, allergic conjunctivitis, atopic dermatitis or atopic diseases in an infant or a toddler, said nutritional composition being selected from infant formula, follow-on formula and growing-up milk, said nutritional composition comprising 0.03-14 wt. % non-denatured lactoferrin, calculated by weight of total protein.</p><p id="p-0019" num="0018">This aspect of the invention may also be worded as a method for preventing or treating allergy, allergic rhinitis, asthma, urticaria, atopic eczema, allergic conjunctivitis, atopic dermatitis or atopic diseases in an infant or a toddler, comprising administering a nutritional composition comprising 0.03-14 wt. % non-denatured lactoferrin, calculated by weight of total protein, said nutritional composition being selected from infant formula, follow-on formula and growing-up milk.</p><p id="p-0020" num="0019">For some jurisdictions, this aspect of the invention may also be worded as the use of non-denatured lactoferrin or a composition comprising non-denatured lactoferrin, for the manufacture of a nutritional composition for preventing or treating allergy, allergic rhinitis, asthma, urticaria, atopic eczema, allergic conjunctivitis, atopic dermatitis or atopic diseases in an infant or a toddler, said composition being selected from infant formula, follow-on formula and growing-up milk and comprising 0.03-14 wt. % non-denatured lactoferrin, calculated by weight of total protein.</p><p id="p-0021" num="0020">Another aspect of the present invention concerns a nutritional composition containing non-denatured lactoferrin for use in enhancing vaccine specific immune response in an infant or a toddler, said nutritional composition being selected from infant formula, follow-on formula and growing-up milk, said nutritional composition comprising 0.03-14 wt. % non-denatured lactoferrin, calculated by weight of total protein.</p><p id="p-0022" num="0021">This latter aspect of the invention may also be worded as a method for enhancing vaccine specific immune response in an infant or a toddler, comprising administering a nutritional composition comprising 0.03-14 wt. % non-denatured lactoferrin, calculated by weight of total protein, said nutritional composition being selected from infant formula, follow-on formula and growing-up milk.</p><p id="p-0023" num="0022">For some jurisdictions, this latter aspect of the invention may also be worded as the use of non-denatured lactoferrin or a composition comprising non-denatured lactoferrin, for the manufacture of a nutritional composition for enhancing vaccine specific immune response in an infant or a toddler, said composition being selected from infant formula, follow-on formula and growing-up milk and comprising 0.03-14 wt. % non-denatured lactoferrin, calculated by weight of total protein.</p><p id="p-0024" num="0023">The term &#x2018;lactoferrin&#x2019; as used herein refers to a globular glycoprotein with a molecular mass of about 80 kDa that is widely represented in various secretory fluids, such as milk, saliva, tears, and nasal secretions. Lactoferrin can be purified from milk or produced through recombinant DNA technology.</p><p id="p-0025" num="0024">The term &#x201c;non-denatured lactoferrin&#x201d; as used herein refers to lactoferrin molecules whose tertiary structure is preserved. Non-denatured lactoferrin is therefor still bioactive.</p><p id="p-0026" num="0025">The term &#x201c;allergy&#x201d; as used herein is defined as an abnormal hypersensitivity to a substance which is normally tolerated and generally considered harmless.</p><p id="p-0027" num="0026">In a preferred embodiment the nutritional composition contains 0.06-11 wt. %, preferably 0.09-8 wt. %, more preferably 0.12-6 wt. % non-denatured lactoferrin, calculated by weight of total protein.</p><p id="p-0028" num="0027">Preferably, at least 70 wt. %, more preferably at least 80 wt. %, most preferably at least 90 wt. % of the total lactoferrin in the composition for use according to the invention is non-denatured lactoferrin.</p><p id="p-0029" num="0028">In a preferred embodiment the nutritional composition is a powder. Preferably, the powder is reconstituted with aqueous liquid to prepare a liquid formula and this liquid formula is subsequently orally administered to the infant or the toddler. Preferably, the aqueous liquid is water.</p><p id="p-0030" num="0029">The water content of the nutritional composition typically does not exceed 20 wt. % by total weight. More preferably, the water content does not exceed 15 wt. %, most preferably the water content does not exceed 10 wt. % by total weight.</p><p id="p-0031" num="0030">Preferably, the reconstituted liquid formula has a pH between 6 and 8, more preferably between 6.5 and 7.5.</p><p id="p-0032" num="0031">It is highly desirable that the reconstituted liquid formula comprises 0.005 to 2 g/L, preferably 0.01 to 1.6 g/L, more preferably 0.015 to 1.2 g/L, most preferably 0.02 to 0.8 g/L of non-denatured lactoferrin.</p><p id="p-0033" num="0032">According to a particularly preferred embodiment, the nutritional composition for use according to the invention is administered in liquid form.</p><p id="p-0034" num="0033">The nutritional composition is preferably administered to an infant or a toddler in an amount sufficient to provide 2-2000 mg non-denatured lactoferrin per day, more preferably 6-1400 mg non-denatured lactoferrin per day and most preferably 10-800 mg non-denatured lactoferrin per day.</p><p id="p-0035" num="0034">Expressed differently, the nutritional composition is preferably administered to an infant or a toddler in an amount sufficient to provide 0.2-600 mg non-denatured lactoferrin per kg of bodyweight per day, more preferably 0.6-400 mg non-denatured lactoferrin per kg of bodyweight per day and most preferably 1-250 mg non-denatured lactoferrin per kg of bodyweight per day.</p><p id="p-0036" num="0035">The nutritional composition is preferably administered to an infant or a toddler who has been exclusively formula fed. In other words, the nutritional composition is preferably administered to an infant or toddler who did not drink colostrum and breastmilk.</p><p id="p-0037" num="0036">The nutritional composition is preferably administered to an infant or toddler of at least 1 month old, more preferably to an infant or toddler of at least 2 months old and most preferably to an infant or toddler of at least 4 months old.</p><p id="p-0038" num="0037">The non-denatured lactoferrin is preferably isolated from milk of a non-human animal or produced by a genetically modified organism. More preferably, the non-denatured lactoferrin is non-denatured bovine, caprine or ovine lactoferrin, most preferably non-denatured bovine lactoferrin. Suitable commercial sources of non-denatured bovine lactoferrin are for example MLF-1M by Milei or Bioferrin&#xae; 2000 HP by Glanbia Nutritionals.</p><p id="p-0039" num="0038">In a preferred embodiment the nutritional composition is for use in enhancing vaccine specific immune response against antigens of an intracellular pathogen. The intracellular pathogen is preferably a virus, more preferably one or more influenza viruses.</p><p id="p-0040" num="0039">Advantageously, the nutritional composition may be used to enhance vaccine specific immune responses of an infant or toddler vaccinated with inactivated vaccine or sub-unit vaccine. The composition according to the present invention allows for improved specific cellular responses upon challenge in vaccinated paediatric subjects. In view of the vulnerability of these subjects, vaccines of lower reactogenicity such as inactivated instead of attenuated and sub-unit instead of whole pathogen based vaccines are more tolerable and therefore, preferred. In view of the developmental stage of the adaptive immune system of these subjects, the compositions according to the invention are of particular advantage in case these types of vaccines are used.</p><p id="p-0041" num="0040">In a preferred embodiment, the nutritional composition for use in enhancing vaccine specific immune response in an infant or a toddler, is administrated orally to an infant or toddler at least 1 day before the vaccination takes place, more preferably at least 2 days before the vaccination takes place and most preferably at least 7 days before the vaccination takes place.</p><p id="p-0042" num="0041">In a preferred embodiment, the nutritional composition for use in enhancing vaccine specific immune response in an infant or a toddler, is administrated for at least once daily for two consecutive days, more preferably at least once daily for 4 consecutive days and most preferably at least once daily for 7 consecutive days.</p><p id="p-0043" num="0042">In another preferred embodiment the nutritional composition is for use in preventing allergy in infants or toddlers or treating allergen sensitized infants or toddlers. Preferably, the nutritional composition is for use in preventing or treating IgE-mediated allergy. Preferably, the nutritional composition is for use in the prevention or treatment of an allergic response to an allergen originating from food, more preferably to an allergen originating from non-dairy food, most preferably to an allergen originating from a non-dairy food selected from peanut, tree nut, shellfish, wheat, soy, egg and/or sesame.</p><p id="p-0044" num="0043">In yet another preferred embodiment, the nutritional composition is for use in the prevention or treatment of an allergic response to an allergen originating from peanut, tree nut, shellfish, wheat, soy, egg, sesame, pollen, mould or dust mite.</p><p id="p-0045" num="0044">In another more preferred embodiment the nutritional composition is for use in the prevention of allergy, allergic rhinitis, asthma, urticaria, atopic eczema, allergic conjunctivitis, atopic dermatitis or atopic diseases in an infant or a toddler. Preferably the nutritional composition is for use in preventing allergy in infants or toddlers. Typically, the nutritional composition is for use in preventing IgE-mediated allergy.</p><p id="p-0046" num="0045">Preferably, the nutritional composition is for use in the prevention of an allergic response to an allergen originating from food, more preferably to an allergen originating from non-dairy food, most preferably to an allergen originating from a non-dairy food selected from peanut, tree nut, shellfish, wheat, soy, egg and/or sesame.</p><p id="p-0047" num="0046">In yet another more preferred embodiment, the nutritional composition is for use in the prevention of an allergic response to an allergen originating from peanut, tree nut, shellfish, wheat, soy, egg, sesame, pollen, mould or dust mite.</p><p id="p-0048" num="0047">The nutritional composition according to the invention is preferably not fermented.</p><p id="p-0049" num="0048">The nutritional composition advantageously comprises 5-20 cal. % protein, including lactoferrin; 30-60 cal. % lipids; and 25-75 cal. % digestible carbohydrates.</p><p id="p-0050" num="0049">The nutritional composition according to the invention is preferably prepared by a process comprising the steps of:<ul id="ul0001" list-style="none">    <li id="ul0001-0001" num="0050">a. providing a mixture of protein, lipids and digestible carbohydrates;</li>    <li id="ul0001-0002" num="0051">b. heating said mixture to at least 72&#xb0; C. to obtain a heated mixture;</li>    <li id="ul0001-0003" num="0052">c. spray drying said heated mixture to obtain a powdered composition; and</li>    <li id="ul0001-0004" num="0053">d. dry-blending non-denatured lactoferrin with the powdered composition to obtain the nutritional composition.</li></ul></p><p id="p-0051" num="0054">Another aspect of the invention relates to a nutritional composition selected from infant formula, follow-on formula and growing-up milk, said nutritional composition comprising<ul id="ul0002" list-style="none">    <li id="ul0002-0001" num="0000">    <ul id="ul0003" list-style="none">        <li id="ul0003-0001" num="0055">30-80 cal. % lipids,</li>        <li id="ul0003-0002" num="0056">5-20 cal. % protein and</li>        <li id="ul0003-0003" num="0057">25-75 cal. % digestible carbohydrates;</li>    </ul>    </li></ul></p><p id="p-0052" num="0058">wherein the protein comprises (i) 0.03-14 wt. % non-denatured lactoferrin calculated by weight of total protein and (ii) one or more protein allergens selected from peanut protein, tree nut protein, shellfish protein, gluten, soy protein, egg protein or sesame protein.</p><p id="p-0053" num="0059">Preferably the protein comprises 0.06-11 wt. %, more preferably 0.09-8 wt. %, most preferably 0.12-6 wt. % non-denatured lactoferrin, calculated by weight of total protein.</p><p id="p-0054" num="0060">Preferably, the non-denatured lactoferrin is non-denatured bovine, caprine or ovine lactoferrin, most preferably non-denatured bovine lactoferrin.</p><p id="p-0055" num="0061">The protein allergen in the nutritional composition may be intact, partially hydrolyzed or extensively hydrolyzed. The term &#x201c;degree of hydrolysis&#x201d; refers to the extent to which peptide bonds are broken by a hydrolysis method. The term &#x201c;partially hydrolyzed&#x201d; means having a degree of hydrolysis which is greater than 0% but less than about 50%. The term &#x201c;extensively hydrolyzed&#x201d; means having a degree of hydrolysis which is greater than or equal to about 50%.</p><p id="p-0056" num="0062">Preferably, the protein allergen is intact or partially hydrolyzed. Typically, the degree of hydrolysis is between 0-50%, more preferably between 5-40%, most preferably between 10-30%.</p><p id="p-0057" num="0063">The nutritional composition preferably contains 0.01-50 mg of protein allergen per gram of protein, more preferably 0.05-10 mg of protein allergen per gram of protein and most preferably 0.1-5 mg of protein allergen per gram of protein.</p><p id="p-0058" num="0064">The aforementioned nutritional composition may be administered to infants or toddlers to reduce the risk that such infants or toddlers will develop an allergy for the one or more protein allergens contained therein. Preferably, the aforementioned nutritional composition is for use in the prevention of food allergy. More preferably, said composition is for use in the prevention of the development of a food allergy in infants or toddlers that have not yet been exposed to the one or more protein allergens contained therein.</p><p id="p-0059" num="0065">Lipid</p><p id="p-0060" num="0066">The nutritional composition comprises lipid. Lipid in the present invention comprises one or more selected from the group consisting of triglycerides, polar lipids (such as phospholipids, cholesterol, glycolipids, sphingomyelin), free fatty acids, monoglycerides and diglycerides.</p><p id="p-0061" num="0067">The lipid provides preferably 30 to 60% of the total calories of the nutritional composition. More preferably the nutritional composition comprises lipid providing 35 to 55% of the total calories, even more preferably the nutritional composition comprises lipids providing 40 to 50% of the total calories. The lipids are preferably present in an amount of 3 to 7 g per 100 kcal, more preferably in an amount of 4 to 6 g lipid per 100 kcal and most preferably in an amount of 4.5 to 5.5 g lipid per 100 kcal. When in liquid form, e.g. as a ready-to-feed liquid, the nutritional composition preferably comprises 2.1 to 6.5 g lipids per 100 ml, more preferably 3.0 to 4.0 g per 100 ml. Based on dry weight the nutritional composition preferably comprises 10 to 50 wt. %, more preferably 12.5 to 40 wt. % lipids, even more preferably 19 to 30 wt. % lipids.</p><p id="p-0062" num="0068">The lipid preferably comprises vegetable lipids. The presence of vegetable lipids advantageously enables an optimal fatty acid profile high in polyunsaturated fatty acids and/or more reminiscent to human milk fat. Lipid from non-human mammalian milk alone, e.g. cow's milk, does not provide an optimal fatty acid profile. The amount of essential fatty acids is too low in non-human mammalian milk.</p><p id="p-0063" num="0069">Preferably the nutritional composition comprises at least one, preferably at least two vegetable lipid sources selected from the group consisting of linseed oil (flaxseed oil), rape seed oil (such as colza oil, low erucic acid rape seed oil and canola oil), sunflower oil, high oleic sunflower oil, safflower oil, high oleic safflower oil, olive oil, coconut oil, palm oil and palm kernel oil.</p><p id="p-0064" num="0070">In a preferred embodiment, the nutritional composition comprises 5 to 100 wt. % vegetable lipids based on total lipids, more preferably 10 to 95 wt. %, more preferably 20 to 80 wt. %, even more preferably 25 to 75 wt. %, most preferably 40 to 70 wt. % vegetable lipids based on total lipids. It is noted therefore that the nutritional composition also may comprise non-vegetable lipids. Non-vegetable lipids may include mammalian milk fat, mammalian milk derived lipid as a preferred source of phospholipid, and fish, marine and/or microbial oils as source of long chain polyunsaturated fatty acids (LC-PUFA).</p><p id="p-0065" num="0071">Triglycerides are the major fraction of the lipids in the nutritional composition. Triglycerides comprise a glycerol moiety to which, via ester bonds, three fatty acid residues are attached, which may be the same or different, and which are generally chosen from saturated and unsaturated fatty acids containing 4 to 26 carbon atoms. Such triglycerides may differ in the fatty acid residues that are present and/or may differ in the respective position(s) of the fatty acid residues to the glycerol backbone (e.g. in the sn-1, sn-2 and/or sn-3 position). Preferably the nutritional composition comprises at least 70 wt. %, more preferably at least 80 wt. %, more preferably at least 85 wt. % triglycerides based on total lipids, even more preferably at least 90 wt. % triglycerides based on total lipids, and most preferably at least 95 wt. % triglycerides based on total lipids.</p><p id="p-0066" num="0072">Lipids that can be used to enhance the amount of PA located at the sn-2 position in triglycerides based on total PA are commercially available&#x2014;e.g. from Loders Croklaan under the name Betapol&#x2122; and/or can be prepared in a manner known per se, for instance as described in EP 0698078 and/or EP 0758846. Another suitable source is InFat&#x2122; of Enzymotec. In case these lipids are obtained by trans- or interesterification of vegetable triglycerides, these sources are in the context of the present invention regarded as vegetable lipids.</p><p id="p-0067" num="0073">A preferred source for triglycerides to enhance PA at the sn-2 or beta position in a triglyceride is non-human animal fat, more preferably non-human mammalian milk fat, even more preferably cow's milk fat. Preferably non-human mammalian milk fat, in particular cow's milk fat, is used in the form of anhydrous milk fat, butter oil, butterfat or butter. Preferably, the source of the milk fat is in a homogenous fat phase, such as butter oil or anhydrous milk fat, and not in the form of oil in water emulsion such as cream.</p><p id="p-0068" num="0074">Preferably the amount of the source of lipid, which comprises triglycerides with an increased amount of palmitic acid residues in the sn-2 position of a triglyceride, that is comprised in the lipid of the nutritional composition, is between 10 and 70 wt. %, more preferably between 20 and 65 wt. %, even more preferably between 30 and 60 wt. % based on total lipid. Such source of lipid is preferably mammalian milk fat, more preferably such source of lipids is non-human mammalian milk fat. The mammalian milk fat is preferably selected from butter, butter fat, butter oil or anhydrous milk fat. Preferably the nutritional composition comprises mammalian milk fat selected from butter, butter fat, butter oil or anhydrous milk fat between 10 and 70 wt. % based on total lipid, more preferably between 20 and 75 wt. %, even more preferably between 30 and 60 wt. % based on total lipid.</p><p id="p-0069" num="0075">In a particularly preferred embodiment, the lipid in the nutritional composition comprises:</p><p id="p-0070" num="0076">a. 30 to 90 wt. % vegetable fat based on total lipid, and</p><p id="p-0071" num="0077">b. 10 to 70 wt. % mammalian milk fat based on total lipid, wherein the mammalian milk fat is selected from butter, butter fat, butter oil or anhydrous milk fat.</p><p id="p-0072" num="0078">More preferably, the lipid in the nutritional composition comprises:</p><p id="p-0073" num="0079">a. 35 to 80 wt. % vegetable fat based on total lipid, and</p><p id="p-0074" num="0080">b. 20 to 65 wt. % mammalian milk fat based on total lipid, wherein the mammalian milk fat is selected from butter, butter fat, butter oil or anhydrous milk fat.</p><p id="p-0075" num="0081">Most preferably, the lipid in the nutritional composition comprises:</p><p id="p-0076" num="0082">a. 40 to 70 wt. % vegetable fat based on total lipid, and</p><p id="p-0077" num="0083">b. 30 to 60 wt. % mammalian milk fat based on total lipid, wherein the mammalian milk fat is selected from butter, butter fat, butter oil or anhydrous milk fat.</p><p id="p-0078" num="0084">In a preferred embodiment, the lipid comprises at least 10 wt. % palmitic acid (PA) based on total fatty acids and at least 15 wt. % of palmitic acid, based on total palmitic acid, is located at the sn-2 position of a triglyceride.</p><p id="p-0079" num="0085">The lipids in the nutritional composition are preferably chosen such that the amount of palmitic acid (PA) that is present in the total lipid of the nutritional composition is at least 10 wt. % based on total fatty acids in the total lipid, preferably at least 15 wt. %. Preferably the amount of PA that is present in the total lipid is below 30 wt. % based on total fatty acids. More preferably the amount of PA that is present in the lipid is from 12 to 26 wt. % based on total fatty acids in the total lipid, even more preferably from 14 to 24 wt. %, even more preferably from 16 to 22 wt. %.</p><p id="p-0080" num="0086">The lipids in the nutritional composition are preferably chosen such that, based on the total PA present in the lipid, at least 15 wt. %, preferably at least 20 wt. %, more preferably at least 25 wt. %, more preferably at least 30 wt. % PA is in the sn-2 or beta position in a triglyceride. Preferably the amount of PA in the sn-2 position in a triglyceride is not more than 45 wt. %, preferably not more than 40 wt. % based on total PA present in the lipid. Preferably the amount of PA in the sn-2 position in a triglyceride is from 25 to 40 wt. % based on total PA present in the total lipid.</p><p id="p-0081" num="0087">SFA relates to saturated fatty acids and/or acyl chains, MUFA relates to mono-unsaturated fatty acid and/or acyl chains, PUFA refers to polyunsaturated fatty acids and/or acyl chains with 2 or more unsaturated bonds; LC-PUFA refers to long chain polyunsaturated fatty acids and/or acyl chains comprising at least 20 carbon atoms in the fatty acyl chain and with 2 or more unsaturated bonds; Medium chain fatty acids (MCFA) refer to fatty acids and/or acyl chains with a chain length of 6, 8 or 10 carbon atoms. n3 or omega-3 PUFA refers to polyunsaturated fatty acids and/or acyl chains with 2 or more unsaturated bonds with an unsaturated bond at the third carbon atom from the methyl end of the fatty acyl chain, n6 or omega-6 PUFA refers to polyunsaturated fatty acids and/or acyl chains with 2 or more unsaturated bonds with an unsaturated bond at the sixth carbon atom from the methyl end of the fatty acyl chain.</p><p id="p-0082" num="0088">DHA refers to docosahexaenoic acid and/or acyl chain (22:6, n3); DPA refers to docosapentaenoic acid and/or acyl chain (22:5 n3). EPA refers to eicosapentaenoic acid and/or acyl chain (20:5 n3); ARA refers to arachidonic acid and/or acyl chain (20:4 n6). LA refers to linoleic acid and/or acyl chain (18:2 n6); ALA refers to alpha-linolenic acid and/or acyl chain (18:3 n3). PA relates to palmitic acid and/or acyl chains (C16:0). BA refers to butyric acid (4:0).</p><p id="p-0083" num="0089">The nutritional composition according to the present use preferably comprises LA. LA is an n6 PUFA and the precursor of n6 LC-PUFA and is an essential fatty acid as it cannot be synthesized by the human body. LA preferably is present in a sufficient amount in order to promote a healthy growth and development, yet in an amount as low as possible to prevent negative, competitive, effects on the formation of n3 PUFA and a too high n6/n3 ratio. The nutritional composition therefore preferably comprises less than 15 wt. %, more preferably less than 12 wt. %, more preferably less than 10 wt. % LA based on total fatty acids. The nutritional composition preferably comprises at least 5 wt. % LA based on fatty acids, preferably at least 6 wt. % LA, more preferably at least 7 wt. % LA based on total fatty acids.</p><p id="p-0084" num="0090">The nutritional composition preferably comprises ALA. ALA is a n3 PUFA and the precursor of n3 LC-PUFA and is an essential fatty acid as it cannot be synthesized by the human body. Preferably ALA is present in a sufficient amount to promote a healthy growth and development of the infant. The nutritional composition therefore preferably comprises at least 1.0 wt. %, more preferably the nutritional composition comprises at least 1.5 wt. %, even more preferably at least 2.0 wt. % ALA based on total fatty acids. Preferably the nutritional composition comprises less than 10 wt. % ALA, more preferably less than 5.0 wt. % based on total fatty acids.</p><p id="p-0085" num="0091">The weight ratio LA/ALA preferably is well balanced in order to ensure an optimal n6/n3 PUFA, n6/n3 LC PUFA and DHA/ARA ratio in the cellular membranes. Therefore, the nutritional composition preferably comprises a weight ratio of LA/ALA from 2 to 20, more preferably from 3 to 15, more preferably from 5 to 12, more preferably from 5 to 10. Preferably the n6 PUFA/n3 PUFA weight ratio is from 3 to 20, more preferably from 3 to 15, more preferably from 5 to 12, more preferably from 5 to 10.</p><p id="p-0086" num="0092">Preferably, the nutritional composition comprises n3 LC-PUFA, such as EPA, DPA and/or DHA, more preferably DHA. As the conversion of ALA to DHA may be less efficient in infants, preferably both ALA and DHA are present in the nutritional composition. Preferably the nutritional composition comprises at least 0.05 wt. %, preferably at least 0.1 wt. %, more preferably at least 0.2 wt. %, of DHA based on total fatty acids. Preferably the nutritional composition comprises not more than 2.0 wt. %, preferably not more than 1.0 wt. % of DHA based on total fatty acids.</p><p id="p-0087" num="0093">The nutritional composition preferably comprises ARA. Preferably the nutritional composition comprises at least 0.05 wt. %, preferably at least 0.1 wt. %, more preferably at least 0.2 wt. % of ARA based on total fatty acids. As the group of n6 fatty acids, especially arachidonic acid (ARA) counteracts the group of n3 fatty acids, especially DHA, the nutritional composition preferably comprises relatively low amounts of ARA. Preferably the nutritional composition comprises not more than 2.0 wt. %, preferably not more than 1.0 wt. % of ARA based on total fatty acids. Preferably the weight ratio between DHA and ARA is between 1:4 to 4:1, more preferably between 1:2 to 2:1, more preferably between 0.6 and 1.5.</p><p id="p-0088" num="0094">Digestible Carbohydrates</p><p id="p-0089" num="0095">The nutritional composition comprises digestible carbohydrates. The digestible carbohydrates preferably provide 25 to 75% of the total calories of the nutritional composition. Preferably the digestible carbohydrates provide 40 to 60% of the total calories. Based on calories the nutritional composition preferably comprises of 5 to 20 g of digestible carbohydrates per 100 kcal, more preferably 6 to 16 g per 100 kcal. When in liquid form, e.g. as a ready-to-feed liquid, the nutritional composition preferably comprises 3 to 30 g digestible carbohydrate per 100 ml, more preferably 6 to 20, even more preferably 7 to 10 g per 100 ml. Based on dry weight the nutritional composition preferably comprises 20 to 80 wt. %, more preferably 40 to 65 wt. % digestible carbohydrates.</p><p id="p-0090" num="0096">Preferred digestible carbohydrate sources are lactose, glucose, sucrose, fructose, galactose, maltose, starch and maltodextrin. Lactose is the main digestible carbohydrate present in human milk. Lactose advantageously has a low glycaemic index. The nutritional composition preferably comprises lactose. The nutritional composition preferably comprises digestible carbohydrate, wherein at least 35 wt. %, more preferably at least 50 wt. %, more preferably at least 75 wt. %, even more preferably at least 90 wt. %, most preferably at least 95 wt. % of the digestible carbohydrate is lactose. Based on dry weight the nutritional composition preferably comprises at least 25 wt. % lactose, preferably at least 40 wt. % lactose.</p><p id="p-0091" num="0097">Protein</p><p id="p-0092" num="0098">The nutritional composition comprises protein. The protein preferably provides 5 to 20% of the total calories. Preferably the nutritional composition comprises protein that provides 6 to 12% of the total calories. Preferably the nutritional composition comprises less than 3.5 g protein per 100 kcal, more preferably the nutritional composition comprises between 1.5 and 2.1 g protein per 100 kcal, even more preferably between 1.6 and 2.0 g protein per 100 kcal. A low protein concentration advantageously is closer to human milk as human milk comprises a lower amount of protein based on total calories compared to cow's milk. The protein concentration in a nutritional composition is determined by the sum of protein, peptides and free amino acids. Based on dry weight the nutritional composition preferably comprises less than 12 wt. % protein, more preferably between 9.6 and 12 wt. %, even more preferably between 10 and 11 wt. %. Based on a ready-to-drink liquid product the nutritional composition preferably comprises less than 1.5 g protein per 100 ml, more preferably between 1.2 and 1.5 g, even more preferably between 1.25 and 1.35 g per 100 ml.</p><p id="p-0093" num="0099">The source of the protein should be selected in such a way that the minimum requirements for essential amino acid content are met and satisfactory growth is ensured. Hence protein sources based on cows' milk proteins such as whey, casein and mixtures thereof and proteins based on soy, potato or pea are preferred. In case whey proteins are used, the protein source is preferably based on acid whey or sweet whey, whey protein isolate or mixtures thereof. Preferably the nutritional composition comprises at least 3 wt. % casein based on dry weight. Preferably the casein is intact and/or non-hydrolyzed.</p><p id="p-0094" num="0100">Non-Digestible Carbohydrates</p><p id="p-0095" num="0101">In one embodiment the nutritional composition preferably comprises non-digestible oligosaccharides. Preferably the nutritional composition comprises non-digestible oligosaccharides with a degree of polymerization (DP) between 2 and 250, more preferably between 3 and 60.</p><p id="p-0096" num="0102">Preferably the nutritional composition comprises fructo-oligosaccharides, galacto-oligosaccharides and/or galacturonic acid oligosaccharides, more preferably fructo-oligosaccharides and/or galacto-oligosaccharides, even more preferably galacto-oligosaccharides, most preferably transgalacto-oligosaccharides. In a preferred embodiment the nutritional compostions comprises a mixture of galacto-oligosaccharides and fructo-oligosaccharides, more preferably transgalacto-oligosaccharides and fructo-oligosaccharides. Suitable non-digestible oligosaccharides are for example VIvinaW&#xae;GOS (FrieslandCampina DOMO), Raftilin&#xae;HP or Raftilose&#xae; (Oraft).</p><p id="p-0097" num="0103">Preferably, the nutritional composition comprises 80 mg to 2 g non-digestible oligosaccharides per 100 ml, more preferably 150 mg to 1.5 g, even more preferably 300 mg to 1 g per 100 ml. Based on dry weight, the nutritional composition preferably comprises 0.25 wt. % to 20 wt. %, more preferably 0.5 wt. % to 10 wt. %, even more preferably 1.5 wt. % to 7.5 wt. % of non-digestible oligosaccharides.</p><p id="p-0098" num="0104">Formula</p><p id="p-0099" num="0105">The use according to the present invention requires the administration of an infant formula, a follow-on formula or a growing-up milk. This means that the composition that is administered is not human milk. It also means that the composition that is administered is not native cow's milk or native milk from another mammal. Alternatively, the terms as used herein, &#x201c;infant formula&#x201d; or &#x201c;follow-on formula&#x201d; or &#x201c;growing-up milk&#x201d; means that it concerns a composition that is artificially made or in other words that it is synthetic. Hence in one embodiment, the nutritional composition that is administered is an artificial infant formula or an artificial follow-on formula or an artificial growing-up milk or a synthetic infant formula or a synthetic follow-on formula or a synthetic growing-up milk.</p><p id="p-0100" num="0106">In the present context, infant formula refers to nutritional compositions, artificially made, intended for infants of 0 to about 4 to 6 months of age and are intended as a substitute for human milk. Typically, infant formulae are suitable to be used as sole source of nutrition. Such infant formulae are also known as starter formula. Follow-on formula for infants starting with at 4 to 6 months of life to 12 months of life are intended to be supplementary feedings to infants that start weaning on other foods. Infant formulae and follow-on formulae are subject to strict regulations, for example for the EU regulations no. 609/2013 and no. 2016/127. In the present context, growing-up milk refers to nutritional compositions, artificially made, intended for infants of 12 months to 36 months, which are intended to be supplementary feedings to infants.</p><p id="p-0101" num="0107">The nutritional composition is preferably an infant formula or a follow-on formula. More preferably the nutritional composition is an infant formula.</p><p id="p-0102" num="0108">The nutritional composition is preferably an infant formula or follow-on formula and preferably comprises 3 to 7 g lipid/100 kcal, preferably 4 to 6 g lipid/100 kcal, more preferably 4.5 to 5.5 g lipid/100 kcal, preferably comprises 1.7 to 3.5 g protein/100 kcal, more preferably 1.8 to 2.1 g protein/100 kcal, more preferably 1.8 to 2.0 g protein/100 kcal and preferably comprises 5 to 20 g digestible carbohydrate/100 kcal, preferably 6 to 16 g digestible carbohydrate/100 kcal, more preferably 10 to 15 g digestible carbohydrate/100 kcal.</p><p id="p-0103" num="0109">Preferably the nutritional composition is an infant formula or follow-on formula, has an energy density of 60 kcal to 75 kcal/100 ml, more preferably 60 to 70 kcal/100 ml, when in a ready-to-drink form. This density ensures an optimal balance between hydration and caloric intake.</p><p id="p-0104" num="0110">The invention is further illustrated by the following non-limiting examples.</p><heading id="h-0005" level="1">EXAMPLES</heading><heading id="h-0006" level="1">Example 1&#x2014;Effect of a Nutritional Composition Comprising Lactoferrin Studied in a Vaccinated Animal Model</heading><p id="p-0105" num="0111">Six-week-old old male specific pathogen-free inbred mice were obtained from Harlan (the Netherlands) and housed under standard housing conditions with a 12 h dark and light cycle. All animals had free access to tap water and the semi-purified AIN-93G diet (Research Diet Services, Wijk bij Duurstede, the Netherlands). The study protocol was reviewed and approved by the Animal Experimental Committee of the Utrecht University.</p><p id="p-0106" num="0112">The vaccination experiment was performed using Influvac (Solvay Pharmaceuticals, Weesp, the Netherlands) from season 2002/2003. It is an inactivated influenza virus vaccine based on isolated haemagglutinin (HA) and neuraminidase antigens of three strains of myxovirus influenza, in a dose equivalent to 30 &#x3bc;g/mL HA per strain (90 &#x3bc;g/mL HA in total). An oil-adjuvant was used in all vaccinations (Stimune, previously known as Specol; Cedi-diagnostics, Lelystad, The Netherlands).</p><p id="p-0107" num="0113">The mice were divided in 4 groups according to the table below:</p><p id="p-0108" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="77pt" align="left"/><colspec colname="2" colwidth="56pt" align="left"/><colspec colname="3" colwidth="63pt" align="left"/><thead><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry>Group (n = 10)</entry><entry>Vaccine</entry><entry>Lactoferrin</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>Control</entry><entry>No (PBS)</entry><entry>No (PBS)</entry></row><row><entry/><entry>Control + LF</entry><entry>No (PBS)</entry><entry>Yes</entry></row><row><entry/><entry>Vaccinated</entry><entry>Yes</entry><entry>No (PBS)</entry></row><row><entry/><entry>Vaccinated + LF</entry><entry>Yes</entry><entry>Yes</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0109" num="0114">The mice groups &#x201c;Control+LF&#x201d; and &#x201c;Vaccinated+LF&#x201d; received oral gavage once daily with a dosage of 200 ug/day for 1 week (7 days) prior to the primary vaccination.</p><p id="p-0110" num="0115">The mice from groups &#x201c;Vaccinated&#x201d; and &#x201c;Vaccinated LF&#x201d; received a primary vaccination (day 0) and a booster vaccination, consisting of a subcutaneous (sc) injection of a 1:1 mix of vaccine and adjuvant in a total volume of 100 &#x3bc;L. The booster vaccination was given 21 days after the primary vaccination.</p><p id="p-0111" num="0116">The experiments ended 10 days after booster vaccination. Blood samples (taken by retro-orbital puncture) were taken at the end of the experiment, centrifuged, after which the serum was collected and stored at &#x2212;80&#xb0; C. until use.</p><p id="p-0112" num="0117">Delayed Type Hypersensitivity (DTH)</p><p id="p-0113" num="0118">Vaccine-specific DTH reactions were induced 9 days after the last vaccination, by subcutaneous injection of 25 &#x3bc;L Influvac (30 &#x3bc;g/mL per haemagglutinin subunit) into the ear pinnea of one ear. As control, the other ear was injected with 25 &#x3bc;L PBS. Ear thickness was measured in duplicate before challenge, and 24 hours thereafter, with a digital micrometer (Mitutoyo Digimatic 293561, Veenendaal, the Netherlands). The influvac specificity of the DTH response was calculated by subtracting the basal ear thickness from the value at 24 hours after challenge and was corrected for the control swelling.</p><p id="p-0114" num="0119">Evaluation of Antibody Responses in Serum</p><p id="p-0115" num="0120">Serum antibody concentrations were measured by ELISA. In short, 96-well plates (Costar EIA/RIA plate, Alphen a/d Rijn, The Netherlands) were coated with 1:100 diluted Influvac in PBS. Blocking reagent was 2% BSA (Sigma, Zwijndrecht, The Netherlands) in PBS. A dilution series of pooled serum that contained anti-vaccine antibodies was added for standard curve calculation. Anti-IgG-HRP (Santa Cruz Biotechnology, Heerhugowaard, The Netherlands), anti-IgG2a-biotin (Becton Dickinson, Heerhugowaard, The Netherlands) antibodies were diluted 1:1000 in dilution buffer. For the biotin-conjugated antibodies, the plates were subsequently incubated with a 1:20,000 dilution of streptavidin-HRP (Biosource, Etten-Leur, The Netherlands). Plates were incubated with ready-to-use TMB substrate (Perbio Science, Etten-Leur, The Netherlands) and were measured in a Bio-Rad Ultramark plate reader. Concentrations in test sera were calculated in arbitrary units (AU), relative to the standard curve of the diluted pooled serum. The concentration of the pooled serum was defined as 1000 AU/mL.</p><p id="p-0116" num="0121">Statistical Analyses</p><p id="p-0117" num="0122">All statistical calculations were performed using SPSS version 12.0.1 software. Statistical differences between test and control groups were analyzed by T-test. All values are presented as Mean t SD. P-values &#x3c;0.05 were considered significant.</p><p id="p-0118" num="0123">Results</p><p id="p-0119" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="63pt" align="center"/><colspec colname="3" colwidth="77pt" align="center"/><thead><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry>Group</entry><entry>DTH (mean &#xb1; SD)</entry><entry>IgG2a (mean &#xb1; SD)</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/><entry>Control</entry><entry>0.5 &#xb1; 0.3</entry><entry>0</entry></row><row><entry/><entry>Control + LF</entry><entry>0.8 &#xb1; 0.4</entry><entry>0</entry></row><row><entry/><entry>Vaccinated</entry><entry>8.8 &#xb1; 1.2</entry><entry>180 &#xb1; 15</entry></row><row><entry/><entry>Vaccinated + LF</entry><entry>14.7 &#xb1; 1.3&#x2002;</entry><entry>290 &#xb1; 75</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0120" num="0124">Vaccinated mice receiving lactoferrin (group Vaccinated+LF) showed significantly (p&#x3c;0.05) increased expression of influenza specific IgG2a in serum as compared to vaccinated mice receiving PBS (group Vaccinated).</p><p id="p-0121" num="0125">Vaccinated mice receiving lactoferrin (group Vaccinated+LF) showed significantly (P&#x3c;0.01) increased influenza-specific DTH responses as compared to vaccinated mice receiving PBS (group Vaccinated).</p><p id="p-0122" num="0126">These findings demonstrate a clear enhancement of specific cellular immune responses, more specifically Th1 responses, in vaccinated subjects receiving lactoferrin orally.</p><heading id="h-0007" level="1">Example 2&#x2014;Effect of a Nutritional Composition Comprising Lactoferrin and the Development of Allergy Symptoms in an Animal Model</heading><p id="p-0123" num="0127">Previously, it was demonstrated that raw cow's milk has the capacity to prevent the development of OVA-induced food allergy in a murine animal model. This protective effect was lost once the milk was heat-treated, e.g. by pasteurization, such as in shop milk.</p><p id="p-0124" num="0128">Animals</p><p id="p-0125" num="0129">Three-week-old, specific pathogen-free, female C3H/HeOuJ mice (The Jackson Laboratory, Bar Harbor, Me., USA) were housed at the animal facility of Utrecht University (Utrecht, The Netherlands) in filter-topped makrolon cages (one cage/group, n=6-8/cage) with standard chip bedding, Kleenex tissues and a plastic shelter, on a 12 h light/dark cycle with access to food (&#x2018;Rat and Mouse Breeder and Grower Expanded&#x2019;; Special Diet Services, Witham, UK) and water adlibitum. Upon arrival, mice were randomly assigned to the control and experimental groups and were habituated to the laboratory conditions for six days prior to the start of the study. All animal procedures were approved by the Ethical Committee for Animal Research of the Utrecht University and were compiled with the European Directive 2010/63/EU on the protection of animals used for scientific purposes (AVD108002015346).</p><p id="p-0126" num="0130">Experimental Design&#x2014;Tolerance Induction, Sensitization and Challenges</p><p id="p-0127" num="0131">Prior to sensitization, mice were orally treated with 0.5 mL PBS (as a control), raw milk, shop milk or shop milk spiked with LF for eight consecutive days (days &#x2212;9 to &#x2212;2). On experimental days 0, 7, 14, 21 and 28, mice (n=8/group) were orally sensitized, by using a blunt needle, to the hen's egg protein OVA (20 mg/0.5 mL PBS; grade V; Sigma-Aldrich) using cholera toxin (CT; 15 &#x3bc;g/0.5 mL PBS; List Biological Laboratories, Campbell, Calif., USA) as an adjuvant. Sham-sensitized control mice (n=6) received CT alone (15 &#x3bc;g/0.5 mL PBS). To remove lipopolysaccharide, OVA solutions were passed through Pierce High Capacity Endotoxin Removal Resin (Thermo Fisher Scientific, Paisley, Scotland) prior to use. On day 33, five days after the last sensitization, all mice were challenged intradermally in both ear pinnae with OVA (10 &#x3bc;g/20 &#x3bc;L PBS) to determine the acute allergic response.</p><p id="p-0128" num="0132">So, there were 4 test groups:</p><p id="p-0129" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="14pt" align="center"/><colspec colname="3" colwidth="63pt" align="left"/><colspec colname="4" colwidth="49pt" align="left"/><colspec colname="5" colwidth="42pt" align="left"/><thead><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry/><entry/><entry>Tolerance</entry><entry>Sensitization</entry><entry>Intradermal</entry></row><row><entry/><entry/><entry>induction</entry><entry>(days: 0, 7, 14,</entry><entry>challenge</entry></row><row><entry>Group</entry><entry>N</entry><entry>(days: &#x2212;9 to &#x2212;2)</entry><entry>21, 28)</entry><entry>(day 33)</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="14pt" align="char" char="."/><colspec colname="3" colwidth="63pt" align="left"/><colspec colname="4" colwidth="49pt" align="left"/><colspec colname="5" colwidth="42pt" align="left"/><tbody valign="top"><row><entry>PBS</entry><entry>6</entry><entry>PBS</entry><entry>PBS + CT</entry><entry>OVA</entry></row><row><entry>Raw milk</entry><entry>8</entry><entry>Raw milk</entry><entry>OVA + CT</entry><entry>OVA</entry></row><row><entry>Shop milk</entry><entry>8</entry><entry>Shop milk</entry><entry>OVA + CT</entry><entry>OVA</entry></row><row><entry>Shop milk +</entry><entry>8</entry><entry>Shop milk +</entry><entry>OVA + CT</entry><entry>OVA</entry></row><row><entry>lactoferrin</entry><entry/><entry>lactoferrin</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0130" num="0133">Milk Types and Bioactive Whey Proteins</p><p id="p-0131" num="0134">Raw, unprocessed, cow's milk was collected from a biodynamic dairy farm legally allowed to sell raw milk (organic &#x2018;Vorzugsmilch&#x2019; (15); Hof Dannwisch, Horst, Germany). Shop milk (full fat, store-bought, milk) was obtained from Melkan Superunie (Beesd, The Netherlands). On the days of milk treatment, part of the shop milk was spiked (0.325 mg/0.5 mL shop milk) with the bioactive whey protein lactoferrin (LF). Bovine milk LF was obtained from Synlait Milk (Canterburg, New Zealand). Mice (about 25 grams) received 8 dosages of 0.5 ml LF spiked milk.</p><p id="p-0132" num="0135">Evaluation of the Acute Allergic Response</p><p id="p-0133" num="0136">To assess the severity of the acute allergic symptoms upon intradermal challenge in both ear pinnae with OVA, the acute allergic skin response, anaphylactic shock symptoms were evaluated by a researcher blinded to treatment. The acute allergic skin response, expressed as &#x394; ear swelling (&#x3bc;m), was calculated by subtracting the mean basal ear thickness from the mean ear thickness measured 1 h after intradermal challenge. Ear thickness at both timepoints was measured in duplicate for each ear using a digital micrometer (Mitutoyo, Veenendaal, The Netherlands). To perform the intradermal challenge and both ear measurements, mice were anesthetized using inhalation of isoflurane (Abbott, Breda, The Netherlands). The severity of the anaphylactic shock symptoms was scored 45 min after the intradermal challenge by using a previously described, validated, scoring table (Xi X M et al., J Allergy Clin Immunol (1999) 103(2 Pt 1): 206-14).</p><p id="p-0134" num="0137">Statistical Analysis</p><p id="p-0135" num="0138">Significant outliers were excluded based on the Grubbs' test. The acute allergic skin response was analyzed with one-way ANOVA followed by Bonferroni's multiple comparisons test for pre-selected groups. The anaphylactic shock symptoms were analyzed with the Kruskal-Wallis test for non-parametric data followed by Dunn's multiple comparisons test for pre-selected groups. Statistical analyses were performed using GraphPad Prism software (version 7.03; GraphPad Software, San Diego, Calif., USA) and results were considered statistically significant when P&#x3c;0.05.</p><p id="p-0136" num="0139">Results</p><p id="p-0137" num="0140">In mice treated with raw milk prior to OVA sensitization, the acute allergic skin response and anaphylactic shock score were reduced compared to mice treated with shop milk. In both cases the reduction was statistically significant different with a p-value below 0.005.</p><p id="p-0138" num="0141">Spiking shop milk with LF significantly reduced the acute allergic skin response compared to shop milk-treated mice (p&#x3c;0.01). Spiking shop milk with LF also significantly lowered the anaphylactic shock score compared to shop milk treated mice (p&#x3c;0.01).</p><p id="p-0139" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="84pt" align="center"/><colspec colname="3" colwidth="91pt" align="center"/><thead><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry>Acute allergic skin response</entry><entry>Anaphylactic shock score</entry></row><row><entry>Group</entry><entry>(mean + SEM)</entry><entry>(score per mouse)</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry>PBS</entry><entry>30.8 (6.9)</entry><entry>0, 0, 0, 0, 0, 0</entry></row><row><entry>Raw milk</entry><entry>59.7 (9.0)</entry><entry>0, 0, 0, 0, 0, 0, 0, 0</entry></row><row><entry>Shop milk</entry><entry>138.6 (8.0)&#x2002;</entry><entry>2, 1, 2, 3, 2, 0, 0, 2</entry></row><row><entry>Shop milk +</entry><entry>&#x2002;65.6 (17.3)</entry><entry>0, 0, 1, 1, 0, 0, 1 (&#x2212;1 outlier)</entry></row><row><entry>lactoferrin</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0140" num="0142">These findings demonstrate that non-denatured lactoferrin is capable of suppressing OVA-induced allergic symptoms.</p><heading id="h-0008" level="1">Example 3&#x2014;Infant Formula Comprising Non-Denatured Lactoferrin</heading><p id="p-0141" num="0143">A mixture of ingredients was provided for preparing an infant formula comprising per 100 ml (66 kcal), 1.5 g protein (cow's milk derived protein, with whey protein and casein in a weight ratio of 6:4), 7 g digestible carbohydrates (mainly lactose), 3.4 g lipid of which vegetable fat (palm oil, low erucic acid rape seed oil, sunflower oil, coconut oil, high oleic acid sunflower oil, soy lecithin) and fish oil and microbial oil as a source of LC-PUFA, 0.8 g non-digestible oligosaccharides (trans galacto-oligosaccharides and long chain fructo oligosaccharide). Minerals, vitamins trace elements and other micronutrients were present as known in the art and in compliance with directives for infant formula.</p><p id="p-0142" num="0144">This mixture was heated to 72&#xb0; C. for 30 seconds and subsequently spray-dried to generate a spray-dried infant formula powder. This infant formula powder was mixed with non-denatured lactoferrin to provide 0.05 g non-denatured lactoferrin per 100 ml infant formula after reconstitution.</p><p id="p-0143" num="0145">The infant formula was provided as a powder with the instruction to reconstitute with water. About 13.2 g powder was reconstituted to 100 ml ready to drink infant formula.</p><?detailed-description description="Detailed Description" end="tail"?></description><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. A method for preventing for preventing or treating allergy, allergic rhinitis, asthma urticaria, atopic eczema, allergic conjunctivitis, atopic dermatitis or atopic diseases in an infant or a toddler comprising administering a nutritional composition comprising 0.03-14 wt % non-denatured lactoferrin, calculated by weight of total protein, said nutritional composition being selected from infant formula follow-on formula and growing-up milk.</claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the composition contains 0.06-11 wt. %, preferably 0.09-8 wt. %, more preferably 0.12-6 wt. % non-denatured lactoferrin, calculated by weight of total protein.</claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein at least 70 wt. %, preferably at least 80 wt. %, most preferably at least 90 wt. % of the total lactoferrin in the composition is non-denatured lactoferrin.</claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. The method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the composition is a powder.</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The method according to <claim-ref idref="CLM-00004">claim 4</claim-ref>, wherein the powder is reconstituted with aqueous liquid to prepare a liquid formula and wherein the liquid formula is subsequently orally administered to the infant or the toddler.</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. The method according to <claim-ref idref="CLM-00005">claim 5</claim-ref>, wherein the reconstituted liquid formula comprises 0.005 to 2 g/L, preferably 0.01 to 1.6 g/L, more preferably 0.015 to 1.2 g/L, most preferably 0.02 to 0.8 g/L of non-denatured lactoferrin.</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the non-denatured lactoferrin is isolated from milk of a non-human animal or produced by a genetically modified organism, wherein the non-denatured lactoferrin is non-denatured bovine, caprine or ovine lactoferrin.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. The method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the treatment is for allergen sensitized infants or toddlers.</claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. The method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the method is for prevention or treatment of IgE-mediated allergy.</claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. The method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the prevention or treatment is of an allergic response to an allergen originating from food, preferably non-dairy food.</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. The method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the prevention or treatment of an allergic response is with respect to an allergen originating from peanut, tree nut, shell fish, wheat, soy, egg, sesame, pollen, mold or dust mite.</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. The method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the composition is not fermented.</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. The method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the nutritional composition comprises 5-20 cal. % protein, including lactoferrin; 30-60 cal. % lipids; and 25-75 cal. % digestible carbohydrates.</claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. The method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the nutritional composition is prepared by a process comprising the steps of:<claim-text>a. providing a mixture of protein, lipids and digestible carbohydrates;</claim-text><claim-text>b. heating said mixture to at least 72&#xb0; C. to obtain a heated mixture;</claim-text><claim-text>c. spray drying said heated mixture to obtain a powdered composition; and</claim-text><claim-text>d. dry-blending non-denatured lactoferrin with the powdered composition to obtain the nutritional composition.</claim-text></claim-text></claim><claim id="CLM-00015" num="00015"><claim-text><b>15</b>. A nutritional composition selected from infant formula, follow-on formula and growing-up milk, said nutritional composition comprising<claim-text>30-60 cal. % lipids,</claim-text><claim-text>5-20 cal. % protein and</claim-text><claim-text>25-75 cal. % digestible carbohydrates;</claim-text><claim-text>wherein the protein comprises (i) 0.03-14 wt. % non-denatured lactoferrin calculated by weight of total protein and (ii) one or more protein allergens selected from peanut protein, tree nut protein, shellfish protein, gluten, soy protein, egg protein or sesame protein.</claim-text></claim-text></claim></claims></us-patent-application>